configuration:
- - CT Version
  - SNOMED=January 31, 2018
document:
- - NC_1
  - '0.'
  - false
  - Title Page
  - false
  - NCI_1
- - NC_2
  - '1.'
  - true
  - PROTOCOL SUMMARY
  - true
  - NCI_2
- - NC_3
  - 1.1.
  - true
  - Synopsis
  - true
  - NCI_3
- - NC_4
  - '1.2'
  - true
  - Schema
  - true
  - NCI_4
- - NC_5
  - 1.3.
  - true
  - Schedule of Activities (SoA)
  - true
  - NCI_5
- - NC_6
  - '2.'
  - true
  - INTRODUCTION
  - true
  - NCI_6
- - NC_7
  - 2.1.
  - true
  - Study Rationale
  - true
  - NCI_7
- - NC_8
  - '2.2'
  - true
  - Background
  - true
  - NCI_8
- - NC_9
  - '2.3'
  - true
  - Benefit-Risk Assessment
  - true
  - NCI_9
- - NC_10
  - 2.3.1
  - true
  - Risk Assessment
  - true
  - NCI_10
- - NC_11
  - 2.3.1.1
  - true
  - Coronavirus (SARS-CoV-2) Disease 2019
  - true
  - NCI_11
- - NC_12
  - 2.3.2
  - true
  - Benefit Assessment
  - true
  - NCI_12
- - NC_13
  - 2.3.3
  - true
  - Overall Benefit-Risk Conclusion
  - true
  - NCI_13
- - NC_14
  - '3.'
  - true
  - OBJECTIVES AND ENDPOINTS
  - true
  - NCI_14
- - NC_15
  - '4.'
  - true
  - STUDY DESIGN
  - true
  - NCI_15
- - NC_16
  - '4.1'
  - true
  - Overall Design
  - true
  - NCI_16
- - NC_17
  - 4.2.
  - true
  - Scientific Rationale for Study Design
  - true
  - NCI_17
- - NC_18
  - 4.2.1
  - true
  - Participant Input into Design
  - true
  - NCI_18
- - NC_19
  - 4.3.
  - true
  - Justification for Dose
  - true
  - NCI_19
- - NC_20
  - 4.4.
  - true
  - End of Study Definition
  - true
  - NCI_20
- - NC_21
  - '5.'
  - true
  - STUDY POPULATION
  - true
  - NCI_21
- - NC_22
  - 5.1.
  - true
  - Inclusion Criteria
  - true
  - NCI_22
- - NC_23
  - '5.2'
  - true
  - Exclusion Criteria
  - true
  - NCI_23
- - NC_24
  - 5.3.
  - true
  - Lifestyle Considerations
  - true
  - NCI_24
- - NC_25
  - 5.4.
  - true
  - Screen Failures
  - true
  - NCI_25
- - NC_26
  - '6.'
  - true
  - STUDY INTERVENTION
  - true
  - NCI_26
- - NC_27
  - 6.1.
  - true
  - Study Intervention(s) Administered
  - true
  - NCI_27
- - NC_28
  - 6.2.
  - true
  - Preparation / Handling / Storage / Accountability
  - true
  - NCI_28
- - NC_29
  - 6.3.
  - true
  - 'Measures to Minimize Bias: Randomization and Blinding'
  - true
  - NCI_29
- - NC_30
  - 6.4.
  - true
  - Study Intervention Compliance
  - true
  - NCI_30
- - NC_31
  - 6.5.
  - true
  - Concomitant Therapy
  - true
  - NCI_31
- - NC_32
  - 6.5.1
  - true
  - Allowed Medicine and Therapy
  - true
  - NCI_32
- - NC_33
  - 6.5.2
  - true
  - Disallowed Medicine and Therapy
  - true
  - NCI_33
- - NC_34
  - 6.6.
  - true
  - Dose Modification
  - true
  - NCI_34
- - NC_35
  - 6.7.
  - true
  - Intervention After the End of the Study
  - true
  - NCI_35
- - NC_36
  - '7.'
  - true
  - DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL
  - true
  - NCI_36
- - NC_37
  - 7.1.
  - true
  - Discontinuation of Study Intervention
  - true
  - NCI_37
- - NC_38
  - 7.2.
  - true
  - Participant Discontinuation/Withdrawal From the Study
  - true
  - NCI_38
- - NC_39
  - '7.3'
  - true
  - Lost to Follow-up
  - true
  - NCI_39
- - NC_40
  - '8.'
  - true
  - STUDY ASSESSMENTS AND PROCEDURES
  - true
  - NCI_40
- - NC_41
  - 8.1.
  - true
  - Efficacy Assessments
  - true
  - NCI_41
- - NC_42
  - 8.1.1
  - true
  - Copper and Molybdenum Balance Measurements
  - true
  - NCI_42
- - NC_43
  - 8.1.1.1
  - true
  - Food and Fluid Collection for Copper and Molybdenum Concentrations
  - true
  - NCI_43
- - NC_44
  - 8.1.1.2
  - true
  - Urine Collection for Measurement of Copper and Molybdenum content
  - true
  - NCI_44
- - NC_45
  - 8.1.1.3
  - true
  - Fecal Collection for Measurement of Copper and Molybdenum Content
  - true
  - NCI_45
- - NC_46
  - 8.2.
  - true
  - Safety Assessments
  - true
  - NCI_46
- - NC_47
  - 8.2.1
  - true
  - Physical Examinations
  - true
  - NCI_47
- - NC_48
  - 8.2.2
  - true
  - Vital Signs
  - true
  - NCI_48
- - NC_49
  - 8.2.3
  - true
  - Electrocardiograms
  - true
  - NCI_49
- - NC_50
  - 8.2.4
  - true
  - Clinical Safety Laboratory Assessments
  - true
  - NCI_50
- - NC_51
  - 8.2.4.1
  - true
  - Bowel and Urine Monitoring
  - true
  - NCI_51
- - NC_52
  - 8.2.4.2
  - true
  - Intake Monitoring
  - true
  - NCI_52
- - NC_53
  - 8.2.5
  - true
  - Suicidal Ideation and Behavior Risk Monitoring
  - true
  - NCI_53
- - NC_54
  - 8.2.6
  - true
  - Pregnancy
  - true
  - NCI_54
- - NC_55
  - 8.3.
  - true
  - Adverse Events and Serious Adverse Events
  - true
  - NCI_55
- - NC_56
  - 8.3.1
  - true
  - Time Period and Frequency for Collecting AE and SAE Information
  - true
  - NCI_56
- - NC_57
  - 8.3.2
  - true
  - Method of Detecting AEs and SAEs
  - true
  - NCI_57
- - NC_58
  - 8.3.3
  - true
  - Follow-up of AEs and SAEs
  - true
  - NCI_58
- - NC_59
  - 8.3.4
  - true
  - Regulatory Reporting Requirements for SAEs
  - true
  - NCI_59
- - NC_60
  - 8.3.5
  - true
  - Adverse Events of Special Interest
  - true
  - NCI_60
- - NC_61
  - 8.3.6
  - true
  - Retained and Biobanked Sample
  - true
  - NCI_61
- - NC_62
  - '8.4'
  - true
  - Treatment of Overdose
  - true
  - NCI_62
- - NC_63
  - '8.5'
  - true
  - Pharmacokinetics
  - true
  - NCI_63
- - NC_64
  - 8.6.
  - true
  - Pharmacodynamics
  - true
  - NCI_64
- - NC_65
  - 8.7.
  - true
  - Genetics
  - true
  - NCI_65
- - NC_66
  - 8.8.
  - true
  - Biomarkers
  - true
  - NCI_66
- - NC_67
  - 8.9.
  - true
  - Immunogenicity Assessments
  - true
  - NCI_67
- - NC_68
  - 8.10.
  - true
  - Health Economics Data and/or Medical Resource Utilization
  - true
  - NCI_68
- - NC_69
  - '9.'
  - true
  - STATISTICAL CONSIDERATIONS
  - true
  - NCI_69
- - NC_70
  - '9.1'
  - true
  - Statistical Hypotheses
  - true
  - NCI_70
- - NC_71
  - 9.1.1
  - true
  - Primary Hypothesis
  - true
  - NCI_71
- - NC_72
  - 9.2.
  - true
  - Sample Size Determination
  - true
  - NCI_72
- - NC_73
  - 9.3.
  - true
  - Populations for Analyses
  - true
  - NCI_73
- - NC_74
  - 9.4.
  - true
  - Statistical Analyses
  - true
  - NCI_74
- - NC_75
  - 9.4.1
  - true
  - Primary Analysis
  - true
  - NCI_75
- - NC_76
  - 9.4.2
  - true
  - Secondary Analyses
  - true
  - NCI_76
- - NC_77
  - 9.4.3
  - true
  - Safety Analysis
  - true
  - NCI_77
- - NC_78
  - 9.4.4
  - true
  - Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses
  - true
  - NCI_78
- - NC_79
  - 9.5.
  - true
  - Interim Analyses
  - true
  - NCI_79
- - NC_80
  - 9.6.
  - true
  - Data Monitoring Committee
  - true
  - NCI_80
- - NC_81
  - 9.7.
  - true
  - Safety Review Committee (SRC)
  - true
  - NCI_81
- - NC_82
  - '10.'
  - true
  - SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
  - true
  - NCI_82
- - NC_83
  - 10.1.
  - true
  - Regulatory, Ethical, and Study Oversight Considerations
  - true
  - NCI_83
- - NC_84
  - 10.1.1
  - true
  - Regulatory and Ethical Considerations
  - true
  - NCI_84
- - NC_85
  - 10.1.2
  - true
  - Financial Disclosure
  - true
  - NCI_85
- - NC_86
  - 10.1.3
  - true
  - Informed Consent Process
  - true
  - NCI_86
- - NC_87
  - 10.1.4
  - true
  - Data Protection
  - true
  - NCI_87
- - NC_88
  - 10.1.5
  - true
  - Dissemination of Clinical Study Data
  - true
  - NCI_88
- - NC_89
  - 10.1.6
  - true
  - Data Quality Assurance
  - true
  - NCI_89
- - NC_90
  - 10.1.7
  - true
  - Source Documents
  - true
  - NCI_90
- - NC_91
  - 10.1.8
  - true
  - Study and Site Start and Closure
  - true
  - NCI_91
- - NC_92
  - 10.1.9
  - true
  - Publication Policy
  - true
  - NCI_92
- - NC_93
  - 10.2.
  - true
  - Clinical Laboratory Tests
  - true
  - NCI_93
- - NC_94
  - 10.3.
  - true
  - "Adverse Events: Definitions and Procedures for Recording, \nEvaluating, Follow-up,\
    \ and Reporting"
  - true
  - NCI_94
- - NC_95
  - 10.3.1
  - true
  - Definition of AE
  - true
  - NCI_95
- - NC_96
  - 10.3.2
  - true
  - Definition of SAE
  - true
  - NCI_96
- - NC_97
  - 10.3.3
  - true
  - Recording and Follow-Up of AE and/or SAE
  - true
  - NCI_97
- - NC_98
  - 10.3.4
  - true
  - Reporting of SAEs
  - true
  - NCI_98
- - NC_99
  - 10.4.
  - true
  - Contraceptive Guidance and Collection of Pregnancy Information
  - true
  - NCI_99
- - NC_100
  - 10.4.1
  - true
  - Definitions and Contraceptive Guidance
  - true
  - NCI_100
- - NC_101
  - 10.4.2
  - true
  - Collection of Pregnancy Information
  - true
  - NCI_101
- - NC_102
  - 10.5.
  - true
  - COVID-19 Vaccine Risk Assessment
  - true
  - NCI_102
- - NC_103
  - 10.6.
  - true
  - Abbreviations
  - true
  - NCI_103
- - NC_104
  - 10.7.
  - true
  - Protocol Amendment History
  - true
  - NCI_104
- - NC_105
  - '11.'
  - true
  - REFERENCES
  - true
  - NCI_105
documentContent:
- - NCI_1
  - '<div xmlns="http://www.w3.org/1999/xhtml"><div class="container">

    <div class="row mt-5">

    <div class="col-md-10 offset-md-1 text-center">

    <p><b>TITLE PAGE</b></p>

    </div>

    </div>

    </div>

    <p><b>Protocol Title: </b><usdm:ref attribute="text" id="StudyTitle_2" klass="StudyTitle"></usdm:ref></p>

    <p><b>Protocol Number: </b><usdm:ref attribute="text" id="StudyIdentifier_1" klass="StudyIdentifier"></usdm:ref></p>

    <p><b>Amendment Number: </b>TBD</p>

    <p><b>Compound: </b>TBD</p>

    <p><b>Study Phase: </b><usdm:ref attribute="decode" id="Code_365" klass="Code"></usdm:ref></p>

    <p><b>Short Title: </b><usdm:ref attribute="text" id="StudyTitle_1" klass="StudyTitle"></usdm:ref></p>

    <p><b>Sponsor Name: </b><usdm:ref attribute="label" id="Organization_1" klass="Organization"></usdm:ref>,
    <usdm:ref attribute="text" id="Address_1" klass="Address"></usdm:ref></p>

    <p><b>Legal Registered Address:</b><usdm:ref attribute="label" id="Organization_1"
    klass="Organization"></usdm:ref>, <usdm:ref attribute="text" id="Address_1" klass="Address"></usdm:ref></p>

    <p><b>Regulatory Agency Identifier Number(s)</b></p>

    <p><usdm:ref attribute="text" id="StudyIdentifier_2" klass="StudyIdentifier"></usdm:ref>,
    <usdm:ref attribute="text" id="StudyIdentifier_3" klass="StudyIdentifier"></usdm:ref>,
    <usdm:ref attribute="text" id="StudyIdentifier_4" klass="StudyIdentifier"></usdm:ref></p>

    <b>Approval Date:</b>

    <p><b><usdm:ref attribute="label" id="GovernanceDate_1" klass="GovernanceDate"></usdm:ref>
    <usdm:ref attribute="dateValue" id="GovernanceDate_1" klass="GovernanceDate"></usdm:ref></b></p>

    <p><b>Amendment 1 18 Aug 2020</b></p>

    <p><b>Amendment 2 19 Mar 2021</b></p>

    <p><b>Amendment 3 31 Aug 2021</b></p>

    <p><b>Amendment 3.1 (US) 18 Mar 2022</b></p>

    <p><b>Sponsor Signatory:</b></p>

    <div class="container">

    <div class="row mt-5">

    <div class="col-md-6">

    <p>____________________________________</p>

    </div>

    <div class="col-md-6">

    <p>____________________________________</p>

    <p><b>Date</b></p>

    </div>

    </div>

    </div>

    <p><b>Medical Monitor Name and Contact Information can be found in the Study Contact
    List.</b></p>

    <div class="container">

    <div class="row mt-5">

    <div class="col-md-10 offset-md-1 text-center">

    <p>INVESTIGATOR''S AGREEMENT</p>

    </div>

    </div>

    </div>

    <p>I have read the study protocol amendment 3.1 and agree to conduct the study
    in accordance with this protocol, all applicable government regulations, the principles
    of the ICH E6 Guidelines for Good Clinical Practice, and the principles of the
    World Medical Association Declaration of Helsinki. I also agree to maintain the
    confidentiality of all information received or developed in connection with this
    protocol.</p>

    <p>____________________________________</p>

    <p>Printed Name of Investigator</p>

    <p>_____________________________________</p>

    <p>Signature of Investigator</p>

    <p>_______________</p>

    <p>Date</p>

    <p><b>PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE</b></p>

    <p><b>Amendment 3.1 (US), 18 Mar 2022</b></p>

    <p>This amendment is considered to be substantial based on the criteria set forth
    in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council
    of the European Union, the US Food and Drug Administration''s (FDA) regulation
    at 21 CFR part 312.30(b), and any applicable local regulations.</p>

    <p><b>Overall Rationale for the Amendment</b></p>

    <p>The main reason for preparation of this amendment was to clarify study procedures
    occurring across different sites in the US, so as to facilitate participant recruitment
    across different regions of the US, and to lessen inconvenience for participants
    without compromising the quality of the study.</p>

    <p><b>Changes to the Protocol</b></p>

    <table class="table align-top table-bordered">

    <tr>

    <th>Section # and Name</th>

    <th>Description of Change</th>

    <th>Brief Rationale and/or Clarifications</th>

    </tr>

    <tr>

    <td><p>Section 1.3 Schedule of Activities (SoA), Table 1</p></td>

    <td><p>Addition of text to the footnote to state that procedures specific to screening
    sites (only in the US) detailed in Section 8</p></td>

    <td><p>As per Section 8 (below).</p></td>

    </tr>

    <tr>

    <td><p>4.2 Scientific Rationale for Study Design</p></td>

    <td><p>Number of days changed from 30 days to 21 days in the following sentence:</p>

    <ul><li><p>However, the physiologic turnover of human gastrointestinal epithelial
    cells is 3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc
    on intestinal copper absorption is expected to be minimal <del>30</del> <ins>21</ins>
    days after discontinuation of zinc.</p></li></ul></td>

    <td><p>To align the number of days with the mention of zinc discontinuation elsewhere
    in the protocol.</p></td>

    </tr>

    <tr>

    <td><p>Section 8 Study Assessments and Procedures</p></td>

    <td><p>Addition of text applicable only to the US that details the possibility
    for sites in the US to only perform screening procedures and not any of the remaining
    study procedures.</p></td>

    <td><p>To facilitate participant recruitment across different regions of the US
    and to lessen inconvenience for participants without compromising the quality
    of the study.</p></td>

    </tr>

    </table></div>'
- - NCI_2
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_3
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Protocol Title: </b><usdm:ref\
    \ attribute=\"text\" id=\"StudyTitle_2\" klass=\"StudyTitle\"></usdm:ref>\n<p><b>Short\
    \ Title: </b><usdm:ref attribute=\"text\" id=\"StudyTitle_1\" klass=\"StudyTitle\"\
    ></usdm:ref></p>\n<p><b>Rationale: </b><usdm:ref attribute=\"rationale\" id=\"\
    StudyVersion_1\" klass=\"StudyVersion\"></usdm:ref></p>\n<p><b>Objectives and\
    \ Endpoints</b></p>\n<table \"=\"\" class=\"table align-top\">\n<tr>\n<th>Objectives</th>\n\
    <th>Endpoints</th>\n</tr>\n<tr>\n<td>\n<p><b>Primary</b></p>\n<p>\n<usdm:ref attribute=\"\
    text\" id=\"Objective_1\" klass=\"Objective\"></usdm:ref>\n</p>\n</td>\n<td>\n\
    <p>\n<usdm:ref attribute=\"text\" id=\"Endpoint_1\" klass=\"Endpoint\"></usdm:ref>\n\
    </p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Secondary</b></p>\n<p><usdm:ref attribute=\"\
    text\" id=\"Objective_2\" klass=\"Objective\"></usdm:ref></p>\n</td>\n<td>\n<p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_2\" klass=\"Endpoint\"></usdm:ref></p>\n</td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_3\" klass=\"Objective\"\
    ></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_3\" klass=\"\
    Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\"\
    \ id=\"Objective_4\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_4\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_5\" klass=\"Objective\"\
    ></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_5\" klass=\"\
    Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\"\
    \ id=\"Objective_6\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_6\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_7\" klass=\"Objective\"\
    ></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_7\" klass=\"\
    Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td>\n<p><b>Safety</b></p>\n<p><usdm:ref\
    \ attribute=\"text\" id=\"Objective_8\" klass=\"Objective\"></usdm:ref></p>\n\
    </td>\n<td>\n<p>Safety parameters:</p>\n<p><usdm:ref attribute=\"text\" id=\"\
    Endpoint_8\" klass=\"Endpoint\"></usdm:ref></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Exploratory</b></p>\n\
    <p><usdm:ref attribute=\"text\" id=\"Objective_9\" klass=\"Objective\"></usdm:ref></p>\n\
    </td>\n<td>\n<p><usdm:ref attribute=\"text\" id=\"Endpoint_9\" klass=\"Endpoint\"\
    ></usdm:ref></p>\n</td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"\
    Objective_10\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"\
    text\" id=\"Endpoint_10\" klass=\"Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n\
    <td><p><usdm:ref attribute=\"text\" id=\"Objective_11\" klass=\"Objective\"></usdm:ref></p></td>\n\
    <td><p><usdm:ref attribute=\"text\" id=\"Endpoint_11\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_12\" klass=\"\
    Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_12\"\
    \ klass=\"Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"\
    text\" id=\"Objective_13\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_13\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_14\" klass=\"\
    Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_14\"\
    \ klass=\"Endpoint\"></usdm:ref></p></td>\n</tr>\n</table>\n<p>Note: The accumulation\
    \ period refers to time from initiation of ALXN1840 (Day 1) to expected steady\
    \ state at Day 10, based on 5 times the half-life of 2 days.</p>\n<p><b>Overall\
    \ Design</b></p>\n<p>This is a single-arm, open-label, repeat-dose study to evaluate\
    \ the effects of ALXN1840 administration on copper balance in participants with\
    \ WD. The safety and tolerability of ALXN1840 in participants with WD will also\
    \ be assessed. ALXN1840 PK in plasma as measured via total molybdenum and plasma\
    \ ultrafiltrate (PUF) molybdenum will be determined after repeated dosing along\
    \ with total molybdenum mass balance at steady state.</p>\n<p><b>Disclosure Statement</b>:\
    \ This is an open-label, 3-period study with 1 arm.</p>\n<p><b>Number of Participants:</b></p>\n\
    <p>The sample size will be approximately 10 participants which will allow a general\
    \ characterization of copper balance in response to ALXN1840.</p>\n<p><b><u>Note</u>:</b>\
    \ \u201CEnrolled\u201D means all participants who sign the informed consent form\
    \ (ICF), are eligible for the study, and are registered on Day -7 when participants\
    \ are assigned a participant number.</p>\n<p><b>Intervention Groups and Duration:</b></p>\n\
    <p>Treatment-experienced (which includes standard of care therapies or ALXN1840)\
    \ and treatment-na\xEFve participants are eligible for this study. Following screening\
    \ and enrollment, participants will have a Run-in Period to support diet equilibration\
    \ (Day -7 through Day -5) and measurement of pretreatment copper and molybdenum\
    \ balance (Day -4 through Day -1). Following the Run-in Period, participants will\
    \ be administered ALXN1840 at 15 mg/day for a treatment period of approximately\
    \ 28 days followed by titration up to 30 mg/day on Day 29. Before titration to\
    \ 30 mg/day, the Safety Review Committee (SRC) will review available safety data\
    \ through Day 23 for each participant.</p>\n<p>Participants will have intake and\
    \ output collection periods from Day -4 through Day -1, from Day 1 through Day\
    \ 8 (initial 15 mg/day collection period), and Day 25 through Day 39. The collection\
    \ periods will support an assessment of both copper and molybdenum balance (as\
    \ a measure of ALXN1840 ADME) at the 15 mg/day and 30 mg/day doses and will allow\
    \ assessment of the effects of duration of treatment on copper elimination and\
    \ copper balance</p>\n<p>Participants may be discharged from the clinical research\
    \ unit (CRU) on Day 9 to return on Day 22 or Day 23 (predose); all procedures\
    \ will start on Day 23. To ensure flexibility, the Outpatient Period during Treatment\
    \ Period 1 may be extended up to an additional 14 days with Investigator approval.\
    \ In this situation, participants will be given additional investigational product\
    \ to support daily dosing throughout the Outpatient Period. In such cases, the\
    \ actual Outpatient Period</p>\n<p>duration will be recorded and the participant\
    \ will continue Inpatient Period 2 at Day 23. During the Outpatient Period, participants\
    \ will use SMS text messaging to confirm study intervention administration. At\
    \ the CRU's discretion, participants may remain in the CRU during the outpatient\
    \ period for safety or to maintain the integrity of the conduct of the study.</p>\n\
    <p><b>Safety Review Committee:</b></p>\n<p>A Safety Review Committee (SRC), composed\
    \ of a minimum of the Investigator, Alexion Medical Monitor, and Alexion Safety\
    \ Physician, will meet at the end of 15 mg/day dosing to confirm proceeding to\
    \ 30 mg/day and as necessary based on any emerging safety concerns.</p></p></div>"
- - NCI_4
  - '<div xmlns="http://www.w3.org/1999/xhtml"><b>Figure 1: Study Schematic</b>

    <img alt="Alt text" src="data:image/png;base64,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'
- - NCI_5
  - '<div xmlns="http://www.w3.org/1999/xhtml"><div class="page soa-page table-responsive"><p><b>Timeline:
    Main Timeline, Potential subject identified</b></p><table class="table table-bordered
    table-sm" style="width:100%"><tr><td><p class="soa-activity-text"></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_1" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_1" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_4" klass="StudyEpoch"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="Encounter_1" klass="Encounter"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Encounter_2" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_3" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_4" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="Encounter_5" klass="Encounter"></usdm:ref></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_6" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_7" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_8" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_9" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_10" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_11" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_12" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_13" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_14" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_15" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_16" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_17" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_18" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_19" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_20" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_21" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_22" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_23" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_24" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_25" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_26" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_27" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_28" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_29" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_30" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_31" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_32" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_33" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_34" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_35" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_36" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_37" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_38" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_39" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_40" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_41" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_42" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_43" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_44" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_45" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_46" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_47" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_48" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_49" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_50" klass="Encounter"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="Timing_1" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_2" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_3" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_4" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_5" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_6" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_7" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_8" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_9" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_10" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_11" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_12" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_13" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_14" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_15" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_16" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_17" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_18" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_19" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_20" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_21" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_22" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_23" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_24" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_25" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_26" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_27" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_28" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_29" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_30" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_31" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_32" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_33" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_34" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_35" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_36" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_37" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_38" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_39" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_40" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_41" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_42" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_43" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_44" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_45" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_46" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_47" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_48" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_49" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_50" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_51" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_52" klass="Timing"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="windowLabel"
    id="Timing_1" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="windowLabel" id="Timing_2" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_3" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_4" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_5" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_6" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_7" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_8" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_9" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_10" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_11" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_12" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_13" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_14" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_15" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_16" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_17" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_18" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_19" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_20" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_21" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_22" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_23" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_24" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_25" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_26" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_27" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_28" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_29" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_30" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_31" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_32" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_33" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_34" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_35" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_36" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_37" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_38" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_39" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_40" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_41" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_42" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_43" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_44" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_45" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_46" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_47" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_48" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_49" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_50" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_51" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_52" klass="Timing"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"><usdm:ref attribute="label" id="Activity_1" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text">X</p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td></tr><tr><td><p class="soa-activity-text"><usdm:ref
    attribute="label" id="Activity_2" klass="Activity"></usdm:ref><sup>1</sup></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text">X</p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text">X</p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td></tr><tr><td><p class="soa-activity-text"><usdm:ref
    attribute="label" id="Activity_3" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text">X<sup>2</sup></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text">X<sup>3</sup></p></td><td><p class="soa-body-text"></p></td></tr><tr><td><p
    class="soa-activity-text"><usdm:ref attribute="label" id="Activity_4" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text">X<sup>4</sup></p></td><td><p class="soa-body-text">X<sup>5</sup></p></td><td><p
    class="soa-body-text">X<sup>6</sup></p></td><td><p class="soa-body-text">X<sup>7</sup></p></td><td><p
    class="soa-body-text">X<sup>8</sup></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td></tr><tr><td><p class="soa-activity-text"><usdm:ref
    attribute="label" id="Activity_5" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text">X</p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text">X</p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text">X</p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p cla'
- - NCI_6
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>ALXN1840 (bis-choline tetrathiomolybdate;
    formerly known as WTX101) is a novel copper binding agent in development for the
    treatment of WD.</p></div>
- - NCI_7
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The principal aim of this exploratory\
    \ study is to investigate the effects of ALXN1840 on copper balance in participants\
    \ with WD. The study will specifically evaluate the effects of 2 different ALXN1840\
    \ dose levels as well as the duration of treatment on copper balance to further\
    \ elucidate the dose response of \u201Cdecoppering\u201D versus \u201Cmaintenance\u201D\
    \ dose in participants with WD.</p>\n<p>ALXN1840 contains the active anion tetrathiomolybdate\
    \ and has been shown to cause negative copper balance when administered to healthy\
    \ animals as well as decopper the liver in animal models of WD (Mills, 1981; Czachor,\
    \ 2002). In Study WTX101-201, which assessed the safety and efficacy of ALXN1840\
    \ in participants with WD, ALXN1840 demonstrated enhanced copper control as measured\
    \ by reduced plasma NCCcorrected for the stable tetrathiomolybdatecopper-albumin\
    \ TPC (Weiss, 2017).</p>\n<p>Depletion of copper by ALXN1840 has been shown to\
    \ occur primarily through fecal elimination in both healthy and WD animal models.\
    \ Sheep injected with 30 mg/day of tetrathiomolybdate for 5 days were shown to\
    \ have an elevation of fecal copper during the treatment period increasing from\
    \ a baseline of approximately 3 mg/day up to approximately 7 mg/day during the\
    \ treatment period, before returning to baseline concentrations (Mason, 1988).\
    \ Similarly, when Long-Evans Cinnamon (LEC) WD model rats were injected intraperitoneally\
    \ with a saline solution of tetrathiomolybdate at a dose of 10 mg/kg body weight\
    \ for 8 consecutive days, the amounts of both copper and molybdenum excreted into\
    \ the feces increased significantly (Ogra, 2000), which may suggest that copper\
    \ is excreted in a complex with tetrathiomolybdate into the feces. While fecal\
    \ copper increases with tetrathiomolybdate, the amount of copper excreted into\
    \ the urine decreased and that of molybdenum increased significantly during treatment\
    \ with tetrathiomolybdate. Molybdenum in the urine was molybdate which does not\
    \ bind copper (data on file). These findings are in line with other studies showing\
    \ enhanced biliary and/or fecal excretion of copper and molybdenum upon administration\
    \ of tetrathiomolybdate in rats and sheep (Komatsu, 2000; Ogra, 1995; Mason, 1988).</p>\n\
    <p>We hypothesize that repeated doses of ALXN1840 may drive a net negative copper\
    \ balance in participants with WD by increasing fecal excretion of copper. In\
    \ this study, copper balance will be calculated as the difference between measured\
    \ copper input in food and drink and measured copper output in urine and feces.\
    \ This method is classically considered the most objective measure of decoppering\
    \ ability with a decoppering agent able to drive a net negative copper balance\
    \ (Hill,1986; Strickland, 1971; Walshe, 1973). The purpose of this study is to\
    \ provide additional descriptive characterization of the effect of ALXN1840 on\
    \ copper balance in participants with WD. Further data obtained may help support\
    \ characterization of a \u201Cdecoppering\u201D versus \u201Cmaintenance\u201D\
    \ dose of ALXN1840, where a decoppering dose would be a dose sufficient to drive\
    \ a net negative copper balance and maintenance would support a more neutral copper\
    \ balance.</p>\n<p>The secondary aim of the study is to characterize the steady-state\
    \ ADME (mass balance) of total molybdenum as a surrogate measure of ALXN1840 disposition\
    \ in participants with WD. To confirm that steady state is adequately characterized\
    \ by the plasma PK, a molybdenum mass balance assessment will be performed on\
    \ Day 25 through Day 28 for the 15 mg/day dose and Day 36 through Day 39 for the\
    \ 30 mg/day dose: if steady state is achieved, molybdenum(out) will equal molybdenum(in).</p></div>"
- - NCI_8
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>ALXN1840 has been selected for\
    \ development in WD due to its improved stability properties over ammonium tetrathiomolybdate,\
    \ which has previously been studied in participants with WD and other indications.\
    \ Ammonium tetrathiomolybdate and bis-choline tetrathiomolybdate nonclinical and\
    \ clinical data reported to date support the efficacy and safety of ALXN1840.</p>\n\
    <p>ALXN1840 rapidly forms stable tetrathiomolybdate-copper-albumin TPCs, which\
    \ stabilize free copper leading to a reduction in the NCC concentrations after\
    \ correction for free copper bound to TPC (NCCcorrected ).</p>\n<p>Studies in\
    \ both healthy and WD animal models showed that treatment with tetrathiomolybdate\
    \ results in removal of copper from the liver. Tetrathiomolybdate administered\
    \ to healthy mice by intraperitoneal injection resulted in a dose-dependent reduction\
    \ in liver copper concentration over a treatment range of 0 - 6 mg/kg/day (human\
    \ equivalent dose [HED] by body surface area [BSA] scaling: 0 - 1 mg/kg/day).\
    \ The results of these studies indicated that only 30% \u2011 40% of copper remained\
    \ after 5 weeks of treatment. Similar liver decoppering (approximately 40% - 60%)\
    \ was also reported in toxic milk mice (a WD animal model) at 5 mg/kg/ day for\
    \ 14 days (HED by BSA scaling: 0.4 mg/kg/day; Mills, 1981; Czachor, 2002). In\
    \ LEC WD model rats, 25 mg/kg/day of ALXN1840 (HED by BSA scaling: 4 mg/kg/day)\
    \ administered by oral gavage for 10 days, resulted in an approximately 50% decrease\
    \ in liver copper concentration. Because ALXN1840 has been shown to have a similar\
    \ mechanism of action in healthy and WD animal models, a mechanism of action study\
    \ in healthy participants is being performed (Study ALXN1840-HV-108) to demonstrate\
    \ that ALXN1840 can result in a change from baseline in copper balance with repeat-dose\
    \ ALXN1840 (30 mg/day) treatment.</p>\n<p>In the Phase 2 proof-of-concept Study\
    \ WTX101-201 in participants with WD, ALXN1840 demonstrated a sustained control\
    \ of free copper as measured by NCCcorrected . Importantly, ALXN1840 treatment\
    \ resulted in improvements in disability and neurologic symptoms as measured by\
    \ the Unified Wilson Disease Rating Scale (UWDRS, Parts II and III) and stabilization\
    \ of liver function (Weiss, 2017). Treatment with ALXN1840 resulted in an acceptable\
    \ safety and tolerability profile when initiated at 15 mg daily with Investigator-driven,\
    \ individual participant titration of dose based on safety, NCCcorrected , and\
    \ symptoms.</p>\n<p>Following single-dose administration of 60 mg ALXN1840, total\
    \ molybdenum peaked at approximately 4.54 hours with a terminal elimination half-life\
    \ measured at approximately 51 hours. In Study WTX101-201, the PK of ALXN1840,\
    \ based on total molybdenum, indicated that exposure in participants with WD at\
    \ a dose of 30 mg appeared consistent with previous results from healthy participants.\
    \ The half-life was estimated to be approximately 24 hours at steady state on\
    \ Days 84 and 168 and was shorter than estimated in previous studies. Based on\
    \ a total molybdenum PK half-life of approximately 24 - 51 hours, total molybdenum\
    \ steady state may conservatively be reached within approximately 10 - 12 days.\
    \ Nevertheless, results (as</p>\n<p>measured by total molybdenum) obtained from\
    \ the ALXN1840 balance study in the LEC WD rat model suggested that approximately\
    \ 30% of a single dose of ALXN1840 remained in the liver by Day 7, indicating\
    \ the possibility of tissue accumulation, particularly in the setting of high\
    \ liver copper concentration (Plitz, 2019).</p>\n<p>If the half-life of ALXN1840\
    \ in liver were longer than that of the systemic compartment, the accumulation\
    \ may not be readily detected in the absence of a longer treatment period and\
    \ with characterization of the terminal elimination period. An alternative approach\
    \ to assessing steady state using total molybdenum PK is to assess whether the\
    \ total molybdenum intake is equal to the total molybdenum output; this approach\
    \ may detect any significant ongoing accumulation in the liver or other tissues.</p>\n\
    <p>Detailed descriptions of the chemistry, pharmacology, efficacy, and safety\
    \ of ALXN1840 are provided in the Investigator's Brochure (IB).</p></div>"
- - NCI_9
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Detailed information about the known
    and expected benefits, risks, and reasonably expected adverse events (AEs) of
    ALXN1840 are presented in the IB. Information about the known or potential risks
    and benefits are detailed in the following sections.</p></div>
- - NCI_10
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Details of the potential risks and
    mitigation strategy are provided in Table 3.</p>

    <p><b>Table 3: Potential Risks and Mitigation Strategy</b></p>

    <table "="" class="table align-top">

    <tr>

    <th>Potential Risk of Clinical Significance</th>

    <th>Summary of Data/Rationale for Risk</th>

    <th>Mitigation Strategy</th>

    </tr>

    <tr>

    <td colspan="3"><b>ALXN1840</b></td>

    </tr>

    <tr>

    <td><p>Dose-dependent elevations in transaminases (ALT and AST)</p></td>

    <td><p>Generally mild to moderate in severity, asymptomatic and reversible with
    dose adjustments were reported, usually after 3 - 6 weeks of treatment.</p>

    <p>Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in
    participants with WD; see the IB.</p></td>

    <td><p>Regular monitoring of liver function tests.</p>

    <p>Dose modification or discontinuation (Section 6.6).</p></td>

    </tr>

    <tr>

    <td><p>Anemia</p></td>

    <td><p>Anemia has been observed in participants with WD, attributed to overtreatment
    and resultant copper depletion; see the IB.</p></td>

    <td><p>Monitoring complete blood count. Dose modification or discontinuation (Section
    6.6).</p></td>

    </tr>

    <tr>

    <td><p>Low white blood cell count (leukopenia, bone marrow toxicity)</p></td>

    <td><p>Leukopenia and bone marrow toxicity (myelosuppression) have been observed
    in participants with WD, attributed to overtreatment and resultant copper depletion.
    Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in participants
    with WD; see the IB.</p></td>

    <td><p>Monitoring of complete blood count. Dose modification or discontinuation
    (Section 6.6).</p></td>

    </tr>

    <tr>

    <td><p>Neurological dysfunction</p></td>

    <td><p>Neurological worsening may occur due to copper mobilization. Peripheral
    neuropathy may be seen with over decoppering; however, symptoms such as myelosuppression
    is typically seen earlier.</p></td>

    <td><p>Regular monitoring for neurologic adverse events. Dose modification or
    discontinuation (Section 6.6).</p></td>

    <tr>

    <td colspan="3"><p><b>Study Procedures</b></p></td>

    </tr>

    <tr>

    <td><p>Risks associated with the study design and procedures</p></td>

    <td><p>Participants will undergo repeated blood draws to measure the PK of the
    study intervention and metabolism. Blood draws may result in ecchymosis, redness,
    and minor pain to the site. On rare occasion, infection or hrombophlebitis can
    occur.</p></td>

    <td><p>Blood draws are optimized for PK. A cannula may be placed to minimize needle
    sticks; however, a catheter may not be left in place for longer than 72 hours
    and should be flushed a minimum of every 8 hours.</p></td>

    </tr></tr></table>

    <p><small>Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase;
    IB = Investigator''s Brochure; PK = pharmacokinetics; WD = Wilson disease.</small></p></div>'
- - NCI_11
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>The COVID-19 pandemic is active at
    the time of this protocol amendment. Given this unique circumstance, specific
    consideration has been given to the potential risks and mitigation measures due
    to COVID-19 vaccine (see Section 10.5).</p></div>
- - NCI_12
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The main objective of effective\
    \ WD treatment is to provide:</p>\n<ul>\n<li><p>Rapid and sustained control of\
    \ copper and mitigation of clinical symptoms of WD through the formation of a\
    \ stable tetrathiomolybdate-copper-albumin TPC. Copper control may prevent tissue\
    \ toxicity, including neurological deterioration that has been reported at the\
    \ initiation of treatment with chelators. This hypothesis is supported by results\
    \ from Study\u202FWTX101-201 in participants with WD (Weiss, 2017).</p></li>\n\
    <li><p>Improved compliance over current chelator therapy through improved tolerability\
    \ and the convenience of a\n implified dosing regimen (once daily) compared to\
    \ current therapeutic options (multiple daily dosing). </p></li>\n</ul>\n<p>Potential\
    \ benefits of study participation for participants include:</p>\n<ul>\n<li><p>Participation\
    \ in a clinical study increases the participant's understanding of the pathophysiology\
    \ and treatment of WD.</p></li>\n<li><p>Removal of total body copper as a definitive\
    \ treatment for WD.</p>\n<li><p>Participants in the study will contribute to improved\
    \ care for other participants with WD in the future.</p></li>\n<ul></ul></li></ul></div>"
- - NCI_13
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Taking into account the measures
    implemented to minimize risk to participants in this study, the potential risks
    identified in association with ALXN1840 are justified by the anticipated benefits
    that may be afforded to participants with WD.</p></div>
- - NCI_14
  - '<div xmlns="http://www.w3.org/1999/xhtml"><table "="" class="table align-top">

    <tr>

    <th>Objectives</th>

    <th>Endpoints</th>

    </tr>

    <tr>

    <td>

    <p><b>Primary</b></p>

    <p>

    <usdm:ref attribute="text" id="Objective_1" klass="Objective"></usdm:ref>

    </p>

    </td>

    <td>

    <p>

    <usdm:ref attribute="text" id="Endpoint_1" klass="Endpoint"></usdm:ref>

    </p>

    </td>

    </tr>

    <tr>

    <td>

    <p><b>Secondary</b></p>

    <p><usdm:ref attribute="text" id="Objective_2" klass="Objective"></usdm:ref></p>

    </td>

    <td>

    <p><usdm:ref attribute="text" id="Endpoint_2" klass="Endpoint"></usdm:ref></p>

    </td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_3" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_3" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_4" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_4" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_5" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_5" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_6" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_6" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_7" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_7" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td>

    <p><b>Safety</b></p>

    <p><usdm:ref attribute="text" id="Objective_8" klass="Objective"></usdm:ref></p>

    </td>

    <td>

    <p>Safety parameters:</p>

    <p><usdm:ref attribute="text" id="Endpoint_8" klass="Endpoint"></usdm:ref></p>

    </td>

    </tr>

    <tr>

    <td>

    <p><b>Exploratory</b></p>

    <p><usdm:ref attribute="text" id="Objective_9" klass="Objective"></usdm:ref></p>

    </td>

    <td>

    <p><usdm:ref attribute="text" id="Endpoint_9" klass="Endpoint"></usdm:ref></p>

    </td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_10" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_10" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_11" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_11" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_12" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_12" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_13" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_13" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_14" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_14" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    </table></div>'
- - NCI_15
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_16
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This study will be conducted as\
    \ an open-label, repeat-dose study to evaluate the effects of ALXN1840 on copper\
    \ balance in participants with WD.</p>\n<p>Treatment-experienced (which includes\
    \ standard of care therapies or ALXN1840) and treatment-na\xEFve participants\
    \ are eligible for this study. Eligible patients will be classified into one of\
    \ two cohorts:</p>\n<ul>\n<li><p>Cohort 1 (treatment experienced): Patients who\
    \ have received WD therapy for &gt; 28 days</p></li>\n<li><p>Cohort 2 (treatment\
    \ na\xEFve): Patients who have received WD therapy for \u2264 28 days</p></li>\n\
    </ul>\n<p>Following screening and enrollment, participants will check-in to the\
    \ CRU on Day -8 for the Run-in Period. The purpose of the Run-in Period is to\
    \ support diet equilibration (Day -7 through Day -5) and measure pretreatment\
    \ copper and molybdenum balance (Day -4 through Day -1). Participants will remain\
    \ on a copper/molybdenum-controlled diet throughout both the Inpatient Period\
    \ 1 (Day -8 to Day 9) and Inpatient Period 2 (Day 23 to Day 40). While not in\
    \ the CRU, participants will be encouraged to adhere to their usual copper-controlled\
    \ diet.</p>\n<p>Participants who are taking copper-chelating therapies (penicillamine\
    \ or trientine) at the time of enrollment will be discontinued from their decoppering\
    \ therapies starting on Day -4 to allow a baseline assessment of copper/molybdenum\
    \ balance prior to ALXN1840 treatment. On Day 1, participants will be initiated\
    \ on 15 mg/day of ALXN1840 for a treatment period of approximately 28 days followed\
    \ by titration up to 30 mg/day on Day 29. Before titration to 30 mg/day, the SRC\
    \ will review available safety data through Day 23 for each participant.</p>\n\
    <p>Participants will have intake and output collection periods from Day -4 through\
    \ Day -1, from Day 1 through Day 8, and Day 25 through Day 39. The collection\
    \ periods will support an assessment of both copper and molybdenum balance (as\
    \ a measure of ALXN1840 ADME) at the 15 mg and 30 mg doses and will allow assessment\
    \ of the effects of duration of treatment on copper elimination and copper balance.</p>\n\
    <p>Collection periods for feces and urine will vary in duration from 3 to 15 days\
    \ to support assessment of both copper and molybdenum balance before and at steady\
    \ state for both 15 mg and 30 mg. Equilibration periods on copper/molybdenum-controlled\
    \ diets will be a minimum of 48 hours. Copper balance will be calculated as the\
    \ mean daily copper balance over each of the 4 collection periods. The interpretation\
    \ of copper balance will be based on the criteria established by Hill,1986 when\
    \ undertaking copper balance studies with zinc treatment. For assessment of ALXN1840\
    \ effect on copper balance, the time period for analysis will take into consideration\
    \ the average bowel transit of approximately 40 hours (male: 33 hours; female:\
    \ 47 hours) (Camilleri, 1986; Metcalf, 1987).</p>\n<p>Throughout the inpatient\
    \ periods, participants will remain on a copper-controlled diet. Meal portions\
    \ will be weighed, and meal sizes will be appropriate to support male and female\
    \ caloric consumption. Participants will be encouraged to complete 100% of all\
    \ meals throughout the inpatient period to support quantification of copper and\
    \ molybdenum intake. If participants are unable to complete the full meal, the\
    \ uneaten portion will be weighed to allow calculation of meal fraction, and copper\
    \ and molybdenum intake will be adjusted based on the fractional intake of the\
    \ meal. In addition to food, fluid intake and type will be measured and recorded\
    \ each day. Samples of all meals and fluids will be sent for bioanalysis to support\
    \ accurate quantification of copper and molybdenum in fluids. In the event that\
    \ items cannot be accurately quantified, items may be balanced during pretreatment\
    \ period and post-treatment period to support the change from baseline assessment.</p>\n\
    <p>During the inpatient collection periods, daily urine will be pooled (24-hour\
    \ collection) with volumes recorded for each 24-hour period; participants will\
    \ be strongly encouraged to void within 2 hours of completion of each 24-hour\
    \ period (ie, dosing time). Stool samples will be individually collected and each\
    \ sample will include a collection date, time, and weight.</p>\n<p>Participants\
    \ may be discharged from the CRU on Day 9 and return on Day 22 or Day 23 (predose);\
    \ all procedures will start on Day 23. To ensure flexibility, the Outpatient Period\
    \ during Treatment Period 1 may be extended up to an additional 14 days with Investigator\
    \ approval. In this situation, participants will be given additional investigational\
    \ product to support daily dosing throughout the Outpatient Period. In such cases,\
    \ the actual Outpatient Period duration will be recorded and the participant will\
    \ continue Inpatient Period 2 at Day 23. During the Outpatient Period, participants\
    \ will use SMS text messaging to confirm study intervention administration. At\
    \ the CRU's discretion, participants may remain in the CRU during the outpatient\
    \ period for safety or to maintain the integrity of the conduct of the study.</p>\n\
    <p>Blood sampling for PK/pharmacodynamic (PD) will occur over the 24-hour dosing\
    \ period on Days 1, 25, 29, and 39. Predose PK samples will be collected at all\
    \ time points during the intake and output collection period to help characterize\
    \ PK during accumulation (Days 1 through 9 for 15 mg and Days 31 through 35 for\
    \ 30 mg) and at steady state (Days 25 through 28 for 15 mg and Days 36 through\
    \ 39 for 30 mg).</p>\n<p>This study incorporates the use of an adaptive design.\
    \ Adaptive features may be implemented at the discretion of the Investigator to\
    \ support conduct of the study. Such adaptive features do not require amendment\
    \ of the protocol. Adaptive features and their limits are described in Table 4.</p>\n\
    <p><b>Table 4. Adaptive Protocol Features</b></p>\n<table \"=\"\" class=\"table\
    \ align-top\">\n<tr>\n<th>Features</th>\n<th>Limits</th>\n</tr>\n<tr>\n<td><p>1.\
    \ Outpatient Period (Day 9 to Day 23) may be extended up to an additional 14 days\
    \ with Investigator approval with adequate supply of study intervention to support\
    \ daily dosing can be provided, and with record of exact duration of Outpatient\
    \ Period is recorded; participants will reinitiate the study on Day 23.</p></td>\n\
    <td><p>\u2022 Not &gt;14 days</p></td>\n</tr>\n<tr>\n<td><p>2. Participants may\
    \ be checked in on Day 22 rather than Day 23 at the Investigator</p></td>\n<td><p>\u2022\
    \ Check-in to clinical research unit allowed 1 day prior discretion.</p></td>\n\
    </tr>\n<tr>\n<td><p>3. In this study, dosing for ALXN1840 will be initiated at\
    \ 15 mg once daily for a minimum of 4 weeks, with an increase to 30 mg after 4\
    \ weeks, unless there are safety concerns that, in the opinion of the Investigator(s)\
    \ and/or \nAlexion, may place participants at undue risk, in which case, patients\
    \ may remain on the 15 mg/day dose for the duration of the study.</p></td>\n<td><p><p>\u2022\
    \ Dose range limit 15 mg every other day to 30 mg/day </p></p></td>\n</tr>\n<tr>\n\
    <td><p>4. The dose should be decreased or interrupted if any of the relevant Dose\
    \ Modification criteria are met (Table 7).</p></td>\n<td><p>\u2022 Dose range\
    \ limit 15 mg every other day to 30 mg/day</p></td>\n</tr>\n</table></div>"
- - NCI_17
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The study is designed as an open-label
    exploratory study to provide a descriptive assessment of copper balance in participants
    with WD, the target population for ALXN1840 therapy. The study is being conducted
    as a repeat-dose study to assess the effect of duration of ALXN1840 treatment
    and the effects of intra-patient dose increase on copper and molybdenum balance
    in participants with WD. The intra-patient dose escalation schedule is similar
    to that employed in the current Phase 3 Study WTX101-301. The similar schedule
    was chosen to characterize the decoppering effects expected early with treatment.
    This study is designed to supplement the mechanism of action study in healthy
    participants (Study ALXN1840-HV-108). While healthy participants are expected
    to be adequate to assess the mechanism of action of ALXN1840, characterization
    of copper balance in the WD population will help to understand if there are differences
    in the magnitude of effect between the 2 populations as this may be important
    to understand the doses that may support a net neutral versus a net negative copper
    balance. Limited nonclinical data on copper elimination with tetrathiomolybdate
    suggested copper excretion may be at least maintained or increased with repeated
    dosing (refer to the current IB).</p>

    <p>Therefore, the duration of the study and multiple collection periods will better
    characterize the pattern of copper elimination over time. Such information may
    be helpful in understanding the decoppering and maintenance phases.</p>

    <p>As the study involves intensive diet control and sampling, the study is planned
    to be conducted in a small number of participants with WD who will be admitted
    to a CRU for 2 inpatient periods. Inpatient Period 1 includes a baseline and initial
    15 mg/day collection period during the accumulation phase followed by an Outpatient
    Period; Inpatient Period 2 with a second collection period to support analysis
    of copper balance at 15 mg/day steady state and a 30 mg/day accumulation and steady
    state.</p>

    <p>During the Outpatient Period, participants will be encouraged to remain on
    a copper-controlled diet; however, to avoid confounding, a diet equilibration
    period is included in each study period. Overall, collection periods are a minimum
    of 3 days and as long as 15 days (which will be subdivided for analyses). Collection
    periods of at least 3 days were used to help minimize the impact of day-to-day
    variability on measurements. In addition, the time period for analysis will take
    into consideration the average bowel transit of approximately 40 hours (male:
    33 hours; female: 47 hours) (Camilleri, 1986; Metcalf, 1987). Because the periods
    are of different lengths, the study will calculate mean daily copper balance.</p>

    <p>While the primary endpoint for the study is an assessment of net copper balance,
    measurement of a pretreatment copper baseline will be helpful to understand the
    magnitude of effect of ALXN1840. To assess the copper baseline during the Inpatient
    Run-in Period, participants will be discontinued from their chelator therapy for
    approximately 4 days prior to initiating ALXN1840. During this period, participants
    will be maintained on a copper-controlled diet to minimize risk to the participants.
    In the Phase 3 study ALXN1840-WD-301, participants discontinue their chelator
    approximately 48 hours prior to initiation of ALXN1840 without reported complications.
    Among participants who discontinue chelator due to intolerance or noncompliance,
    the time from chelator discontinuation to the onset or worsening of symptoms varies
    from as little as 1 or 2 weeks to as long as months or years (Scheinberg, 1987).
    To prevent confounding of the study results, participants must be off zinc therapy
    for a minimum of 21 days prior to Day 1 because zinc works through upregulation
    of metallothionein (MT) in enterocytes resulting in elevation of fecal copper
    excretion. Previously, reports in the literature suggest that it can take up to
    3 weeks or longer for zinc treatment to have an efficacious effect on copper balance
    (Brewer, 1983), so a delayed time to reversal of this effect could also occur.
    However, the physiologic turnover of human gastrointestinal epithelial cells is
    3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc on intestinal
    copper absorption is expected to be minimal 21 days after discontinuation of zinc.</p>

    <p>Following ALXN1840 administration, the active drug moiety tetrathiomolybdate
    rapidly binds copper to form TPC, mostly in the liver and blood, and presents
    as such in the systemic circulation. If TPC is not rapidly formed, tetrathiomolybdate
    spontaneously undergoes serial hydrolysis to form molybdate, the most common form
    of nutrient molybdenum, and is excreted in the urine. Total molybdenum concentration
    has been measured as a surrogate of ALXN1840 PK; however, total molybdenum concentration
    cannot distinguish whether the molybdenum is protein bound (mostly as TPC), free
    active drug as ALXN1840, intermediate hydrolysis products, or molybdate. To better
    characterize the amount of non-TPC-bound drug and its unbound degradation products,
    plasma PUF-molybdenum has also been measured, which represents the free parent
    drug (ALXN1840), short-lived intermediate hydrolysis products, and molybdate,
    which may have originated from the tetrathiomolybdate or from food intake as a
    micronutrient. Total molybdenum PK and free molybdenum PK serve as surrogate measures
    of ALXN1840 PK. To better characterize the ADME of ALXN1840, the PK of both total
    molybdenum and PUF-molybdenum will be characterized and described.</p>

    <p>This study is designed to provide an extensive assessment of copper and molybdenum
    balance over the first 40 days of treatment with ALXN1840 and support a more robust
    understanding of the effects of duration of treatment and dose of ALXN1840 on
    copper balance. Half-life estimates for total molybdenum in Study WTX101-201 were
    reported to be approximately 24 hours at steady state on Days 84 and 168, while
    in healthy participants, total molybdenum half-life was measured closer to 51
    hours. With a half-life within this range, the sample collection periods include
    assessment of copper and molybdenum balance both during accumulation and at steady
    state for both the 15 mg/day and 30 mg/day doses. The study will include both
    intake and output collection as well as PK and copper assessments (ie, ceruloplasmin-bound
    copper and labile bound copper [LBC]) to inform the relationship between balance
    measurements and copper and molybdenum levels in the blood.</p>

    <p>Finally, preclinical data from ALXN1840 ADME study suggest the potential for
    molybdenum accumulation in the liver of participants with WD; therefore, an assessment
    of molybdenum balance will help determine whether steady state has been reached
    as defined by a molybdenum balance of neutral during the collection period. Because
    molybdenum is a necessary micronutrient and serves as a cofactor for a number
    of enzymes and may exist in intracellular stores, small variations in molybdenum
    balance could be due to molybdate rather than ALXN1840.</p></div>'
- - NCI_18
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Not applicable.</p></div>
- - NCI_19
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>ALXN1840 at 60 mg single dose has
    been shown to have an adequate safety profile and be well-tolerated in healthy
    male and female participants in the Phase 1 bioavailability Studies WTX101-101
    and WTX101-102. In addition, preliminary data from Study WTX101-106 have also
    shown ALXN1840 to be well tolerated in healthy Japanese and non-Japanese male
    and female participants at a single dose of 15 mg or 60 mg. While no repeat-dose
    studies have been performed in healthy participants, bis-choline tetrathiomolybdate
    (ALXN1840) has been tested in a range of oncologic indications with a maximum
    tolerated dose of 300 mg/day (Lowndes, 2008).</p>

    <p>In the Phase 2 Study WTX101-201 conducted in participants with WD, the daily
    ALXN1840 doses were 15 mg for 6 (21%) participants, 30 mg for 13 (46%) participants,
    and 60 mg (32%) for 9 participants at Week 24 when the primary endpoint assessment
    was conducted, or at the last dose received for participants with early discontinuation.
    The 15 to 60 mg/day dose range has been demonstrated to be efficacious with a
    favorable safety profile in treating participants with WD (Weiss, 2017). Based
    on these Phase 2 study results, the ongoing Phase 3 Study WTX101-301 in participants
    with WD has been testing the efficacy and safety of ALXN1840 at a dose titration
    range from 15 mg to 60 mg daily with data to date supporting an acceptable safety
    profile.</p>

    <p>Similar to the Phase 2 study, in Study WTX101-301, participants are started
    at a dose of 15 mg/day and, after review of all safety information, participants
    may be titrated up to 30 mg/day after approximately 4 weeks. Based on the results
    of Study WTX101-201, doses ranging from 15 mg/day to 60 mg/day were adequate to
    significantly decrease non-ceruloplasmin corrected copper concentrations corrected
    for TPC (NCCcorrected ) and, in many cases, return the NCC to normal concentrations
    of copper control. Given the robust improvement in copper control, it is hypothesized
    that doses within the 15 to 30 mg/day range will be adequate to drive a net negative
    copper balance. The current study will explore copper balance in response to treatment
    with ALXN1840, with the purpose of informing the dose and dosing duration required
    to result in adequate copper elimination to drive a measurable net negative copper
    balance. Copper balance will be assessed for the 15 mg/day dose at the beginning
    and end of the 15 mg/day treatment period, and at the beginning of the 30 mg/day
    treatment period. Copper balance will be assessed for the 30 mg/day dose at Days
    31 through 35 and Days 36 through 39. The multiple collection periods will support
    assessment of duration of treatment and dose on copper elimination and overall
    copper balance.</p>

    <p>In this study, dosing for ALXN1840 will be initiated at 15 mg once daily for
    a minimum of 4 weeks, with an increase to 30 mg after 4 weeks, unless there are
    safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may
    place participants at undue risk, in which case, participants may remain on the
    15 mg/day dose for the duration of the study. Further dose adjustments will be
    made as appropriate.</p>

    <p>The dose should be decreased or interrupted if any of the relevant Dose Modification
    Criteria are met. Deviation from the dose modification guidelines must be agreed
    with the Alexion Medical Monitor.</p></div>'
- - NCI_20
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>A participant is considered to have
    completed the study if he/she has completed all phases of the study including
    the last scheduled procedure shown in the Schedule of Activities (SoA). The end
    of the study is defined as the date the last participant completes the last visit
    shown in the SoA (Section 1.3).</p></div>
- - NCI_21
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Prospective approval of protocol
    deviations to recruitment and enrollment criteria, also known as protocol waivers
    or exemptions, is not permitted.</p></div>
- - NCI_22
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><i>Age</i></p>\n<usdm:ref attribute=\"\
    identifier\" id=\"EligibilityCriterion_1\" klass=\"EligibilityCriterion\"></usdm:ref>\
    \ <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_1\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<i>Type of Participants and Disease Characteristics</i>\n<usdm:ref\
    \ attribute=\"identifier\" id=\"EligibilityCriterion_2\" klass=\"EligibilityCriterion\"\
    ></usdm:ref> <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_2\" klass=\"\
    EligibilityCriterionItem\"></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"\
    EligibilityCriterion_3\" klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref\
    \ attribute=\"text\" id=\"EligibilityCriterionItem_3\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_4\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_4\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_5\" klass=\"EligibilityCriterion\"\
    ></usdm:ref> <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_5\" klass=\"\
    EligibilityCriterionItem\"></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"\
    EligibilityCriterion_6\" klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref\
    \ attribute=\"text\" id=\"EligibilityCriterionItem_6\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_7\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_7\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_8\" klass=\"EligibilityCriterion\"\
    ></usdm:ref> <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_8\" klass=\"\
    EligibilityCriterionItem\"></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"\
    EligibilityCriterion_9\" klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref\
    \ attribute=\"text\" id=\"EligibilityCriterionItem_9\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_10\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_10\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <p><i>Sex</i></p>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_11\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_11\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <i>Informed Consent</i>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_12\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_12\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <p><b>5.2. Exclusion Criteria</b><span class=\"s22\"><b>x</b></span><span class=\"\
    s20\"><b>c</b></span><span class=\"s37\"><b>l</b></span><span class=\"s19\"><b>u</b></span><span\
    \ class=\"s20\"><b>s</b></span><span class=\"s37\"><b>i</b></span><span class=\"\
    s22\"><b>on</b></span> <span class=\"s21\"><b>C</b></span><span class=\"s20\"\
    ><b>r</b></span><span class=\"s37\"><b>it</b></span><span class=\"s20\"><b>er</b></span><span\
    \ class=\"s37\"><b>i</b></span><span class=\"s22\"><b>a</b></span>\n<i>Medical\
    \ Conditions</i></p>\n<p>1. Decompensated cirrhosis or model for end-stage liver\
    \ disease (MELD) score &gt; 13.</p>\n<p>2. Modified Nazer score &gt; 7 (Dhawan,\
    \ 2005).</p>\n<p>3. Clinically significant gastrointestinal bleed within past\
    \ 3 months.</p>\n<p>4. Alanine aminotransferase (ALT) &gt; 2 \xD7 upper limit\
    \ of normal (ULN).</p>\n<p>5. Marked neurological disease requiring assistance\
    \ with self-care or activities of daily life.</p>\n<p>6. Hemoglobin less than\
    \ lower limit of the reference range for age and sex.</p>\n<p>7. Active infection\
    \ with hepatitis B virus (positive hepatitis B surface antigen) or C virus \n\
    (participants with positive hepatitis C antibody result would require confirmation\
    \ of \nactive disease with a positive hepatitis C polymerase chain reaction test),\
    \ or seropositivity \nfor human immunodeficiency virus (HIV).</p>\n<p>ALXN1840-WD-204</p>\n\
    <p>8. History or presence of/significant history of or current cardiovascular,\
    \ respiratory, hepatic, \nrenal, gastrointestinal, endocrinological, hematological,\
    \ or neurological disorders, or \npsychiatric disorder that in the opinion of\
    \ the Investigator may constitute a risk when \ntaking the study intervention;\
    \ or may interfere with the interpretation of data. \n<i>Prior/Concomitant Therapy</i></p>\n\
    <p>9. Previous treatment with ALXN1840 or other form of tetrathiomolybdate within\
    \ 1 year prior \nto dosing.</p>\n<p>10. Previous treatment with zinc within 21\
    \ days prior to Day 1. \n<i>Prior/Concurrent Clinical Study Experience</i></p>\n\
    <p>11. The use of an experimental or unapproved/unlicensed therapy at the same\
    \ time or within 90 \ndays or 5 half-lives, whichever is longer, prior to the\
    \ Screening Visit. \n<i>Diagnostic Assessments</i></p>\n<p>12. Participants in\
    \ renal failure, defined as in end-stage renal disease on dialysis (chronic kidney\
    \ \ndisease [CKD] stage 5) or creatinine clearance &lt; 30 mL/min (Levey, 2006).\
    \ \n<i>Other Exclusions</i></p>\n<p>13. Pregnant (or females who are planning\
    \ to become pregnant) or breastfeeding females \n(women of childbearing potential\
    \ must have a negative serum pregnancy test result at \nscreening).</p>\n<p>14.\
    \ Known sensitivity to ALXN1840, ALXN1840 excipients (anhydrous dicalcium phosphate,\
    \ \nanhydrous sodium carbonate), or any of the ingredients contained in ALXN1840\
    \ or \nrelated compounds.</p>\n<p>15. In the opinion of the Investigator, the\
    \ participant and/or their legal guardian is likely to be \nnon-compliant or uncooperative\
    \ during the study.</p>\n<p>16. History of illicit drug abuse, history of significant\
    \ alcohol abuse within 1 year prior to the \nScreening Visit, or clinical evidence\
    \ of substance and/or alcohol abuse within the 2 years \nbefore screening. Alcohol\
    \ abuse is defined as regular weekly intake of more than 14 units \n(for both\
    \ males and females), using the following National Health Service (NHS) alcohol\
    \ \ntracker http://www.nhs.uk/Tools/Pages/drinks-tracker.aspx.</p>\n<p>17. Positive\
    \ urine drug toxicology screen at Screening or on Day -8 (cannabinoids will not\
    \ be \ntested).</p>\n<p>18. Alcohol consumption within 48 hours prior to study\
    \ intervention administration or positive \nalcohol breath test at screening or\
    \ on Day -8.</p>\n<p>19. Participants unwilling to consistently complete every\
    \ meal and tolerate a controlled, limited \nmenu for the duration of the study.</p></div>"
- - NCI_23
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><i>Medical Conditions</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_13" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_13" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_14" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_14" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_15" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_15" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_16" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_16" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_17" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_17" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_18" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_18" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_19" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_19" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_20" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_20" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Prior/Concomitant Therapy</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_21" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_21" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_22" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_22" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Prior/Concurrent Clinical Study Experience</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_23" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_23" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Diagnostic Assessments</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_24" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_24" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Other Exclusions</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_25" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_25" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_26" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_26" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_27" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_27" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_28" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_28" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_29" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_29" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_30" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_30" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_31" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_31" klass="EligibilityCriterionItem"></usdm:ref></div>'
- - NCI_24
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Participants must be able and\
    \ willing to adhere to the lifestyle restrictions detailed in Table 5.</p>\n<p><b>Table\
    \ 5: Participant Lifestyle Considerations</b></p>\n<table class=\"table align-top\"\
    >\n<tr>\n<th>Restrictions</th>\n<th>Timeframe Restriction Applies</th>\n<th>Restrictions\
    \ End</th>\n</tr>\n<tr>\n<td>\n<p><b>Food</b><br/>Participants will remain on\
    \ a copper/molybdenum-controlled diet. Standardized copper- and\n        molybdenum-controlled\
    \ meals will be provided. Male participants will receive larger meals than female\n\
    \        participants, with adequate meal size to ensure appropriate daily caloric\
    \ intake. If a participant is unable to\n        eat 100% of the food, the remaining\
    \ food will be weighed and reported in the CRF to support copper/molybdenum\n\
    \        determination as a fraction of the total meal. Participants will be expected\
    \ to fast overnight. During the\n        dosing period, participants will be administered\
    \ ALXN1840 with 240 mL of water each morning; participants must\n        remain\
    \ fasted for a least 2 hours after dose administration.</p>\n</td>\n<td>\n<p>Dietary\
    \ restrictions will remain in place during Inpatient Periods 1 and 2.</p>\n</td>\n\
    <td>\n<p>Participants may return to routine diet after completion of Day 40.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p><b>Fluids</b><br/>All participants will drink water\
    \ from the same large water bottle dispenser. There will be\n        no set maximum\
    \ volume of water that the participants must consume, but there will be a minimal\
    \ volume that they\n        must consume each day (1.5 L). The precise volume\
    \ that each participant consumes will be measured.</p>\n</td>\n<td>\n<p>Water\
    \ restrictions will remain in place during Inpatient Periods 1 and 2.</p>\n</td>\n\
    <td>\n<p>Participants may return to routine fluid intake after completion of Day\
    \ 40.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Alcohol</b></p>\n</td>\n<td>\n<p> 48\
    \ hours before check-in to the CRU (Day -8 and Day 22/23) and until discharge\
    \ on Day 40, and 48 hours before\n        each study Outpatient/Follow-up Visit.</p>\n\
    </td>\n<td>\n<p>Discharge from the CRU and completion of EOS Visit.</p>\n</td>\n\
    </tr>\n<tr>\n<td>\n<p><b>Physical activity</b><br/> Participants will carry out\
    \ daily scheduled light exercise. This is to help\n        encourage\n       \
    \ regular bowel movements and for health benefits to the participants.</p>\n<p>Participants\
    \ must refrain from strenuous activity for 24 hours prior to each study visit\
    \ for the duration of\n        the study.</p>\n</td>\n<td>\n<p>48 hours prior\
    \ to check-in to the CRU (Day -8 and Day 22/23) and until discharge on Day 40.</p>\n\
    </td>\n<td>\n<p>Restrictions end after completion of EOS Visit.</p>\n</td>\n</tr>\n\
    <tr>\n<td>\n<p><b>Concomitant medication</b><br/>\n        Concomitant medication\
    \ guidelines are as per Section 6.5.</p>\n<p>Note: If participants have a medical\
    \ need to take any new medication(s) prescribed to them by a doctor, they\n  \
    \      should follow the medical advice but inform the Investigator as soon as\
    \ possible afterwards. Investigator in\n        consultation with Alexion should\
    \ determine participant's continued suitability to remain in the study.</p>\n\
    </td>\n<td>\n<p>Signing of informed consent until EOS Visit.</p>\n</td>\n<td>\n\
    <p>Restrictions ends after completion of EOS Visit.</p>\n</td>\n</tr>\n<tr>\n\
    <td>\n<p><b>Nonprescription/over-the-counter medication</b><br/> Any nonprescription/over-the-counter\
    \ medication may be\n        taken under the direction of the Investigator. Over-the-counter\
    \ medications may be given if they are not\n        expected to impact the outcome\
    \ of the study. Acetaminophen should be limited to 1000 mg/day. Herbal remedies\n\
    \        must be discontinued at least 7 days prior to first admission until study\
    \ completion.</p>\n</td>\n<td>\n<p>Allowed under direction of Investigator.</p>\n\
    </td>\n<td>\n<p>After the EOS Visit.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>St John's\
    \ wort</b><br/>\n        Any herbal remedy or dietary supplement containing St\
    \ John's wort.</p>\n</td>\n<td>\n<p>2 weeks before the planned first study intervention\
    \ is administered.</p>\n</td>\n<td>\n<p>After EOS Visit.</p>\n</td>\n</tr>\n<tr>\n\
    <td>\n<p><b>Blood and plasma donation</b></p>\n</td>\n<td>\n<p>Blood donation\
    \ or blood loss in excess of 500 mL in the 60 days prior to screening (Section\
    \ 5.2).</p>\n</td>\n<td>\n<p>1 month after EOS Visit.</p>\n</td>\n</tr>\n<tr>\n\
    <td>\n<p><b>Contraception</b><br/>Participants must consistently and correctly\
    \ use one or more of the appropriate\n        contraceptive methods described\
    \ in Section 10.4.</p>\n</td>\n<td>\n<p>Start times for contraceptives vary according\
    \ to method used (see Section 5.1 [inclusion criteria]).</p>\n</td>\n<td>\n<p>See\
    \ Section 10.4.</p>\n</td>\n</tr>\n</table>\n<p><small>Abbreviations: CRF = case\
    \ report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule\
    \ of Activities.</small></p></div>"
- - NCI_25
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Screen failures are defined as participants
    who consent to participate in the clinical study but are not subsequently assigned
    to study intervention. A minimal set of screen failure information is required
    to ensure transparent reporting of screen failure participants to meet the Consolidated
    Standards of Reporting Trials (CONSORT) publishing requirements and to respond
    to queries from regulatory authorities. Minimal information includes demography,
    screen failure details (eg, failed eligibility criteria), and any AEs, including
    any serious adverse events (SAEs) and any related concomitant medication, occurring
    during the Screening Period.</p>

    <p>Individuals who do not meet the criteria for participation in this study (screen
    failure) due to a reason that is expected to resolve or has resolved may be rescreened
    based on discussion and agreement between the Investigator and the Medical Monitor.
    Rescreened participants are not required to reconsent as long as they have signed
    the latest version of the ICF.</p></div>'
- - NCI_26
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Study intervention is defined as
    any investigational intervention(s), marketed product(s), placebo, or medical
    device(s) intended to be administered to a study participant according to the
    study protocol.</p></div>
- - NCI_27
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Details of ALXN1840 administered\
    \ in the study are provided in Table 6.</p>\n<p><b>Table 6: Study Intervention\
    \ Dosage and Mode of Administration</b></p>\n<table class=\"table align-top\"\
    >\n<tr>\n<th>\n<p>Drug Name</p>\n</th>\n<td>\n<p>ALXN1840 (formerly WTX101)</p>\n\
    </td>\n</tr>\n<tr>\n<th>\n<p>Type</p>\n</th>\n<td>\n<p>Drug</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>Dose formulation</p>\n</th>\n<td>\n<p>Tablet</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>Unit dose strength(s)</p>\n</th>\n<td>\n<p>15 mg ALXN1840 containing\
    \ 7.8 mg of tetrathiomolybdic acid</p>\n</td>\n</tr>\n<tr>\n<th>\n<p>Dosage level(s)</p>\n\
    </th>\n<td>\n<p>Repeat doses of 15 mg/day or 30 mg/day (administered as 2 \xD7\
    \ 15 mg ALXN1840 tablets) for 40 days</p>\n</td>\n</tr>\n<tr>\n<th>\n<p>Route\
    \ of administration</p>\n</th>\n<td>\n<p>Oral</p>\n</td>\n</tr>\n<tr>\n<th>\n\
    <p>Use</p>\n</th>\n<td>\n<p> Experimental/study intervention</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>IMP and NIMP</p>\n</th>\n<td>\n<p>IMP</p>\n</td>\n</tr>\n<tr>\n\
    <th>\n<p>Sourcing</p>\n</th>\n<td>\n<p>Provided by Alexion</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>Packaging and labeling</p>\n</th>\n<td>\n<p>ALXN1840 will be provided\
    \ in treatment kits that will each have a unique identification number and be\
    \ packaged\n        and labelled in accordance with all applicable regulatory\
    \ requirements. At a minimum, the treatment kit label\n        will provide the\
    \ following information: Alexion study identification, batch number, directions\
    \ for use, required\n        storage conditions, caution statements (including\
    \ \u201CNew Drug-Limited by Federal Law to Investigational Use\u201D\n       \
    \ language), study identification, and expiry date.</p>\n</td>\n</tr>\n<tr>\n\
    <th>\n<p>Current/former name(s) or alias(es)</p>\n</th>\n<td>\n<p>bis-choline\
    \ tetrathiomolybdate</p>\n</td>\n</tr>\n</table>\n<p><small>Abbreviations: IMP\
    \ = investigational medicinal product; NIMP = noninvestigational medicinal product.</small></p></div>"
- - NCI_28
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ol>\n<li>\n<p>The Investigator or\
    \ designee must confirm appropriate temperature conditions have been maintained\
    \ during transit\n      for all study intervention received and any discrepancies\
    \ are reported and resolved before use of the study\n      intervention.</p>\n\
    <ol type=\"a\">\n<li>\n<p>The ALXN1840 treatment kits should be stored at refrigerated\
    \ conditions, 2\xB0C to 8\xB0C (36\xB0F to 46\xB0F).</p>\n</li>\n</ol>\n</li>\n\
    <li>\n<p>Only participants enrolled in the study may receive the study intervention\
    \ and only\n      authorized site staff may supply or administer the study intervention.\
    \ All study\n      intervention must be stored in a secure, environmentally controlled,\
    \ and monitored\n      (manual or automated) area in accordance with the labeled\
    \ storage conditions with access\n      limited to the Investigator and authorized\
    \ site staff.</p>\n</li>\n<li>\n<p>Authorized site staff will instruct participants\
    \ on study intervention storage and how to\n      correctly dose themselves during\
    \ the Outpatient Period. A sufficient number of kits\n      should be dispensed\
    \ to the participant to cover the need until check-in for Treatment\n      Period\
    \ 2. Participants will return all unused study intervention and empty kits so\
    \ that\n      study drug compliance may be calculated.</p>\n</li>\n<li>\n<p>The\
    \ Investigator and/or qualified delegate (ie, pharmacist) is responsible for study\
    \ intervention accountability,\n      reconciliation, and record maintenance (ie,\
    \ receipt, reconciliation, and final disposition records).</p>\n<ol type=\"a\"\
    >\n<li>\n<p>This responsibility includes the reporting of any product complaints\
    \ to XXXXXXX within 1 business day. A\n          product complaint is\n      \
    \    defined as any written, electronic, or oral communication that alleges deficiencies\
    \ related to the identity,\n          quality, durability, reliability, usability,\
    \ safety, effectiveness, or performance of a product or clinical\n          study\
    \ material and/or its packaging components after it is has been released for distribution\
    \ to an end\n          customer that affects the performance of such product.</p>\n\
    </li>\n</ol>\n</li>\n<li>\n<p>Further guidance and information for the final disposition\
    \ of unused study interventions are provided in the\n      Pharmacy Manual.</p>\n\
    </li>\n</ol></div>"
- - NCI_29
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Blinding and randomization are not
    applicable. This is an open-label study in which all participants are expected
    to receive ALXN1840.</p></div>
- - NCI_30
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>While in the CRU, participants will
    receive study intervention directly from the Investigator or designee, under medical
    supervision. The date and time of each dose administered in the clinic will be
    recorded in the source documents and in the case report form (CRF) (if the CRF
    is not the source document). The dose of study intervention and study participant
    identification will be confirmed at the time of dosing by a member of the study
    site staff other than the person administering the study intervention.</p>

    <p>During the Outpatient Period, participants will use SMS text messaging to confirm
    study intervention administration. Compliance with ALXN1840 during the Outpatient
    Period will be assessed by means of tablet counts of used and partially used treatment
    kits returned to the site by the participant. Any deviation from the prescribed
    dosing regimen including extra doses, missed doses, and drug interruptions will
    be documented in the source documents and CRF.</p>

    <p>Reasons for not following study intervention administration as described in
    the protocol should be clearly recorded in the source documents.</p>

    <p>A record of the number of ALXN1840 tablets dispensed to and taken by each participant
    must be maintained and reconciled with study intervention and compliance records.
    Study intervention start and stop dates, including dates for drug delays and/or
    dose reductions will also be recorded in the CRF.</p></div>'
- - NCI_31
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Any medication or vaccine (including
    over-the-counter or prescription medicines, vitamins, and/or herbal supplements),
    or other specific categories of interest, that the participant is receiving from
    14 days prior to study enrollment (Day -7) until the EOS Visit must be recorded
    along with:</p>

    <ul>

    <li><p>Reason for use</p></li>

    <li><p>Dates of administration including start and end dates</p></li>

    <li><p>Dosage information including dose and frequency</p></li>

    </ul>

    <p>The Medical Monitor should be contacted if there are any questions regarding
    concomitant or prior therapy.</p>

    <p>Medications specific for WD taken at any time prior to the study will also
    be recorded, including ALXN1840 received in a previous clinical study (clinical
    study number and subject ID should be noted).</p></div>'
- - NCI_32
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Paracetamol/acetaminophen\
    \ at doses of a maximum 1000 mg per day is permitted for use \nas an exception\
    \ with the approval of the Investigator.</p></li>\n<li><p>As per the ALXN1840\
    \ IB, in this study, Investigators should use caution in the \ncoadministration\
    \ of drugs known to be substrates of cytochromes 2C9 and 2B6 (CYP2C9 \nand CYP2B6).\
    \ Common substrates of CYP2C9 include ibuprofen, which is permitted in \nthis\
    \ study. The Investigator must use ibuprofen with caution during the conduct of\
    \ the \nstudy, and the ibuprofen dose must not exceed 1200 mg in any 24-hour period.\
    \ Ibuprofen \nmay only be used with approval of the Investigator.</p></li>\n<li><p>Concomitant\
    \ procedures are not allowed unless medically indicated and/or permitted by \n\
    Alexion or the Investigator or delegate.</p></li>\n<li><p>Concomitant medications\
    \ may be used during the study if deemed medically indicated by \nthe Investigator.\
    \ The Investigator or designee will notify Alexion of any AEs requiring \nadministration\
    \ of prescription medication(s) while on study.</p></li>\n</ul></div>"
- - NCI_33
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Participants must abstain from taking
    prescription medications within 14 days or 5 half-lives (whichever is longer)
    of Day -7 or nonprescription drugs (including vitamins and dietary or herbal supplements)
    within 7 days or 5 half-lives (whichever is longer) before Day -7 and until completion
    of the follow-up visit, except as described in Section 6.5.1.</p></div>
- - NCI_34
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Participants will be initiated\
    \ on ALXN1840 at 15 mg once daily and increased to 30 mg once daily on Day 29.\
    \ Specific criteria for dose reduction, temporary interruption of dosing, or restriction\
    \ of dose increases of ALXN1840 are detailed in Table 7. Repeat testing of parameters\
    \ meeting dose modification criteria should follow the instructions in Table 7.\
    \ Results from nonscheduled safety laboratory assessments must be recorded in\
    \ the CRF.</p>\n<p>Alexion should be notified within 24 hours of any laboratory,\
    \ vital sign, electrocardiogram (ECG) abnormality, or AE that are considered of\
    \ clinical concern by the Investigator. Investigators must notify Alexion immediately\
    \ of study intervention discontinuation. The decision to discontinue study intervention\
    \ should not be delayed for causality assessment.</p>\n<p><b>Table 7: ALXN1840\
    \ Dose Modifications for Individual Participants</b></p>\n<table class=\"table\
    \ align-top\">\n<tr>\n<th>Test</th>\n<th>Result</th>\n<th>Conditions</th>\n<th>Action\
    \ with ALXN1840 Dosing</th>\n<th>Changes in Safety Monitoring<sup>a</sup></th>\n\
    <th>Rechallenge<sup>b,c,d</sup></th>\n</tr>\n<tr>\n<td rowspan=\"4\">\n<p>ALT\
    \ </p>\n</td>\n<td>\n<p>&gt;5\xD7 \u2191 from baseline</p>\n</td>\n<td>\n<p>ALT\
    \ above reference range at baseline</p>\n</td>\n<td>Temporary interruption </td>\n\
    <td>\n<p>Contact participant within 48 hours to arrange repeat testing (weekly\
    \ repeat testing)</p>\n</td>\n<td>\n<p>At 15 mg QOD when ALT &lt; 2 \xD7 \u2191\
    \ from baseline.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt; 5 \xD7 ULN</p>\n</td>\n\
    <td>\n<p>ALT within reference range at baseline</p>\n</td>\n<td>\n<p>Temporary\
    \ interruption</p>\n</td>\n<td>\n<p>Contact participant within 48 hours to arrange\
    \ repeat testing (weekly repeat testing)</p>\n</td>\n<td>\n<p>At 15 mg QOD when\
    \ ALT &lt; 2 \xD7 ULN.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;2\xD7 \u2191 from\
    \ baseline&lt;&lt; /p&gt;\n    </p></td>\n<td>\n<p>ALT above reference range at\
    \ baseline</p>\n</td>\n<td>\n<p>Reduce dose to previous dose level if up-titration\
    \ has occurred or reduce dose to 15 mg QOD if on 15 mg QD. No\n        further\
    \ dose \u2191 until resolution of abnormality.</p>\n</td>\n<td>\n<p>Weekly repeat\
    \ testing</p>\n</td>\n<td>\n<p>Not applicable.</p>\n</td>\n</tr>\n<tr>\n<td>\n\
    <p>&gt; 2 \xD7 ULN</p>\n</td>\n<td>\n<p>ALT within reference range at baseline</p>\n\
    </td>\n<td>\n<p>Reduce dose to previous dose level if up-titration has occurred\
    \ or reduce dose to 15 mg QOD if on 15 mg QD. No\n        further dose \u2191\
    \ until resolution of abnormality.</p>\n</td>\n<td>\n<p>Weekly repeat testing\
    \ </p>\n</td>\n<td>\n<p>Not applicable.</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"\
    2\">\n<p>Hemoglobin</p>\n</td>\n<td>\n<p>&lt; 8 g/dL in the absence of bleeding</p>\n\
    </td>\n<td>\n<p>None</p>\n</td>\n<td>\n<p>Temporary interruption </p>\n</td>\n\
    <td>\n<p>Weekly repeat testing </p>\n</td>\n<td>\n<p>At 15 mg QOD when hemoglobin\
    \ and other hematology parameters (neutrophils and platelets) are at baseline\n\
    \        concentration.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt; 30% \u2193 from\
    \ baseline</p>\n</td>\n<td>\n<p>None</p>\n</td>\n<td>\n<p>Reduce dose to previous\
    \ dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15\
    \ mg QD. No\n        further dose \u2191 until resolution of abnormality.</p>\n\
    </td>\n<td>\n<p>Weekly repeat testing</p>\n</td>\n<td>\n<p>Not applicable.</p>\n\
    </td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p>Platelets</p>\n</td>\n<td>\n<p>&lt;\
    \ 30,000 \xB5L</p>\n</td>\n<td>\n<p>None</p>\n</td>\n<td>\n<p>Temporary interruption</p>\n\
    </td>\n<td>\n<p>Weekly repeat testing</p>\n</td>\n<td>\n<p>At 15 mg QOD when platelets\
    \ and other hematology parameters (neutrophils and hemoglobin) are at baseline\n\
    \        concentration.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt; 30% \u2193 from\
    \ baseline</p>\n</td>\n<td>\n<p>Platelets below reference range at baseline</p>\n\
    </td>\n<td>\n<p>Reduce dose to previous dose level if up-titration has occurred\
    \ or reduce dose to 15 mg QOD if on 15 mg QD. No\n        further dose \u2191\
    \ until resolution of abnormality.</p>\n</td>\n<td>\n<p>Weekly repeat testing\
    \ </p>\n</td>\n<td>\n<p>Not applicable.</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"\
    2\">\n<p>Neutrophils</p>\n</td>\n<td>\n<p>&lt; 1.0 \xD7 103 /\xB5L</p>\n</td>\n\
    <td>\n<p>None</p>\n</td>\n<td>\n<p>Temporary interruption</p>\n</td>\n<td>\n<p>Weekly\
    \ repeat testing</p>\n</td>\n<td>\n<p>At 15 mg QOD when neutrophils and other\
    \ hematology parameters (hemoglobin and platelets) are at baseline\n        concentration.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>&gt; 30% \u2193 from baseline</p>\n</td>\n<td>\n\
    <p>Neutrophils below reference range at baseline</p>\n</td>\n<td>\n<p>Reduce dose\
    \ to previous dose level if up-titration has occurred or reduce dose to 15 mg\
    \ QOD if on 15 mg QD. No\n        further dose \u2191 until resolution of abnormality.</p>\n\
    </td>\n<td>\n<p>Weekly repeat testing</p>\n</td>\n<td>\n<p>Not applicable.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Bilirubin</p>\n</td>\n<td>\n<p>&gt; 2 \xD7 ULN</p>\n\
    </td>\n<td>\n<p>Accompanied by ALT &gt; 3 \xD7 ULN, indicative of liver injury</p>\n\
    </td>\n<td>\n<p>Temporary interruption</p>\n</td>\n<td>\n<p>Weekly repeat testing</p>\n\
    </td>\n<td>\n<p>At 15 mg QOD or less frequent, when bilirubin is below ULN. Rechallenge\
    \ under these conditions requires\n        approval of the Alexion Medical Monitor.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Neurological assessment</p>\n</td>\n<td colspan=\"\
    2\">\n<p>Evidence of neurologic worsening by AEs or by neurologic physical exam\
    \ assessment</p>\n</td>\n<td>\n<p>Investigator and Alexion Medical Monitor will\
    \ evaluate the need for dose modification (interruption, increase\n        or\
    \ decrease) based on copper control parameters and relevant clinical data. Rationale\
    \ for dosing decision must\n        be documented in study record and reevaluated\
    \ at the next study visit.</p>\n</td>\n<td>\n<p>All neurologic worsening should\
    \ be documented as AEs and followed up until study completion or resolution of\n\
    \        symptoms.</p>\n</td>\n<td>\n<p>Discuss with the Alexion Medical Monitor.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Psychiatric assessment</p>\n</td>\n<td colspan=\"\
    2\">\n<p>Evidence of clinically significant acute psychiatric worsening which\
    \ may include but not limited to\n        suicidality, acute depression, or psychosis.</p>\n\
    </td>\n<td>\n<p>Investigator and Alexion Medical Monitor will evaluate the need\
    \ for dose modification (interruption, increase\n        or decrease) based on\
    \ copper control parameters and relevant clinical data. Rationale for dosing decision\
    \ must\n        be documented in study record and reevaluated at the next study\
    \ visit.</p>\n</td>\n<td>\n<p>Worsening psychiatric symptoms will be documented\
    \ as adverse events in the eCRF and will be followed until\n        completion\
    \ of the study or resolution of symptoms.</p>\n</td>\n<td>\n<p>Discuss with the\
    \ Alexion Medical Monitor.</p>\n</td>\n</tr>\n</table>\n<p><sup>a</sup> For changes\
    \ in safety monitoring, weekly repeat testing for laboratory parameters can be\
    \ completed by a home healthcare nurse if a routine study visit is not scheduled\
    \ during this time period.</p>\n<p><sup>b</sup> A maximum of 3 rechallenges will\
    \ be allowed. \n<p><sup>c</sup> For rechallenges, participants who were on 15\
    \ mg QOD should be rechallenged at the 15 mg QOD dose.</p>\n<p><sup>d</sup> The\
    \ Investigator, in consultation with the Medical Monitor, may change dose and\
    \ dose frequency in participants who require rechallenge.</p>\n<p><small>Abbreviations:\
    \ AEs = adverse event; ALT = alanine aminotransferase; eCRF = electronic case\
    \ report form; QD = once daily; QOD = every other day; ULN = upper limit of normal.</small></p></p></div>"
- - NCI_35
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Following completion of both inpatient
    periods of the study (ie, Day 40), participants will either:</p>

    <ul>

    <li><p>transition to therapy that was discontinued before enrollment, or</p></li>

    <li><p>transition to other standard of care therapy as directed by the treating
    physician, or</p></li>

    <li><p>at the discretion of the treating physician, consider and request continuation
    of ALXN1840 treatment permissible under local regulations for preapproval access.
    </p></li>

    </ul>

    All participants should return to the CRU for the EOS Visit on Day 54 (+/- 2 days).</div>'
- - NCI_36
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_37
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>In rare instances, it may be necessary
    for a participant to permanently discontinue (definitive discontinuation) the
    study intervention. If the study intervention is definitively discontinued, the
    participant should remain in the study to be evaluated for safety follow-up. See
    the Schedule of Activities (SoA, Section 1.3) for data to be collected at the
    time of discontinuation of study intervention and follow-up and for any further
    evaluations that need to be completed.</p>

    <p>Discontinuation of study intervention for abnormal liver function should be
    considered by the Investigator when a participant meets one of the conditions
    outlined in the Dose Modification criteria (Section 6.6) or if the Investigator
    believes that it is in best interest of the participant.</p>

    <p>If a clinically significant finding is identified (including, but not limited
    to changes from baseline in QT interval corrected using Fridericia''s formula
    [QTcF]) after enrollment, the Investigator or qualified designee will determine
    if the participant can continue in the study and if any change in participant
    management is needed. This review of the ECG printed at the time of collection
    must be documented. Any new clinically relevant finding should be reported as
    an AE.</p>

    <p>Participants must be considered for discontinuation from study intervention
    if any of the following occur during the study:</p>

    <ul>

    <li><p>Serious hypersensitivity reaction;</p></li>

    <li><p>Severe uncontrolled infection;</p></li>

    <li><p>Use of disallowed medication;</p></li>

    <li><p>Pregnancy or planned pregnancy (see Section 8.2.6); or</p></li>

    <li><p>Alexion or the Investigator deems it is necessary for the participant.</p></li>

    </ul>

    <p>See the SoA (Table 1) for samples and data to be collected at the time of study
    intervention discontinuation and follow-up and for any further evaluations that
    need to be completed.</p></div>'
- - NCI_38
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>All efforts should be made to ensure participants are willing to comply
    with study participation prior to conducting the screening procedures. The study
    staff should notify Alexion and their site monitor of all study withdrawals as
    soon as possible. The reason for participant discontinuation must be recorded
    in the source documents and CRF.</p></li>

    <li><p>A participant may withdraw from the study at any time at his/her own request,
    or may be withdrawn at any time at the discretion of the Investigator for safety,
    behavioral, compliance, or administrative reasons.</p></li>

    <li><p>At the time of discontinuation from the study, if possible, an early discontinuation
    visit should be conducted, as shown in the SoA. See SoA (Section 1.3) for data
    to be collected at the time of study discontinuation and follow-up and for any
    further evaluations that need to be completed.</p></li>

    <li><p>The participant will be permanently discontinued both from the study intervention
    and from the study at that time.</p></li>

    <li><p>If the participant withdraws consent for disclosure of future information,
    Alexion may retain and continue to use any data collected before such a withdrawal
    of consent.</p></li>

    <li><p>If a participant withdraws from the study, he/she may request destruction
    of any samples taken and not tested, and the Investigator must document this in
    the site study records. </p></li></ul></div>'
- - NCI_39
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A participant will be considered\
    \ lost to follow-up if he or she repeatedly fails to return for scheduled visits\
    \ and is unable to be contacted by the study site.</p>\n<p>The following actions\
    \ must be taken if a participant fails to return to the clinic for a required\
    \ study visit:</p>\n<ul>\n<li><p>\u2022 The site must attempt to contact the participant\
    \ and reschedule the missed visit as soon as possible and counsel the participant\
    \ on the importance of maintaining the assigned visit schedule and ascertain whether\
    \ or not the participant wishes to and/or should continue in the study.</p></li>\n\
    <li><p>Before a participant is deemed lost to follow-up, the Investigator or designee\
    \ must make every effort to regain contact with the participant (where possible,\
    \ 3 telephone calls and, if necessary, a certified letter to the participant's\
    \ last known mailing address or local equivalent methods). These contact attempts\
    \ should be documented in the participant's medical record.</p></li>\n<li><p>Should\
    \ the participant continue to be unreachable, he/she will be considered to have\
    \ withdrawn from the study.</p></li>\n</ul>\n<p>Discontinuation of specific sites\
    \ or of the study as a whole are handled as part of Section 10.1.8.</p></div>"
- - NCI_40
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Study procedures and\
    \ their timing are summarized in the SoA (Section 1.3). Protocol waivers or exemptions\
    \ are not allowed.</p></li>\n<li><p>Immediate safety concerns should be discussed\
    \ with Alexion immediately upon occurrence or awareness to determine if the participant\
    \ should continue or discontinue study intervention.</p></li>\n<li><p>Adherence\
    \ to the study design requirements, including those specified in the SoA, is essential\
    \ and required for study conduct.</p></li>\n<li><p>All screening evaluations must\
    \ be completed and reviewed to confirm that potential participants meet all eligibility\
    \ criteria. The Investigator will maintain a screening log to record details of\
    \ all participants screened and to confirm eligibility or record reasons for screening\
    \ failure, as applicable.</p></li>\n<li><p>The following only applies to sites\
    \ in the US.</p>\n<ul type=\"a\">\n<li><p>In the US only, it is permissible for\
    \ study visits for individual participants to occur at more than 1 site. Some\
    \ sites may perform screening procedures only and not any of the remaining study\
    \ procedures. These sites will be known as \u201Cscreening sites\u201D. The procedures\
    \ performed at screening sites are defined in the Screening column (Study Days\
    \ -42 to -9 and -21) of the SoA (Section 1.3). Following the completion of screening\
    \ procedures at a screening site, eligible participants will be transferred to\
    \ the CRU, where the remaining study procedures and visits will occur. Site-to-site\
    \ transfer of the participant will be documented accordingly.</p></li>\n</ul>\n\
    </li></ul></div>"
- - NCI_41
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Copper and Molybdenum Balance
    Measurements</b></p>

    <p>Copper and molybdenum balance measurements will be made on all intake (ie,
    investigational agent, food and fluids) and all output (urine and feces) from
    participants as indicated in the SoA. The copper and molybdenum concentration
    of each sample will be determined by inductively coupled plasma mass spectrometry
    (ICP-MS). Copper and molybdenum content of all intake and output will be calculated
    based on the volume or weight of intake and output and the concentration of representative
    samples.</p>

    <p><b>8.1.1.1. Food and Fluid Collection for Copper and Molybdenum Concentrations</b></p>

    <p>Samples of all meal and fluid batches will be collected and analyzed for measurement
    of copper and molybdenum content. A minimum of 3 complete portions/meals from
    each food and liquid batch will be sent for analysis. All participants will drink
    water from the same large water bottle dispenser. Samples of water from this dispenser
    will be collected and analyzed for copper and molybdenum content.</p>

    <p>Samples will be collected, stored and shipped as detailed in the Laboratory
    Manual. All sample handling procedures will be documented in detail in the Laboratory
    Manual. Copper and</p>

    <p>ALXN1840-WD-204</p>

    <p>molybdenum concentration of each food sample (ng/g) and each fluid sample (ng/mL)
    sample will be determined by ICP-MS.</p>

    <p><b>8.1.1.2 . Urine Collection for Measurement of Copper and Molybdenum content</b></p>

    <p>Urine samples to measure copper and molybdenum content will be collected periodically
    as described in the SoA (Table 1). Samples will be collected, stored and shipped
    as detailed in the Laboratory Manual. For each 24-hour collection period, urine
    will be pooled for analysis and volumes will be recorded. All sample handling
    procedures will be documented in detail as described in the Laboratory Manual.
    Copper and molybdenum concentration (ng/mL) of each 24-hour urine sample will
    be determined by ICP-MS.</p>

    <p><b>8.1.1.3 . Fecal Collection for Measurement of Copper and Molybdenum Content</b></p>

    <p>Fecal samples to measure copper and molybdenum content will be collected periodically
    as described in the SoA (Table 1). Samples will be collected, stored, and shipped
    as detailed in the Laboratory Manual. Fecal samples will be individually collected,
    weighed, and stored. The weight and time of each bowel movement will be recorded.
    All sample handling procedures will be documented in detail in the Laboratory
    Manual. Copper and molybdenum concentration (ng/g) of each stool sample will be
    determined by ICP-MS; each sample will be analyzed using a minimum of technical
    triplicates.</p></div>'
- - NCI_42
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Copper and molybdenum balance measurements
    will be made on all intake (ie, investigational agent, food and fluids) and all
    output (urine and feces) from participants as indicated in the SoA. The copper
    and molybdenum concentration of each sample will be determined by inductively
    coupled plasma mass spectrometry (ICP-MS). Copper and molybdenum content of all
    intake and output will be calculated based on the volume or weight of intake and
    output and the concentration of representative samples.</p></div>
- - NCI_43
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Samples of all meal and fluid batches
    will be collected and analyzed for measurement of copper and molybdenum content.
    A minimum of 3 complete portions/meals from each food and liquid batch will be
    sent for analysis. All participants will drink water from the same large water
    bottle dispenser. Samples of water from this dispenser will be collected and analyzed
    for copper and molybdenum content.</p>

    <p>Samples will be collected, stored and shipped as detailed in the Laboratory
    Manual. All sample handling procedures will be documented in detail in the Laboratory
    Manual. Copper and molybdenum concentration of each food sample (ng/g) and each
    fluid sample (ng/mL) sample will be determined by ICP-MS.</p></div>'
- - NCI_44
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Urine samples to measure copper and
    molybdenum content will be collected periodically as described in the SoA (Table
    1). Samples will be collected, stored and shipped as detailed in the Laboratory
    Manual. For each 24-hour collection period, urine will be pooled for analysis
    and volumes will be recorded. All sample handling procedures will be documented
    in detail as described in the Laboratory Manual. Copper and molybdenum concentration
    (ng/mL) of each 24-hour urine sample will be determined by ICP-MS.</p></div>
- - NCI_45
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Fecal samples to measure copper and
    molybdenum content will be collected periodically as described in the SoA (Table
    1). Samples will be collected, stored, and shipped as detailed in the Laboratory
    Manual. Fecal samples will be individually collected, weighed, and stored. The
    weight and time of each bowel movement will be recorded. All sample handling procedures
    will be documented in detail in the Laboratory Manual. Copper and molybdenum concentration
    (ng/g) of each stool sample will be determined by ICP-MS; each sample will be
    analyzed using a minimum of technical triplicates.</p></div>
- - NCI_46
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Planned time points for all safety
    assessments are provided in the SoA (Section 1.3).</p>

    <p>When multiple procedures are scheduled to occur at the same time, the following
    order of events should be strictly adhered to whenever possible: ECG, vital signs,
    blood sampling, study intervention administration, and meal.</p>

    <p>Pharmacokinetic collection should occur as close as possible to the scheduled
    time.</p>

    <p>All routine safety laboratory samples should be drawn following a minimum of
    8 hours fasting.</p></div>'
- - NCI_47
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li><p>A complete physical examination\
    \ will include, at a minimum, assessments of the \ncardiovascular, respiratory,\
    \ gastrointestinal, and neurological systems. Height (at \nScreening only) and\
    \ weight (as per the SoA for physical examinations) will also be \nmeasured and\
    \ recorded. A symptom-driven physical examination may be performed at \nother\
    \ times, at the Principal Investigator's discretion. </p></li></ul></div>"
- - NCI_48
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Body temperature, heart\
    \ rate, respiratory rate, and systolic and diastolic blood pressure (mm Hg) will\
    \ be assessed using consistent methods and equipment to allow comparability and\
    \ reproducibility throughout the study.</p></li>\n<li><p>\u2022 Blood pressure\
    \ and heart rate measurements will be assessed with a completely automated device.\
    \ Manual techniques will be used only if an automated device is not available.</p></li>\n\
    <li><p>\u2022 Blood pressure and heart rate measurements should be preceded by\
    \ at least 5 minutes of rest for the participant in a quiet setting without distractions\
    \ (eg, television, cell phones). Ideally, the same arm for each participant should\
    \ be used for measurements.</p></li>\n<li><p>\u2022 Vital signs will be measured\
    \ in a supine position after 5 minutes rest and will include temperature, systolic\
    \ and diastolic blood pressure, and heart rate. Vital signs will consist of a\
    \ single pulse and blood pressure measurement. If vital signs are abnormal as\
    \ defined by inclusion/ exclusion criteria, 2 additional vital signs measurements\
    \ will be made. The average of the 3 vital signs measurements will be recorded\
    \ in the CRF and used to determine participant eligibility. The average of the\
    \ blood pressure readings will be recorded in the CRF. </p></li>\n</ul></div>"
- - NCI_49
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>\u2022 Triplicate 12-lead\
    \ ECGs will be conducted as outlined in the SoA (see Section 1.3) to obtain heart\
    \ rate, PR, QRS, QT, and QTc intervals. Refer to Section 7 for QTc withdrawal\
    \ criteria and any additional QTc readings that may be necessary. As with vital\
    \ signs, if ECG interval measurements are abnormal, an additional triplicate will\
    \ be performed and recorded in the CRF. </p></li></ul>\n</div>"
- - NCI_50
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>\u2022 See Section 10.2\
    \ for the list of clinical laboratory tests to be performed and to the SoA (Section\
    \ 1.3) for the timing and frequency.</p></li>\n<li><p>\u2022 The Investigator\
    \ must review the laboratory report, document this review, and record any clinically\
    \ relevant changes occurring during the study in the AE section of the CRF. The\
    \ laboratory reports must be filed with the source documents. Clinically significant\
    \ laboratory values are those deemed by the Investigator to be clinically significant\
    \ resulting in further evaluation or treatment or those associated with an AE\
    \ or clinical \nsigns or symptoms.</p></li>\n<li><p>\u2022 All laboratory tests\
    \ with values considered abnormal and clinically significant during participation\
    \ in the study or after the last dose of study intervention should be repeated\
    \ until the values return to normal or baseline or are no longer considered clinically\
    \ significant by the Investigator or Medical Monitor.</p>\n<ul>\n<li><p>If such\
    \ values do not return to normal/baseline within a period of time judged reasonable\
    \ by the Investigator, the etiology should be identified, and Alexion notified.</p></li>\n\
    <li><p>All protocol-required laboratory assessments, as defined in Section 10.2,\
    \ must be conducted in accordance with the laboratory manual and the SoA.</p></li>\n\
    <li><p>All laboratory values from non-protocol-specified laboratory assessments\
    \ must also be recorded in the CRF.</p></li>\n</ul></li></ul></div>"
- - NCI_51
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Participant's bowel movements and
    urination will be monitored by the clinical staff. The clinical staff will record
    in the CRF each time a fecal and urine sample is collected. All urine and feces
    must be collected from Day -4 through Day -1, Day 1 through Day 8, Day 25 through
    Day 39.</p></div>
- - NCI_52
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>To support accurate quantification
    of copper/molybdenum intake, each participant's intake including both food and
    fluids will be monitored and recorded. Following each standardized meal, the clinical
    staff will record 100% completion of each meal including all liquids. If a participant
    is unable to eat 100% of the food for a given meal, the remaining food will be
    weighed and reported in the CRF to support accurate determination of copper/molybdenum
    as a fraction of the total meal. Similarly, if participants do not complete 100%
    of non-water fluids with meal, the remaining volume will be measured and recorded
    in the CRF. In the case of water intake, the staff will record daily water volume
    intake in the CRF.</p></div>
- - NCI_53
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Suicidal ideation and behavioral
    changes will be recorded as adverse events and may, at the discretion of the Investigator,
    result in withdrawal of the participation from the study and urgent referral for
    psychiatric treatment.</p></div>
- - NCI_54
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Pregnancy data from\
    \ female participants and female spouses/partners of male participants \nwill\
    \ be collected from the signing of the ICF and at the time points specified in\
    \ the SoA. \nAny female participant who becomes pregnant while participating in\
    \ the study will be \ndiscontinued from the study intervention. If a pregnancy\
    \ is reported, the Investigator must \nimmediately inform Alexion within 24 hours\
    \ of awareness of the pregnancy and follow \nthe procedures outlined in Section\
    \ 10.4.</p></li>\n<li><p>For all Alexion products, both in development or post\
    \ approval, exposure during \npregnancy must be recorded and the pregnancy followed,\
    \ until the outcome of the \npregnancy is known (ie, spontaneous miscarriage,\
    \ elective termination, normal birth, or \ncongenital abnormality), even if the\
    \ participant discontinues the study intervention or \nwithdraws from the study.\
    \ The corresponding infant must be followed for 3 months \npostpartum.</p></li>\n\
    <li><p>Pregnancy is not considered as an AE (Section 10.4) unless there is a suspicion\
    \ that the \nstudy intervention may have interfered with the effectiveness of\
    \ a contraceptive \nmedication. However, complications of pregnancy and abnormal\
    \ outcomes of pregnancy \nare AEs and may meet the criteria for an SAE (eg, ectopic\
    \ pregnancy, spontaneous \nabortion, intrauterine fetal demise, neonatal death,\
    \ or congenital anomaly) (Section 8.3). \nElective abortions without complications\
    \ should not be reported as AEs.</p></li>\n</ul></div>"
- - NCI_55
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The definitions of AEs and SAEs
    can be found in Section 10.3.</p>

    <p>All AEs will be reported to the Investigator or qualified designee by the participant
    (or, when appropriate, by a caregiver, surrogate, or the participant''s legally
    authorized representative).</p>

    <p>The Investigator and any qualified designees are responsible for detecting,
    documenting, and recording events that meet the definition of an AE or SAE and
    remain responsible for following up AEs that are serious, considered related to
    the study intervention or study procedures, or that caused the participant to
    discontinue the study intervention (see Section 7).</p>

    <p>Procedures for recording, evaluating, follow-up, and reporting AEs and SAEs
    are outlined in Section 10.3.</p></div>'
- - NCI_56
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>All AEs and SAEs will be collected
    from the signing of the ICF until the EOS Visit.</p>

    <p>All SAEs will be recorded and reported to Alexion or the designee immediately
    and under no circumstance should this exceed 24 hours, as indicated in Section
    10.3. The Investigator will submit any updated SAE data to Alexion within 24 hours
    of it being available.</p>

    <p>Investigators are not obligated to actively seek AE or SAE data after conclusion
    of the study participation. However, if the Investigator learns of any SAE, including
    a death, at any time after a participant has been discharged from the study, and
    he/she considers the event to be reasonably related to the study intervention
    or study participation, the Investigator must promptly notify Alexion.</p></div>'
- - NCI_57
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The method of recording, evaluating,
    and assessing causality of AE and SAE and the procedures for completing and transmitting
    SAE reports are provided in Section 10.3.</p>

    <p>Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended
    and non-leading verbal questioning of the participant is the preferred method
    to inquire about AE occurrences.</p></div>'
- - NCI_58
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>After the initial AE/SAE report,
    the Investigator is required to proactively follow up on each participant at subsequent
    visits/contacts. All SAEs will be followed up until resolution, stabilization,
    the event is otherwise explained, or the participant is lost to follow-up (as
    defined in Section 7.3). Further information on follow-up procedures is provided
    in Section 10.3.</p></div>
- - NCI_59
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Prompt notification\
    \ of an SAE by the Investigator to Alexion is essential so that legal obligations\
    \ and ethical responsibilities toward the safety of participants and the safety\
    \ of a study intervention under clinical investigation are met.</p></li>\n<li><p>Alexion\
    \ has a legal responsibility to notify both the local regulatory authority and\
    \ other regulatory agencies about the safety of a study intervention under clinical\
    \ investigation. Alexion will comply with country-specific regulatory requirements\
    \ relating to safety reporting to the regulatory authority, Institutional Review\
    \ Boards (IRBs)/ Independent Ethics Committees (IECs), and Investigators.</p></li>\n\
    <li><p>Suspected unexpected serious adverse reactions (SUSARs) must be reported\
    \ according to local regulatory requirements and Alexion policy and forwarded\
    \ to Investigators as necessary.</p></li>\n<li><p>An Investigator who receives\
    \ an Investigator safety report describing an SAE or other \nspecific safety information\
    \ (eg, summary or listing of SAEs) from Alexion will review and then file it along\
    \ with the IB and will notify the IRB/IEC, if appropriate according to local requirements.\
    \ </p></li>\n</ul></div>"
- - NCI_60
  - <div xmlns="http://www.w3.org/1999/xhtml">There are no adverse events of special
    interest for this study.</div>
- - NCI_61
  - <div xmlns="http://www.w3.org/1999/xhtml">A single biobanked serum sample will
    be collected predose from each participant to serve as a retained sample during
    the study. Samples will remain on site and will be discarded following the completion
    of the clinical study report. The sample will not be used for genetic testing
    (see Section 8.7).</div>
- - NCI_62
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For this study, any dose of ALXN1840\
    \ greater than that specified in the protocol will be considered an overdose.\
    \ </p>\n<p>Alexion does not recommend specific treatment for an overdose. </p>\n\
    <p>Overdoses are medication errors that are not considered AEs unless there is\
    \ an untoward medical occurrence resulting from the overdose. </p>\n<p>In the\
    \ event of an overdose or suspected overdose, the Investigator/treating physician\
    \ should:</p>\n<ol>\n<li><p>Contact the Medical Monitor immediately.</p></li>\n\
    <li><p>Closely monitor the participant for any AE/SAE.</p></li>\n<li><p>Obtain\
    \ a plasma sample for PK analysis if requested by the Medical Monitor (determined\
    \ \non a case-by-case basis).</p></li>\n<li><p>Document the quantity of the excess\
    \ dose as well as the duration of the overdose in the CRF.</p></li>\n</ol>\n<p>Decisions\
    \ regarding dose interruptions or modifications will be made by the Investigator\
    \ in consultation with the Medical Monitor based on the clinical evaluation of\
    \ the participant.</p></div>"
- - NCI_63
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Whole blood samples\
    \ will be collected for the measurement of plasma concentrations of total molybdenum\
    \ and PUF-molybdenum as specified in the SoA (Table 1) via ICP-MS. Samples collected\
    \ within \xB1\u202F10% or 30 min, whichever is less, of the scheduled time will\
    \ not be considered a protocol deviation.</p></li>\n<li><p>Instructions for the\
    \ collection and handling of biological samples will be provided by Alexion. The\
    \ actual date and time (24-hour clock time) of each sample will be recorded.</p></li>\n\
    <li><p>Total molybdenum and PUF-molybdenum are surrogate measures of ALXN1840\
    \ and concentrations will be used to evaluate the PK of ALXN1840. Samples collected\
    \ for analyses of plasma concentrations may also be used to evaluate safety aspects\
    \ related to concerns arising during or after the study.</p></li>\n<li><p>Excess/additional\
    \ samples may be stored for up to 5 years and used for PD and/or diagnostic biomarker\
    \ development and research to understand the pathways associated with the mechanism\
    \ of action of ALXN1840. These samples will not be used for genetic analyses (ie,\
    \ RNA or DNA analyses).</p></li>\n<li><p>Genetic analyses will not be performed\
    \ on these whole blood samples. Participant confidentiality will be maintained.</p></li>\n\
    <li><p>See also Section 8.1.1 for details of molybdenum measured in food, drinks,\
    \ urine, and \nfeces.</p></li>\n</ul></div>"
- - NCI_64
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Plasma total and PUF-copper, ceruloplasmin,
    ceruloplasmin-bound copper, and LBC will be assessed during the study.</p>

    <p>Blood samples will be collected as described in the SoA (Table 1) for plasma
    isolation as per the Laboratory Manual. Plasma samples will be used for ICP-MS
    measurement of total copper and PUF-copper, ceruloplasmin, ceruloplasmin-bound
    copper, and non-ceruloplasmin-bound copper measured via PUF-copper, and/or LBC,
    or assessed via NCC/NCCcorrected methods at the time points indicated in the SoA
    (Table 1).</p></div>'
- - NCI_65
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Genetics will not be evaluated in
    this study.</p></div>
- - NCI_66
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Please see Section 8.6 for details
    of total copper and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and
    non-ceruloplasmin-bound copper as measured via PUF-copper, and/or LBC, or assessed
    via NCC/NCCcorrected methods, and Section 8.1.1 for details of copper measured
    in food, drink, urine, and feces.</p></div>
- - NCI_67
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Not applicable.</p></div>
- - NCI_68
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Health economic and medical resource
    utilization parameters are not evaluated in this study.</p></div>
- - NCI_69
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><b>9.1.1. Primary Hypothesis</b></p>

    <p>ALXN1840-WD-204</p>

    <p>As this study is an exploratory study, no formal hypothesis testing is being
    conducted. Study results will be summarized using descriptive statistics.</p></div>'
- - NCI_70
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><b>9.1.1. Primary Hypothesis</b></p>

    <p>ALXN1840-WD-204</p>

    <p>As this study is an exploratory study, no formal hypothesis testing is being
    conducted. Study results will be summarized using descriptive statistics.</p></div>'
- - NCI_71
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>As this study is an exploratory study,
    no formal hypothesis testing is being conducted. Study results will be summarized
    using descriptive statistics.</p></div>
- - NCI_72
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>The sample size will be approximately
    10 participants which will allow a general characterization of copper balance
    in response to ALXN1840.</p></div>
- - NCI_73
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The population sets used for analysis
    are defined Table 8.</p>

    <p><b>Table 8: Populations for Analysis</b></p>

    <table class="table align-top">

    <tr>

    <td><p>Screened</p></td><td><p>All participants who sign the ICF.</p></td>

    </tr>

    <tr>

    <td><p>Enrolled</p></td><td><p>All participants who sign the ICF, are eligible
    for the study, and are registered on Day -7 when participants are assigned a participant
    number.</p></td>

    </tr>

    <tr>

    <td><p>Safety Analysis Set</p></td><td><p>All participants who receive at least
    1 dose of ALXN1840 treatment</p></td>

    </tr>

    <tr>

    <td><p>Full Analysis Set</p></td><td><p>All participants who receive at least
    1 dose of ALXN1840 treatment.</p></td>

    </tr>

    <tr>

    <td><p>Per Protocol Set</p></td><td><p>All participants who received at least
    1 dose of ALXN1840, had Baseline and all post Baseline values of copper intake
    (in food and drink) and copper output (in feces and urine), and were 100% compliant
    with study drug dosing. Participants with major protocol deviations that are likely
    to impact the primary endpoint analysis will be excluded from the Per Protocol
    (PP) Set. Major protocol deviations, and the PP Set, will be defined, documented,
    and agreed within Alexion prior to database lock.</p></td>

    </tr>

    <tr>

    <td><p>Pharmacokinetic/Pharmacodynamic Analysis Set</p></td>

    <td><p>All participants who have sufficient plasma samples to enable the calculation
    of PK parameters and provide PK/PD profiles.</p></td>

    </tr>

    </table>

    <p><small>Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK
    = pharmacokinetic.</small></p></div>'
- - NCI_74
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Statistical methods described\
    \ in this section will be further elaborated in a separate Statistical Analysis\
    \ Plan (SAP). Summary statistics will be computed and displayed by visit where\
    \ applicable and will be presented by cohort (treatment experienced/treatment\
    \ na\xEFve), and overall Descriptive statistics for continuous variables will\
    \ minimally include the number of participants, mean, standard deviation, minimum,\
    \ median, and maximum. For categorical variables, frequencies, and percentages\
    \ will be presented. Graphical displays will be provided as appropriate.</p>\n\
    <p>Analyses will be performed using the SAS\xAE software Version 9.4 or higher.</p></div>"
- - NCI_75
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The primary objective of this study
    is to demonstrate a net negative copper balance with daily repeat-dose ALXN1840
    treatment (15 mg and 30 mg) in participants with WD.</p>

    <p>The primary analysis will be performed using the Full Analysis Set. Average
    daily copper balance and molybdenum balance will be calculated over the following
    periods:</p>

    <ol>

    <li><p>Day -4 through Day -1 representing predose baseline</p></li>

    <li><p>Days 1 through 8 representing the ALXN1840 15 mg/day accumulation period
    </p></li>

    <li><p>Days 25 through 28 representing the ALXN1840 15 mg/day steady-state period</p></li>

    <li><p>Days 31 through 35, representing the ALXN1840 30 mg/day accumulation period
    </p></li>

    <li><p>Days 36 through 39 representing the ALXN1840 30 mg/day steady-state period</p></li>

    </ol>

    <p>As ALXN1840 is expected to increase copper excretion through fecal excretion,
    copper in stool will be critical for determining copper balance. Because stools
    can be irregular, assessment of copper and molybdenum balance will only include
    data up to the day of the final bowel movement. For example, for the period Day
    1 through Day 8, if the final bowel movement occurs on Day 7, average daily copper
    balance for the Day 1 through Day 8 period will only include data from Day 1 through
    Day 7.</p>

    <p>In the case of the 15 mg/day steady-state period (ie, Day 25 through Day 28),
    stool data collected on Days 29 - 30 samples may be used if needed to support
    assessments for the 15 mg/day dose. Use of these stool data (as needed) are consistent
    with an approximately 2-day gastrointestinal transit time.</p>

    <p>In the case of stool irregularity, and to support assessment of copper output
    over time, bowel movement copper and molybdenum outputs may be averaged over the
    days between bowel movement (or start of study) to ensure an approximate value
    for each 24-hour period.</p></div>'
- - NCI_76
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary analyses will be performed
    using the Full Analysis Set. The secondary continuous endpoints (including copper
    balance, molybdenum balance, and 24-hour urine excretion of copper and molybdenum)
    will be analyzed using the same methods described for the primary analysis.</p></div>
- - NCI_77
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Safety analyses will be performed
    using the Safety Analysis Set.</p>

    <p>Safety analyses will include all AEs, ECGs, clinical laboratory data, physical
    examinations, and vital sign measurements using descriptive statistics.</p>

    <p>No inferential statistical analyses are planned for the safety parameters of
    this study. The incidence of AEs and SAEs will be summarized by System Organ Class
    and Preferred Term for each treatment and overall, and by relationship to study
    intervention. Adverse events will also be summarized by treatment and overall
    by severity. Serious AEs and AEs resulting in withdrawal from the study will be
    listed. Participants having multiple AEs within a category (eg, overall, System
    Organ Class, Preferred Term) will be counted once in that category. For severity
    tables, a participant''s most severe event within a category will be counted.</p>

    <p>Changes from baseline in vital sign measurements and laboratory assessments
    (eg, chemistry, hematology, coagulation, and urinalysis) will be summarized by
    treatment. Laboratory parameter values will be graded according to the National
    Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Shift
    tables by treatment will be produced for these laboratory</p>

    <p>ALXN1840-WD-204</p>

    <p>parameters. These tables will summarize the number of participants with each
    baseline grade relative to the reference ranges and changes to the worst highest
    grade assessed post dose during the study.</p>

    <p>Electrocardiogram parameters will be measured at the specified time points
    as per the SoA (Table 1), including heart rate, PR, RR, QRS, QT, and QTcF intervals.
    The average of the triplicate ECG readings at the time points collected will be
    calculated, and changes from pretreatment baseline values will be assessed by
    each treatment.</p>

    <p>All concomitant medications will be coded and summarized using the World Health
    Organization (WHO) Drug Dictionary.</p></div>'
- - NCI_78
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For PK, PD, and biomarker endpoints,\
    \ analyses will be performed using the PK/PD Analysis Set. The following plasma\
    \ PK parameters will be calculated for total molybdenum and PUF molybdenum (as\
    \ surrogate measures of ALXN1840 PK) using noncompartmental methods with Phoenix\xAE\
    \ WinNonlin\xAE (Certara USA Inc., Princeton, New Jersey) Version 8.0 or higher\
    \ or SAS Version 9.3 or higher (SAS Institute Inc., Cary, North Carolina), as\
    \ applicable. Calculations will be based on the actual sampling times recorded\
    \ during the study.</p>\n<ul>\n<li><p>Time delay between the time of dosing and\
    \ time of appearance of molybdenum concentration (Tlag ) in plasma</p></li>\n\
    <li><p>Maximum observed concentration ( Cmax )</p></li>\n<li><p>Time to maximum\
    \ concentration (tmax )</p></li>\n<li><p>Trough (predose) concentration observed\
    \ at the start of the dosing interval (Ctrough )</p></li>\n<li><p>Area under the\
    \ plasma concentration versus time curve (AUC) from time 0 to the last quantifiable\
    \ concentration (AUCt )</p></li>\n<li><p>AUC over the dosing interval (AUCtau\
    \ )</p></li>\n<li><p>Accumulation ratio (AR) calculated as:</p>\n<p>For 15 mg/day:</p>\n\
    <p>\u2212 C<sub>max,Day25</sub>/C<sub>max,Day1</sub></p>\n<p>\u2212 C<sub>trough,Day26</sub>\
    \ /Ctrough,Day2</p>\n<p>\u2212 AUC<sub>tau,Day25</sub> /AUC<sub> tau,Day1</sub></p>\n\
    <p>For 30 mg/day:</p>\n<p>\u2212 C<sub>max,Day39 </sub>/C <sub>max,Day29,adjusted\
    \ </sub></p>\n<p>\u2212 C<sub>trough,Day40</sub> /C <sub>trough,Day30,adjusted\
    \ </sub></p>\n<p>\u2212 AUC<sub>tau,Day39 </sub>/AUC <sub>tau,Day29,adjusted </sub></p>\n\
    <p>Note: total molybdenum and PUF molybdenum concentration-time profiles on Day\
    \ 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr)\
    \ and subtracted from the observed Day 29 concentration-time profiles after the\
    \ first 30 mg</p>\n<p>ALXN1840 dose for the estimation of the C <sub>max,Day29,adjusted</sub>\
    \ , C <sub>trough,Day30,adjusted</sub> , and AUC <sub>tau,Day29,adjusted</sub>\
    \ .</p></li>\n<li><p>Apparent terminal phase elimination rate constant (\u03BB\
    <sub>z</sub> )</p></li>\n<li><p>Terminal elimination half-life (t<sub>\xBD</sub>\
    \ )</p></li>\n<li><p>Apparent total body clearance (CL/F) of ALXN1840 from plasma</p></li>\n\
    <li><p>Apparent volume of distribution (V<sub>d</sub> /F).</p></li>\n</ul>\n<p>Additional\
    \ plasma PK parameters may be calculated if deemed appropriate.</p>\n<p>Plasma\
    \ concentrations of total molybdenum and PUF molybdenum vs. time data will be\
    \ presented in a data listing by participant. Plasma concentration data will be\
    \ summarized separately by analyte and time point for each treatment by day using\
    \ the following descriptive statistics: number of participants, arithmetic mean,\
    \ geometric mean (GM), SD, coefficient of variation (CV), GMCV, median, minimum,\
    \ and maximum. Mean plasma concentration versus scheduled time profiles will be\
    \ presented in figures on both linear and semilogarithmic scales. Individual plasma\
    \ concentration versus actual time profiles will be presented similarly.</p>\n\
    <p>Pharmacokinetic parameters derived from plasma concentrations of total molybdenum\
    \ and PUF molybdenum will be presented in data listings and summarized separately\
    \ using the following descriptive statistics: number of participants, arithmetic\
    \ mean, GM, SD, arithmetic CV, GMCV, median, minimum, and maximum. Geometric mean\
    \ and geometric CV will be presented for Cmax and AUCs only.</p>\n<p>For PD (total\
    \ and PUF copper and LBC) and biomarker endpoints (ceruloplasmin, ceruloplasmin-bound\
    \ copper), concentration-time data will be listed and summarized with descriptive\
    \ statistics and plotted. The same analyses will be conducted on the absolute\
    \ and percent changes from baseline of these concentration-time data.</p></div>"
- - NCI_79
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Marketing Authorisation Application(s)
    may be submitted before all patients complete the Treatment Periods; therefore,
    interim analyses of safety and efficacy data may be performed to support these
    submissions. These analyses will be descriptive only; they will not include formal
    hypothesis testing and will not be used to adapt the study. Full details will
    be provided in the SAP.</p></div>
- - NCI_80
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>There will not be a Data Monitoring
    Committee, but provision is included for an SRC (Section 9.7).</p></div>
- - NCI_81
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>A SRC, composed of a minimum of the
    Investigator, Alexion Medical Monitor, and Alexion Safety Physician, will meet
    at the end of 15 mg/day dosing to confirm proceeding to 30 mg/day and as necessary
    based on any emerging safety concerns as described in Section 6.6.</p></div>
- - NCI_82
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_83
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_84
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>This study will be conducted\
    \ in accordance with the protocol and with the following:</p>\n<p>\u2212 Consensus\
    \ ethical principles derived from international guidelines including the Declaration\
    \ of Helsinki and Council for International Organizations of Medical Sciences\
    \ (CIOMS) International Ethical Guidelines</p>\n<p>\u2212 Applicable International\
    \ Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines </p>\n\
    <p>\u2212 Applicable laws and regulations </p></li>\n<li><p>The protocol, protocol\
    \ substantial amendments, ICF, IB, and other relevant documents (eg, advertisements)\
    \ must be submitted to an IRB/IEC by the Investigator and reviewed and approved\
    \ by the IRB/IEC before the study is initiated.</p></li>\n<li><p>Any substantial\
    \ amendments to the protocol will require IRB/IEC approval before implementation\
    \ of changes made to the study design, except for changes necessary to eliminate\
    \ an immediate hazard to study participants.</p></li>\n<li><p>The Investigator\
    \ will notify the IRB/IEC of deviations from the study protocol or GCP as defined\
    \ by UK legislation as a serious breach or as required by IRB/IEC procedures.</p></li>\n\
    <li><p>The Investigator will be responsible for the following:</p>\n<p>\u2212\
    \ Providing written summaries of the status of the study to the IRB/IEC annually\
    \ or more frequently in accordance with the requirements, policies, and procedures\
    \ established by the IRB/IEC</p>\n<p>\u2212 Notifying the IRB/IEC of SAEs or other\
    \ significant safety findings as required by IRB/IEC procedures</p>\n<p>\u2212\
    \ Providing oversight of the conduct of the study at the site and adherence to\
    \ requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC,\
    \ Directive 2001/20/EC, European regulation 536/2014 for clinical studies (if\
    \ applicable), and all other applicable local regulations</p></li>\n</ul></div>"
- - NCI_85
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Investigators and Subinvestigators
    will provide Alexion with sufficient, accurate financial information as requested
    to allow Alexion to submit complete and accurate financial certification or disclosure
    statements to the appropriate regulatory authorities. Investigators are responsible
    for providing information on financial interests during the course of the study
    and for 1 year after completion of the study.</p></div>
- - NCI_86
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>It is the responsibility of the Investigator to obtain signed (written
    or electronic signature) informed consent from all study participants prior to
    any study-related procedures including screening assessments.</p></li>

    <li><p>The Investigator or his/her representative will explain the nature of the
    study (including but not limited to the objectives, potential benefits and risks,
    inconveniences, and the participant''s rights and responsibilities) to the participant
    or his/her legally authorized representative, defined according to local and country
    regulations where the study is taking place, and answer all questions regarding
    the study.</p></li>

    <li><p>Participants must be informed that their participation is voluntary. Participants
    or their legally authorized representative will be required to sign a statement
    of informed consent or a certified translation if applicable, that meets the requirements
    of 21 CFR 50, local regulations, EU General Data Protection Regulation (GDPR),
    ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements,
    where applicable, and the IRB/IEC or study center.</p></li>

    <li><p>The medical record must include a statement that signed (written or electronic)
    informed consent was obtained before the participant was screened in the study
    and the date the written consent was obtained. The authorized person obtaining
    the informed consent must also sign the ICF/ICFs.</p></li>

    <li><p>Participants must be reconsented to the most current version of the ICF/ICFs
    during their participation in the study.</p></li>

    <li><p>A copy of the signed (written or electronic) informed consent documentation
    (ie, a complete set of participant information sheets and fully executed signature
    pages) must be provided to the participant or the participant''s legally authorized
    representative, as applicable. This document may require translation into the
    local language. Signed (written or electronic) consent [or assent] forms must
    remain in each participant''s study file and must be available for verification
    at any time.</p></li>

    </ul>

    <p>The ICF will contain a separate section that addresses the use of remaining
    mandatory samples for optional exploratory research. The Investigator or authorized
    designee will explain to each participant or their legally authorized representative
    the objectives of the exploratory research. If sharing exploratory research results
    with the Investigator is not planned, the ICF should mention it. Participants
    or their legally authorized representative will be told that they are free to
    refuse to participate and may withdraw their consent at any time and for any reason
    during the storage period. A separate signature will be required to document a
    participant''s agreement to allow any remaining specimens to be used for exploratory
    research. Participants who decline to participate in this optional research will
    not provide this separate signature.</p></div>'
- - NCI_87
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>Participants will be assigned a unique identifier by Alexion. Any participant
    records or datasets that are transferred to Alexion will contain the identifier
    only; participant names or any information which would make the participant identifiable
    will not be transferred.</p></li>

    <li><p>Participants must be informed that their personal study-related data will
    be used by Alexion in accordance with local data protection law. The level of
    disclosure must also be explained to the participants who will be required to
    give consent for their data to be used as described in the informed consent.</p></li>

    <li><p>Participants must be informed that their medical records may be examined
    by Clinical Quality Assurance auditors or other authorized personnel appointed
    by Alexion, appropriate IRB/IEC members, and inspectors from regulatory authorities.</p></li>

    </ul></div>'
- - NCI_88
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Study-related information and study
    results may be posted on publicly accessible clinical study databases (eg, www.clinicaltrials.gov
    or www.clinicaltrialsregister.eu), as appropriate, and in accordance with national,
    regional, and local regulations.</p></div>
- - NCI_89
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>All participant data relating to the study will be recorded on printed
    or electronic CRF unless transmitted to Alexion or designee electronically (eg,
    laboratory data). The Investigator is responsible for verifying that data entries
    are accurate and correct by physically or electronically signing the CRF.</p></li>

    <li><p>The Investigator must maintain accurate documentation (source data) that
    supports the information entered in the CRF.</p></li>

    <li><p>The Investigator must permit study-related monitoring, audits, IRB/IEC
    review, and regulatory agency inspections and provide direct access to source
    data documents.</p></li>

    <li><p>Alexion or designee is responsible for the data management of this study
    including quality checking of the data.</p></li>

    <li><p>Study monitors will perform ongoing source data verification to confirm
    that data entered into the CRF by authorized site personnel are accurate, complete,
    and verifiable from source documents; that the safety and rights of participants
    are being protected; and that the study is being conducted in accordance with
    the currently approved protocol and any other study agreements, ICH GCP, and all
    applicable regulatory requirements.</p></li>

    <li><p>Records and documents, including signed ICFs, pertaining to the conduct
    of this study must be retained by the Investigator for a minimum of 25 years after
    study completion, unless local regulations or institutional policies require a
    longer retention period. No records may be destroyed during the retention period
    without the written approval of Alexion. No records may be transferred to another
    location or party without written notification to Alexion.</p></li>

    </ul></div>'
- - NCI_90
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Source documents provide evidence
    for the existence of the participant and substantiate the integrity of the data
    collected. The Investigator or designee will prepare and maintain adequate</p>

    <p>and accurate source documents (eg, medical records, ECGs, AE and concomitant
    medication reporting, raw data collection forms) designed to record all observations
    and other pertinent data for each participant.</p>

    <p>Data reported on the CRF that are transcribed from source documents must be
    consistent with the source documents or the discrepancies must be explained. The
    Investigator may need to request previous medical records or transfer records,
    depending on the study. Also, current medical records must be available. Source
    documents are filed at the Investigator''s site.</p></div>'
- - NCI_91
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The study start date is the date
    on which the first participant is consented.</p>

    <p>Alexion reserves the right to close the study site or terminate the study at
    any time for any reason at the sole discretion of Alexion. Study sites will be
    closed after the study is completed or following the decision to close or terminate
    the study. A study site is considered closed when all participants have completed
    the end of study or early discontinuation visit, all data have been collected
    and entered into electronic data capture (EDC) system, all required documents
    and study supplies have been collected, and a study-site closure visit has been
    performed.</p>

    <p>The Investigator may initiate study-site closure at any time, provided there
    is reasonable cause and sufficient notice is given in advance of the intended
    termination.</p>

    <p>Reasons for the early closure of a study site by Alexion or Investigator may
    include but are not limited to:</p>

    <ul>

    <li><p>Failure of the Investigator to comply with the protocol, the requirements
    of the IRB/IEC or local health authorities, Alexion''s procedures, or GCP guidelines</p></li>

    <li><p>Inadequate recruitment of participants by the Investigator</p></li>

    <li><p>Discontinuation of further study intervention development</p></li>

    </ul>

    <p>If the study is prematurely terminated or suspended, Alexion shall promptly
    inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract
    research organization(s) used in the study of the reason for termination or suspension,
    as specified by the applicable regulatory requirements. The Investigator shall
    promptly inform the participant and should assure appropriate participant therapy
    and/or follow-up.</p></div>'
- - NCI_92
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>The full terms regarding publication
    of the results of this study are outlined in the applicable Clinical Study Agreement.</p></div>
- - NCI_93
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>The tests detailed in\
    \ Table 9 will be performed by the local laboratory.</p></li>\n<li><p>Protocol-specific\
    \ requirements for inclusion or exclusion of participants are detailed in Section\
    \ 5.</p></li>\n<li><p>Additional tests may be performed at any time during the\
    \ study as determined necessary by the Investigator or required by local regulations.</p></li>\n\
    <li><p>Pregnancy testing: Women of childbearing potential should only be enrolled\
    \ after a negative serum pregnancy test result at Screening. Additional urine\
    \ pregnancy testing will be standard for the protocol unless serum testing is\
    \ required by site policies, local regulation, or IRB/IEC and should be performed\
    \ per the time points specified in the SoA (Section 1.3). Screening pregnancy\
    \ criteria are detailed in Section 5.1.</p></li>\n</ul>\n<p><b>Table 9: Protocol-Required\
    \ Safety Laboratory Assessments</b></p>\n<table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td colspan=\"2\"><p><b>Clinical Chemistry</b></p></td>\n</tr>\n<tr>\n\
    <td><p>\n<p>Blood urea nitrogen (BUN) &amp; <usdm:ref attribute=\"label\" id=\"\
    BiomedicalConcept_10\" klass=\"BiomedicalConcept\"></usdm:ref></p>\n</p></td><td><p>Alanine\
    \ aminotransferase</p></td>\n</tr>\n<tr>\n<td><p>Potassium</p></td><td><p>Alkaline\
    \ phosphatase</p></td>\n</tr>\n<tr>\n<td><p>Creatinine</p></td><td><p>Urea</p></td>\n\
    </tr>\n<tr>\n<td><p>Creatine kinase</p></td><td><p>Magnesium</p></td>\n</tr>\n\
    <tr>\n<td><p>Sodium</p></td><td><p>Iron</p></td>\n</tr>\n<tr>\n<td><p>Chloride</p></td><td><p>Zinc</p></td>\n\
    </tr>\n<tr>\n<td><p>Potassium</p></td><td><p>Total and direct bilirubin</p></td>\n\
    </tr>\n<tr>\n<td><p>Glucose</p></td><td><p>Total protein</p></td>\n</tr>\n<tr>\n\
    <td><p>Total carbon dioxide</p></td><td><p>Albumin</p></td>\n</tr>\n<tr>\n<td><p>Aspartate\
    \ aminotransferase</p></td><td><p>Calcium</p></td>\n</tr>\n<tr>\n<td><p>Gamma\
    \ glutamyltransferase</p></td><td><p>Phosphate</p></td>\n</tr>\n<tr>\n<td colspan=\"\
    2\"><p><b>Hematology</b></p></td>\n</tr>\n<tr>\n<td><p>Hematocrit</p></td><td><p>Red\
    \ blood cell count<sup>a</sup></p></td>\n</tr>\n<tr>\n<td><p>Platelets</p></td><td><p>Mean\
    \ corpuscular volume</p></td>\n</tr>\n<tr>\n<td><p>White blood cell count</p></td><td><p>Mean\
    \ cell hemoglobin concentration</p></td>\n</tr>\n<tr>\n<td><p>Mean cell hemoglobin</p></td><td><p>Lymphocytes</p></td>\n\
    </tr>\n<tr>\n<td><p>Neutrophils</p></td><td><p>Eosinophils</p></td>\n</tr>\n<tr>\n\
    <td><p>Monocytes</p></td><td><p>Prothrombin time</p></td>\n</tr>\n<tr>\n<td><p>Basophils</p></td><td><p>International\
    \ normalized ratio</p></td>\n</tr>\n<tr>\n<td><p>Hemoglobin</p></td><td><p>Partial\
    \ thromboplastin time</p></td>\n</tr>\n<tr>\n<td colspan=\"2\"><p><b>Urinalysis</b></p></td>\n\
    </tr>\n<tr>\n<td><p>Bilirubin</p></td><td><p>Blood</p></td>\n</tr>\n<tr>\n<td><p>Glucose</p></td><td><p>Ketones</p></td>\n\
    </tr>\n<tr>\n<td><p>Leukocytes</p></td><td><p>Microscopy</p></td>\n</tr>\n<tr>\n\
    <td><p>Nitrite</p></td><td><p>pH</p></td>\n</tr>\n<tr>\n<td><p>Protein</p></td><td><p>Specific\
    \ gravity</p></td>\n</tr>\n<tr>\n<td><p>Urobilinogen</p></td><td><p>Red blood\
    \ cells</p></td>\n</tr>\n<tr>\n<td><p>Bacteria</p></td><td><p></p></td>\n</tr>\n\
    <tr>\n<td colspan=\"2\"><p><b>Other Tests</b></p></td>\n</tr>\n<tr>\n<td><p>HIV,\
    \ hepatitis B, and hepatitis C screen</p></td><td><p>Total copper and total molybdenum</p></td>\n\
    </tr>\n<tr>\n<td><p>Ceruloplasmin (serum and plasma)</p></td><td><p>PUF-molybdenum\
    \ and PUF-copper</p></td>\n</tr>\n<tr>\n<td><p>Ceruloplasmin-bound copper</p></td><td><p>Labile\
    \ bound copper</p></td>\n</tr>\n<tr>\n<td><p>24-hour urine copper and molybdenum</p></td><td><p>Serum\
    \ and urine pregnancy test</p></td>\n</tr>\n<tr>\n<td><p>Urine drug screen</p></td><td><p></p></td>\n\
    </tr>\n</table>\n<p><sup>a</sup> Including nucleated red blood cells.</p>\n<p><small>Details\
    \ of liver chemistry stopping criteria and required actions and follow-up assessments\
    \ after liver stopping or monitoring event are given in Section 6.6 . All events\
    \ of alanine aminotransferase (ALT) \u2265 3 \xD7 upper limit of normal (ULN)\
    \ and bilirubin \u2265 2 \xD7 ULN (&gt; 35% direct bilirubin) or ALT \u2265 3\
    \ \xD7 ULN and international normalized ratio (INR) &gt; 1.5, if INR measured\
    \ which may indicate severe liver injury (possible Hy's Law), must be reported\
    \ as an SAE (excluding studies of hepatic impairment or cirrhosis).</small></p>\n\
    <p><small>Abbreviations: HIV= human immunodeficiency virus; PUF = plasma ultrafiltrate;\
    \ SAE = serious adverse event.</small></p>\n<p>Investigators must document their\
    \ review of each laboratory safety report.</p></div>"
- - NCI_94
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_95
  - '<div xmlns="http://www.w3.org/1999/xhtml"><table class="table align-top table-bordered">

    <tr>

    <td><p><b>AE Definition</b></p></td>

    </tr>

    <tr>

    <td>

    <ul>

    <li><p>An AE is any untoward medical occurrence in a participant, temporally associated
    with the use of study intervention, whether or not considered related to the study
    intervention.</p></li>

    <li><p>Note: An AE can therefore be any unfavorable and unintended sign (including
    an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally
    associated with the use of study intervention .</p></li>

    </ul>

    </td>

    </tr>

    </table>

    <table class="table align-top table-bordered">

    <tr>

    <td><p><b>Events Meeting the AE Definition</b></p></td>

    </tr>

    <tr>

    <td>

    <ul>

    <li><p>Any abnormal laboratory test results (hematology, clinical chemistry, or
    urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs
    measurements), including those that worsen from baseline, considered clinically
    significant in the medical and scientific judgment of the Investigator (ie, not
    related to progression of underlying disease).</p></li>

    <li><p>Exacerbation of a chronic or intermittent pre-existing condition including
    either an increase in frequency and/or intensity of the condition.</p></li>

    <li><p>New conditions detected or diagnosed after study intervention administration
    even though it may have been present before the start of the study.</p></li>

    <li><p>Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.</p></li>

    <li><p>Signs, symptoms, or the clinical sequelae of a suspected overdose of either
    study intervention or a concomitant medication. Overdose per se will not be reported
    as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming
    intent. Such overdoses should be reported regardless of sequelae.</p></li>

    </ul>

    </td>

    </tr>

    </table>

    <table class="table align-top table-bordered">

    <tr>

    <td><p><b>Events Meeting the AE Definition</b></p></td>

    </tr>

    <tr>

    <td>

    <ul>

    <li><p>Medical or surgical procedure (eg, endoscopy, appendectomy): The condition
    that leads to the procedure is the AE. Situations in which an untoward medical
    occurrence did not occur (eg, hospitalization for elective surgery if planned
    before the signing the ICF, admissions for social reasons or for convenience).</p></li>

    <li><p>Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s)
    present or detected at the start of the study that do not worsen.</p></li>

    <li><p>A medication error (including intentional misuse, abuse, and overdose of
    the product) or use other than what is defined in the protocol is not considered
    an AE unless there is an untoward medical occurrence as a result of a medication
    error.</p></li>

    <li><p>Cases of pregnancy that occur during maternal or paternal exposure to study
    intervention are to be reported within 24 hours of Investigator/site awareness.
    Data on fetal outcome and breastfeeding will be collected for regulatory reporting
    and safety evaluation.</p></li>

    <li><p>Any clinically significant abnormal laboratory findings or other abnormal
    safety assessments which are associated with the underlying disease, unless judged
    by the Investigator to be more severe than expected for the participant''s condition.</p></li>

    <li><p>The disease/disorder being studied or expected progression, signs, or symptoms
    of the disease/disorder being studied, unless more severe than expected for the
    participant''s condition.</p></li>

    <li><p>Situations in which an untoward medical occurrence did not occur (social
    and/or convenience admission to a hospital).</p></li>

    </ul>

    </td>

    </tr>

    </table></div>'
- - NCI_96
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>If an event is not an AE per definition\
    \ above, then it cannot be an SAE even if serious conditions are met (eg, hospitalization\
    \ for signs/symptoms of the disease under study, death due to progression of disease).</p>\n\
    <table class=\"table align-top table-bordered\">\n<tr>\n<td><p><b>An SAE is defined\
    \ as any untoward medical occurrence that, at any dose:</b></p></td>\n</tr>\n\
    <tr>\n<td>\n<p><b>1. Results in death</b></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>2.\
    \ Is life-threatening</b></p>\n<p>The term \u201Clife-threatening\u201D in the\
    \ definition of \u201Cserious\u201D refers to an event in which the participant\
    \ was at risk of death at the time of the event. It does not refer to an event,\
    \ which hypothetically might have caused death, if it was more severe.</p>\n</td>\n\
    </tr>\n<tr>\n<td>\n<p><b>3. Requires inpatient hospitalization or prolongation\
    \ of existing hospitalization</b></p>\n<p>In general, hospitalization signifies\
    \ that the participant has been detained (usually involving at least an overnight\
    \ stay) at the hospital or emergency ward for observation and/or treatment that\
    \ would not have been appropriate in the physician's office or outpatient setting.\
    \ Complications that occur during hospitalization are AEs. If a complication prolongs\
    \ hospitalization or fulfills any other serious criteria, the event is serious.\
    \ When in doubt as to whether \u201Chospitalization\u201D occurred or was necessary,\
    \ the AE should be considered serious.</p>\n<p>Hospitalization for elective treatment\
    \ of a pre-existing condition that did not worsen from baseline is not considered\
    \ an AE.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>4. Results in persistent disability/incapacity</b></p>\n\
    <ul>\n<li><p>The term disability means a substantial disruption of a person's\
    \ ability to conduct normal life functions.</p></li>\n<li><p>This definition is\
    \ not intended to include experiences of relatively minor medical significance\
    \ such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental\
    \ trauma (eg, sprained ankle) which may interfere with or prevent everyday life\
    \ functions but do not constitute a substantial disruption.</p></li>\n</ul>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p><b>5. Is a congenital anomaly/birth defect</b></p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p><b>6. Other situations:</b></p>\n<ul>\n<li><p>Medical\
    \ or scientific judgment should be exercised in deciding whether SAE reporting\
    \ is appropriate in other situations such as important medical events that may\
    \ not be immediately life-threatening or result in death or hospitalization but\
    \ may jeopardize the participant or may require medical or surgical intervention\
    \ to prevent one of the other outcomes listed in the above definition. These events\
    \ should usually be considered serious.</p></li>\n<li><p>Examples of such events\
    \ include invasive or malignant cancers, intensive treatment in an emergency room\
    \ or at home for allergic bronchospasm, blood dyscrasias or convulsions that do\
    \ not result in hospitalization, or development of drug dependency or drug abuse.</p></li>\n\
    </ul>\n</td>\n</tr>\n</table>\n<table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b>A suspected unexpected serious adverse reaction (SUSAR) is\
    \ defined as:</b></p></td>\n</tr>\n<tr>\n<td>\n<p>A serious event that is not\
    \ listed in the Reference Safety Information of the Investigator's Brochure and\
    \ that the Investigator or Sponsor identifies as related to investigational product\
    \ or procedure. United States Title 21 CFR 312.32 and European Union Clinical\
    \ Trial Directive 2001/20/EC and the associated detailed guidances or national\
    \ regulatory requirements in participating countries require the reporting of\
    \ SUSARs. Alexion has procedures that will be followed for the recording and expedited\
    \ reporting of SUSARs that are consistent with global regulations and the associated\
    \ detailed guidances. Suspected unexpected serious adverse reactions will be reported\
    \ to the national competent authority and IRBs/IECs where applicable.</p>\n</td>\n\
    </tr>\n</table></div>"
- - NCI_97
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b>Recording of AE and/or SAE</b></p></td>\n</tr>\n<tr>\n<td>\n\
    <ul>\n<li><p>When an AE/SAE occurs, it is the responsibility of the Investigator\
    \ to review all documentation (eg, hospital progress notes, laboratory reports,\
    \ and diagnostics reports) related to the event.</p></li>\n<li><p>The Investigator\
    \ will then record all relevant AE/SAE information in the CRF.</p></li>\n<li><p>It\
    \ is not acceptable for the Investigator to send photocopies of the participant's\
    \ medical records to Alexion in lieu of completion of the AE/SAE CRF page.</p></li>\n\
    </ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Recording of AE and/or SAE</b></p>\n<ul>\n\
    <li><p>There may be instances when copies of medical records for certain cases\
    \ are requested by Alexion. In this case, all participant identifiers, with the\
    \ exception of the participant number, will be redacted on the copies of the medical\
    \ records before submission to Alexion.</p></li>\n<li><p>The Investigator will\
    \ attempt to establish a diagnosis of the event based on signs, symptoms, and/or\
    \ other clinical information. Whenever possible, the diagnosis (not the individual\
    \ signs/symptoms) will be documented as the AE/SAE.</p></li>\n</ul></td>\n</tr>\n\
    <tr>\n<td>\n<p><b>Assessment of Severity</b> </p>\nThe Investigator will make\
    \ an assessment of severity for each AE and SAE reported during the study and\
    \ assign it to one of the following categories from National Cancer Institute\
    \ CTCAE v5.0, published 27 Nov 2017:\n<ul>\n<li><p>Grade 1: Mild (awareness of\
    \ sign or symptom, but easily tolerated)</p></li>\n<li><p>Grade 2: Moderate (discomfort\
    \ sufficient to cause interference with normal activities)</p></li>\n<li><p>Grade\
    \ 3: Severe (incapacitating, with inability to perform normal activities)</p></li>\n\
    <li><p>Grade 4: Life-threatening</p></li>\n<li><p>Grade 5: Fatal</p></li>\n</ul>\n\
    </td>\n</tr>\n</table>\n<table class=\"table align-top table-bordered\">\n<tr>\n\
    <td>\n<p><b>Assessment of Causality</b></p>\n</td>\n</tr>\n<tr>\n<td>\n<ul>\n\
    <li>\n<p>The Investigator is obligated to assess the relationship between the\
    \ study intervention and each occurrence\n            of each AE or SAE. An nvestigator\
    \ causality assessment must be provided for all AEs (both nonserious and\n   \
    \         serious). This assessment must be recorded in the CRF and on any additional\
    \ forms, as appropriate. The\n            definitions for the causality assessments\
    \ are as follows:</p>\n<ul>\n<li><p>Not related: There is no reasonable possibility\
    \ the study intervention caused the AE.</p></li>\n<ul>\n<li><p>The AE has a more\
    \ likely alternative etiology; it may be due to underlying or concurrent illness,\
    \ complications, concurrent treatments, or effects of another concurrent drug.</p></li>\n\
    <li><p>The event does not follow a reasonable temporal relationship to administration\
    \ of the study intervention.</p></li>\n</ul>\n<li><p>Related: There is a reasonable\
    \ possibility the study intervention caused the AE.</p></li>\n<ul>\n<li><p>The\
    \ AE has a temporal relationship to the administration of the study intervention.</p></li>\n\
    <li><p>The event does not have a likely alternative etiology.</p></li>\n<li><p>The\
    \ event corresponds with the known pharmaceutical profile of the study intervention.</p></li>\n\
    <li><p>There is improvement on discontinuation and/or reappearance on rechallenge.</p></li>\n\
    </ul>\n</ul>\n</li>\n<li><p>The Investigator will use clinical judgment to determine\
    \ the relationship.</p></li>\n<li><p>Alternative causes, such as underlying disease(s),\
    \ concomitant therapy, and other risk factors, as well as\n        the  temporal\
    \ relationship of the event to study intervention administration will be considered\
    \ and investigated.</p></li>\n<li><p>The Investigator will also consult the IB\
    \ and/or Product Information, for marketed products, in his/her\n        assessment.</p></li>\n\
    <li><p>For each AE/SAE, the Investigator <b>must</b> document in the medical notes\
    \ that he/she has reviewed the\n        AE/SAE and has provided an assessment\
    \ of causality.</p></li>\n<li><p>There may be situations in which an SAE has occurred,\
    \ and the Investigator has minimal information to\n        include in the initial\
    \ report to Alexion. However, it is very important that the Investigator always\
    \ make an\n        assessment of causality for every event before the initial\
    \ transmission of the SAE data to Alexion.</p></li>\n<li><p>The Investigator may\
    \ change his/her opinion of causality in light of follow-up information and send\
    \ an SAE\n        follow-up report with the updated causality assessment.</p></li>\n\
    <li><p>The causality assessment is one of the criteria used when determining regulatory\
    \ reporting requirements.</p></li>\n</ul>\n</td>\n</tr>\n</table>\n<table class=\"\
    table align-top table-bordered\">\n<tr>\n<td><p><b>Follow-up of AEs and SAEs</b></p></td>\n\
    </tr>\n<tr>\n<td>\n<ul>\n<li><p>The Investigator is obligated to perform or arrange\
    \ for the conduct of supplemental measurements and/or evaluations as medically\
    \ indicated or as requested by Alexion to elucidate the nature and/or causality\
    \ of the AE or SAE as fully as possible. This may include additional laboratory\
    \ tests or investigations, histopathological examinations, or consultation with\
    \ other health care professionals.</p></li>\n<li><p>If a participant dies during\
    \ participation in the study or during a recognized follow-up period, the Investigator\
    \ will provide Alexion with a copy of any post-mortem findings including histopathology.</p></li>\n\
    <li><p>New or updated information will be recorded in the originally completed\
    \ CRF.</p></li>\n<li><p>The Investigator will submit any updated SAE data to Alexion\
    \ within 24 hours of receipt of the information. </p></li>\n<ul>\n</ul></ul></td>\n\
    </tr></table></div>"
- - NCI_98
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b><b>SAE Reporting to Alexion via Paper Safety Reporting Form</b></b></p></td>\n\
    </tr>\n<tr>\n<td>\n<ul>\n<li><p>All SAEs will be recorded and reported to Alexion\
    \ or designee immediately and within 24 hours awareness.</p></li>\n<li><p>All\
    \ SAEs will be reported using the Safety Reporting Form and submitted to Alexion\
    \ GDS. The Investigator must complete, sign, and date the SAE pages, verify the\
    \ accuracy of the information recorded on the SAE pages with the corresponding\
    \ source documents, and send a copy via email or facsimile to the contact information\
    \ provided below: </p></li>\n<p>\u2212 Email: XXXXXXX or Fax: XXXXXX</p>\n<li><p>Additional\
    \ follow-up information, if required or available, should be entered into the\
    \ CRF and sent to Alexion GDS within 24 hours of the Investigator or study site\
    \ staff becoming aware of this additional information via the reporting process\
    \ outlined above.</p></li>\n<li><p>For all SAEs, the Investigator must provide\
    \ the following:</p></li>\n<p>\u2212 Appropriate and requested follow-up information\
    \ in the time frame detailed above </p>\n<p>\u2212 Causality of the SAE(s) </p>\n\
    <p>\u2212 Treatment of/intervention for the SAE(s) </p>\n<p>\u2212 Outcome of\
    \ the SAE(s) </p>\n<p>\u2212 Medical records and laboratory/diagnostic information</p>\n\
    <li><p>All paper forms and follow-up information submitted to Alexion GDS must\
    \ be accompanied by a cover page signed by the Investigator.</p></li>\n<li><p>Paper\
    \ source documents and/or reports should be kept in the appropriate section of\
    \ the study file .</p></li>\n</ul>\n</td>\n</tr>\n</table></div>"
- - NCI_99
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NCI_100
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b>CONTRACEPTIVES<sup>a</sup> ALLOWED DURING THE STUDY INCLUDE:\
    \ Highly Effective Methodsb That Have Low User Dependency</b></p></td>\n</tr>\n\
    <tr>\n<td><ul><li><p>Implantable progestogen-only hormone contraception associated\
    \ with inhibition of ovulationc</p></li></ul></td>\n</tr>\n<tr>\n<td><ul><li><p>Intrauterine\
    \ device (IUD): female participants with a copper-containing IUD are excluded\
    \ from study</p></li></ul></td>\n</tr>\n<tr>\n<td><ul><li><p>Intrauterine hormone-releasing\
    \ system (IUS)c</p></li></ul></td>\n</tr>\n<tr>\n<td><ul><li><p>Bilateral tubal\
    \ occlusion</p></li></ul></td>\n</tr>\n<tr>\n<td><p><ul><li>Vasectomized partner\
    \ </li></ul></p>\n<ul><li><p>Vasectomy is a highly effective contraceptive method\
    \ provided that the partner is the sole sexual partner of the woman of childbearing\
    \ potential and the absence of sperm has been confirmed. If not, an additional\
    \ highly effective method of contraception should be used. Spermatogenesis cycle\
    \ is approximately 90 days.</p></li></ul></td>\n</tr>\n<tr>\n<td><p><b>Highly\
    \ Effective Methods<sup>b</sup> That Are User Dependent</b></p></td>\n</tr>\n\
    <tr>\n<td><ul><li><p>Combined (estrogen- and progestogen-containing) hormonal\
    \ contraception associated with inhibition of ovulation </p></li>\n<ul>\n<li><p>Oral</p></li>\n\
    <li><p>Injectable </p></li>\n<li><p>Intravaginal </p></li>\n<li><p>Transdermal</p></li>\n\
    </ul></ul>\n</td></tr>\n<tr>\n<td><ul><li><p>Progestogen-only hormone contraception\
    \ associated with inhibition of ovulation<sup>c</sup></p>\n<ul>\n<li><p>Oral</p></li>\n\
    <li><p>Injectable </p></li>\n</ul></li></ul>\n</td></tr>\n<tr>\n<td><ul><li><p>Sexual\
    \ abstinence </p>\n<ul>\n<li><p>Sexual abstinence is considered a highly effective\
    \ method only if defined as refraining from heterosexual intercourse during the\
    \ entire period of risk associated with the study intervention. The reliability\
    \ of sexual abstinence needs to be evaluated in relation to the duration of the\
    \ study and the preferred and usual lifestyle of the participant.</p>\n</li></ul></li></ul>\n\
    </td></tr>\n<tr>\n<td><p>Female participants of non-childbearing potential are\
    \ exempt from contraception requirements. Non-childbearing potential for female\
    \ participants is defined as any of the following:</p>\n<ul>\n<li><p>Prior to\
    \ first menses</p>\n<li><p>Postmenopausal, as documented by amenorrhea for at\
    \ least 1 year prior to the Day 1 visit and follicle stimulating hormone serum\
    \ levels consistent with postmenopausal status</p>\n<li><p>Permanent sterilization\
    \ at least 6 weeks prior to the Day 1 visit:</p>\n<li><p>Hysteroscopic sterilization</p>\n\
    <li><p>Bilateral tubal ligation or bilateral salpingectomy </p>\n<li><p>Hysterectomy\
    \ </p>\n<li><p>Bilateral oophorectomy</p>\n</li></li></li></li></li></li></li></ul>\n\
    </td>\n</tr></table>\n<p><small>Note: Periodic abstinence (calendar, symptothermal,\
    \ post-ovulation methods), withdrawal (coitus interruptus), spermicides only,\
    \ and lactational amenorrhea method (LAM) are not acceptable methods of contraception\
    \ for this study. Male condom and female condom should not be used together (due\
    \ to risk of failure with friction).</small></p>\n<p><small><sup>a</sup>Contraceptive\
    \ use by men or women should be consistent with local regulations regarding the\
    \ use of contraceptive \nmethods for those participating in clinical studies.</small></p>\n\
    <p><small><sup>b</sup>Failure rate of &lt; 1% per year when used consistently\
    \ and correctly. Typical use failure rates differ from those when used consistently\
    \ and correctly.</small></p>\n<p><small><sup>c</sup>If locally required, in accordance\
    \ with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive\
    \ methods are limited to those which inhibit ovulation as the primary mode of\
    \ action.</small></p></div>"
- - NCI_101
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>If a female participant or a male\
    \ participant's female spouse/partner becomes pregnant after the first dose of\
    \ ALXN1840 through 3 months after the end of systemic exposure of the study intervention,\
    \ the Investigator must submit the \u201CPregnancy/Breastfeeding Reporting and\
    \ Outcome Form\u201D to Alexion Global Drug Safety (GDS) via fax or email (see\
    \ Section 10.3 for contact information). When the outcome of the pregnancy becomes\
    \ known, the form should be updated and submitted to Alexion GDS. If additional\
    \ follow-up is required, the Investigator will be requested to provide the information.</p>\n\
    <p>Exposure of an infant to an Alexion product during breastfeeding must also\
    \ be reported (via the \u201CPregnancy/Breastfeeding Reporting and Outcome Form\u201D\
    ) and any AEs experienced by the infant must be reported to Alexion GDS or designee\
    \ via email or facsimile (see Section 10.3 for contact information).</p></div>"
- - NCI_102
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>ALXN1840-WD-204</p>\n<p>To date,\
    \ following a review of the limited available COVID-19 vaccine data (eg, Pfizer/BioNTech,\
    \ Moderna, AstraZeneca), it is unlikely that the immune response to a COVID-19\
    \ vaccine will be diminished with concomitant ALXN1840 administration, based on\
    \ ALXN1840's mechanism of action. There is currently no information available\
    \ evaluating the safety or efficacy of COVID-19 vaccines in participants treated\
    \ with ALXN1840.</p>\n<p>Local and national guidelines should be consulted for\
    \ recommendations related to COVID-19 vaccination. Alexion suggests that participants\
    \ complete vaccination series before study participation, if feasible. The decision\
    \ to allow COVID-19 vaccinated participants to continue in the study should be\
    \ made by the investigator on a participant-by-participant basis.</p>\n<p>The\
    \ potential risks identified and mitigation measures put in place in light of\
    \ the COVID-19 vaccination rollout are provided in Table 10.</p>\n<p><b>Table\
    \ 10: Potential Risks and Mitigation Measures due to COVID-19 Vaccine</b></p>\n\
    <table class=\"table align-top table-bordered\">\n<tr>\n<td><p><b>Risks category</b></p></td><td><p>\
    \ Summary of Data/ Rationale for Risk</p></td><td><p><b>Mitigation Strategy</b></p></td>\n\
    </tr>\n<tr>\n<td <p=\"\" colspan=\"3\"><b>Potential risks</b></td>\n</tr>\n<tr>\n\
    <td><p>Data quality and integrity</p></td>\n<td><p>Missing data due to appointments\
    \ for COVID-19 vaccination or side effects of COVID-19 vaccine may impact study\
    \ visit schedules and \nincrease missed visits and/or participant study discontinuations,\
    \ inadvertently resulting in missing data (eg, for protocol-specified procedures)./p&gt;</p></td>\n\
    <td><p>It will be important to capture specific information in the eCRF that explains\
    \ the reason the data is missing (eg, missed study visits due to appointments\
    \ for COVID-19 vaccination or side effects of COVID-19 vaccine).</p></td>\n</tr></table>\n\
    <p><small>Abbreviation: COVID-19 = coronavirus disease 2019.</small></p></div>"
- - NCI_103
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A list of abbreviations and terms\
    \ used in this study protocol is provided in Table 11.</p>\n<p><b>Table 11: List\
    \ of Abbreviations and Definitions of Terms</b></p>\n<table class=\"table align-top\
    \ table-bordered\">\n<tr><th><p>Abbreviation</p></th><th><p>Definition</p></th></tr>\n\
    <tr><td><p>\u03BBz</p></td><td><p>apparent terminal-phase elimination rate constant</p></td></tr>\n\
    <tr><td><p>ADME</p></td><td><p>absorption, distribution, metabolism, and excretion</p></td></tr>\n\
    <tr><td><p>AE</p></td><td><p>adverse event</p></td></tr>\n<tr><td><p>ALT</p></td><td><p>alanine\
    \ aminotransferase</p></td></tr>\n<tr><td><p>AST</p></td><td><p>aspartate aminotransferase</p></td></tr>\n\
    <tr><td><p>AUC</p></td><td><p>area under the plasma concentration versus time\
    \ curve</p></td></tr>\n<tr><td><p>AUCt</p></td><td><p>area under the plasma concentration\
    \ versus time curve from time 0 to the last quantifiable concentration</p></td></tr>\n\
    <tr><td><p>AUC</p></td><td><p>area under the plasma concentration versus time\
    \ curve from zero to infinity</p></td></tr>\n<tr><td><p>BSA</p></td><td><p>body\
    \ surface area</p></td></tr>\n<tr><td><p>CFR</p></td><td><p>Code of Federal Regulations</p></td></tr>\n\
    <tr><td><p>CIOMS</p></td><td><p>Council for International Organizations of Medical\
    \ Sciences</p></td></tr>\n<tr><td><p>CKD</p></td><td><p>chronic kidney disease</p></td></tr>\n\
    <tr><td><p>CL/F</p></td><td><p>apparent total body clearance</p></td></tr>\n<tr><td><p>Cmax</p></td><td><p>maximum\
    \ observed concentration</p></td></tr>\n<tr><td><p>CONSORT</p></td><td><p>Consolidated\
    \ Standards of Reporting Trials</p></td></tr>\n<tr><td><p>COVID-19</p></td><td><p>Coronavirus\
    \ disease</p></td></tr>\n<tr><td><p>CRF</p></td><td><p>case report form</p></td></tr>\n\
    <tr><td><p>CRU</p></td><td><p>clinical research unit</p></td></tr>\n<tr><td><p>CTCAE</p></td><td><p>Common\
    \ Terminology Criteria for Adverse Events</p></td></tr>\n<tr><td><p>CYP</p></td><td><p>cytochrome\
    \ P450</p></td></tr>\n<tr><td><p>CYP2C9/2B6</p></td><td><p>cytochromes 2C9 and\
    \ 2B6</p></td></tr>\n<tr><td><p>EDC</p></td><td><p>electronic data capture</p></td></tr>\n\
    <tr><td><p>EOS</p></td><td><p>End of Study</p></td></tr>\n<tr><td><p>GCP</p></td><td><p>Good\
    \ Clinical Practice</p></td></tr>\n<tr><td><p>GDPR</p></td><td><p>General Data\
    \ Protection Regulation</p></td></tr>\n<tr><td><p>GDS</p></td><td><p>Global Drug\
    \ Safety</p></td></tr>\n<tr><td><p>HED</p></td><td><p>human equivalent dose</p></td></tr>\n\
    <tr><td><p>HIPAA</p></td><td><p>Health Insurance Portability and Accountability\
    \ Act</p></td></tr>\n<tr><td><p>HIV</p></td><td><p>human immunodeficiency virus</p></td></tr>\n\
    <tr><td><p>IB</p></td><td><p>Investigator's Brochure</p></td></tr>\n<tr><td><p>ICH</p></td><td><p>International\
    \ Council for Harmonisation</p></td></tr>\n<tr><td><p>ICF</p></td><td><p>informed\
    \ consent form</p></td></tr>\n<tr><td><p>ICP-MS</p></td><td><p>inductively coupled\
    \ plasma mass spectrometry</p></td></tr>\n<tr><td><p>IEC</p></td><td><p>Independent\
    \ Ethics Committee</p></td></tr>\n<tr><td><p>IRB</p></td><td><p>Institutional\
    \ Review Board</p></td></tr>\n<tr><td><p>IUD</p></td><td><p>intrauterine device</p></td></tr>\n\
    <tr><td><p>IUS</p></td><td><p>intrauterine hormone-releasing system</p></td></tr>\n\
    <tr><td><p>LBC</p></td><td><p>labile bound copper</p></td></tr>\n<tr><td><p>LEC</p></td><td><p>Long-Evans\
    \ Cinnamon</p></td></tr>\n<tr><td><p>MELD</p></td><td><p>model for end-stage liver\
    \ disease</p></td></tr>\n<tr><td><p>MT</p></td><td><p>metallothionein</p></td></tr>\n\
    <tr><td><p>NCC</p></td><td><p>non-ceruloplasmin-bound copper</p></td></tr>\n<tr><td><p>NCCcorrected</p></td><td><p>corrected\
    \ NCC</p></td></tr>\n<tr><td><p>NHS</p></td><td><p>National Health Service</p></td></tr>\n\
    <tr><td><p>PD</p></td><td><p>pharmacodynamic</p></td></tr>\n<tr><td><p>PK</p></td><td><p>pharmacokinetic(s)</p></td></tr>\n\
    <tr><td><p>PUF</p></td><td><p>plasma ultrafiltrate</p></td></tr>\n<tr><td><p>QTcF</p></td><td><p>QT\
    \ interval corrected for heart rate using Fridericia's formula</p></td></tr>\n\
    <tr><td><p>SAE</p></td><td><p>serious adverse event</p></td></tr>\n<tr><td><p>SAP</p></td><td><p>Statistical\
    \ Analysis Plan</p></td></tr>\n<tr><td><p>SoA</p></td><td><p>Schedule of Activities</p></td></tr>\n\
    <tr><td><p>SRC</p></td><td><p>Safety Review Committee</p></td></tr>\n<tr><td><p>SUSAR</p></td><td><p>suspected\
    \ unexpected serious adverse reaction</p></td></tr>\n<tr><td><p>TEAE</p></td><td><p>treatment-emergent\
    \ adverse event</p></td></tr>\n<tr><td><p>t\xBD</p></td><td><p>terminal elimination\
    \ half-life</p></td></tr>\n<tr><td><p>Tlag</p></td><td><p> time delay between\
    \ the time of dosing and time of appearance of molybdenum concentration</p></td></tr>\n\
    <tr><td><p>tmax</p></td><td><p>time to maximum concentration</p></td></tr>\n<tr><td><p>TPC</p></td><td><p>tripartite\
    \ complex</p></td></tr>\n<tr><td><p>TTM</p></td><td><p>tetrathiomolybdate</p></td></tr>\n\
    <tr><td><p>ULN</p></td><td><p>upper limit of normal</p></td></tr>\n<tr><td><p>UWDRS</p></td><td><p>Unified\
    \ Wilson Disease Rating Scale</p></td></tr>\n<tr><td><p>Vd /F</p></td><td><p>apparent\
    \ volume of distribution</p></td></tr>\n<tr><td><p>WD</p></td><td><p>Wilson disease</p></td></tr>\n\
    <tr><td><p>WHO</p></td><td><p>World Health Organization</p></td></tr>\n</table></div>"
- - NCI_104
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The Protocol Amendment Summary\
    \ of Changes Table for the current amendment is located directly before the Table\
    \ of Contents.</p>\n<table class=\"table align-top table-bordered\">\n<tr>\n<th\
    \ colspan=\"2\"><p>DOCUMENT HISTORY</p></th>\n</tr>\n<tr>\n<th><p>Document</p></th><th><p>Date</p></th>\n\
    </tr>\n<tr>\n<td><p>Original Protocol</p></td><td><p>12 May 2020</p></td>\n</tr>\n\
    <tr>\n<td><p>Amendment 1</p></td><td><p>18 Aug 2020</p></td>\n</tr>\n<tr>\n<td><p>Amendment\
    \ 2</p></td><td><p>19 Mar 2021</p></td>\n</tr>\n<tr>\n<td><p>Amendment 3</p></td><td><p>31\
    \ Aug 2021</p></td>\n</tr>\n<tr>\n<td><p>Amendment 3.1 (US)</p></td><td><p>18\
    \ Mar 2022</p></td>\n</tr>\n</table>\n<p><b>Amendment 1 (18 Aug 2020)</b></p>\n\
    <p>This amendment was considered to be substantial based on the criteria set forth\
    \ in Article 10(a) of Directive 2001/20/EC of the European Parliament and the\
    \ Council of the European Union.</p>\n<p><b>Overall Rationale for the Amendment</b></p>\n\
    <p>The main reason for preparation of this amendment was to update procedures\
    \ outlined in the Schedule of Activities, remove contradictory text on the reporting\
    \ of serious adverse events, and add details of an interim analysis. Additional,\
    \ minor changes are included in the table below.</p>\n<p><b>Changes to the Protocol</b></p>\n\
    <table class=\"table align-top table-bordered\">\n<tr>\n<th>Section # and Name</th><th>Description\
    \ of Change</th><th>Brief Rationale and/or Clarifications</th>\n</tr>\n<tr>\n\
    <td><p>Section 1.3, Schedule of Activities, Section 4.1, Overall Design, Section\
    \ 6.4, Study Intervention Compliance</p></td>\n<td><p>Procedures updated include\
    \ Wilson disease history and treatment; study intervention compliance during outpatient\
    \ period captured with study dosing diary; light exercise.</p></td>\n<td><p>Data\
    \ collected for analysis of patient population and study intervention compliance,\
    \ and to compare endpoints with other ALXN1840 studies.</p></td>\n</tr>\n<tr>\n\
    <td><p>Section 2, Introduction Section 2.2, Background</p></td>\n<td><p>Removal\
    \ of text relating to primary biliary cholangitis.</p></td>\n<td><p>To reflect\
    \ that development of ALXN1840 is for Wilson disease.</p></td>\n</tr>\n<tr>\n\
    <td><p>Section 6.7, Intervention After the End of Study</p></td>\n<td><p>Text\
    \ updated regarding access to study intervention after the end of study.</p></td>\n\
    <td><p>To clarify the option for study intervention access at the end of study.</p></td>\n\
    </tr>\n<tr>\n<td><p>Section 9.3, Populations for Analysis</p></td>\n<td><p>Definition\
    \ of the Per Protocol set was updated.</p></td>\n<td><p>To align the definition\
    \ with the Statistical Analysis Plan.</p></td>\n</tr>\n<tr>\n<td><p>Section 9.5,\
    \ Interim Analyses</p></td>\n<td><p> Text pertaining to an interim analysis was\
    \ added.</p></td>\n<td><p>Interim data may support Marketing Authorisation Application(s).</p></td>\n\
    </tr>\n<tr>\n<td><p>Section 10.3.2, Definition of SAE</p></td>\n<td><p> Definition\
    \ of SUSAR was added.</p></td>\n<td><p>To align with current Alexion approved\
    \ language</p></td>\n</tr>\n<tr>\n<td><p>Section 10.3.4, Reporting of SAEs </p></td>\n\
    <td><p>Removal of contradictory text on SAE reporting via an electronic data collection\
    \ tool.</p></td>\n<td><p>SAE reporting will be via a paper safety reporting form.</p></td>\n\
    </tr>\n<tr>\n<td><p>All </p></td>\n<td><p>Minor editorial updates and corrections</p></td>\n\
    <td><p>For clarification, and to ensure accuracy and consistency throughout the\
    \ protocol</p></td>\n</tr></table>\n<p><b>Amendment 2 (19 Mar 2021)</b></p>\n\
    <p>This amendment was considered to be substantial based on the criteria set forth\
    \ in Article 10(a) of Directive 2001/20/EC of the European Parliament and the\
    \ Council of the European Union.</p>\n<p><b>Overall Rationale for the Amendment</b></p>\n\
    <p>The main reason for preparation of this amendment was to revise the exclusion\
    \ criterion for a urine drug screen. Changes implemented via Administrative Letter\
    \ 1 and Administrative Letter 2, as well as COVID vaccination guidance, have also\
    \ been incorporated.</p>\n<p><b>Changes to the Protocol</b></p>\n<table class=\"\
    table align-top table-bordered\">\n<tr>\n<th>Section # and Name</th>\n<th>Description\
    \ of Change</th>\n<th>Brief Rationale and/or Clarifications</th>\n</tr>\n<tr>\n\
    <td>\n<p>Section 1.1, Synopsis; Section 9.2, Sample Size Determination</p>\n</td>\n\
    <td>\n<p>The number of participants changed from \u201Cup to 10\u201D to \u201C\
    approximately 10\u201D.</p>\n</td>\n<td>\n<p>Clarification of sample size.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Section 1.1, Synopsis; Section 1.2, Schema; Section\
    \ 1.3, Schedule of Activities; Section 4.1, Overall Design;\n        Section 6.4,\
    \ Study Intervention Compliance</p>\n</td>\n<td>\n<p>SMS text messaging will replace\
    \ the dosing diary as the method of confirming treatment compliance during the\n\
    \        outpatient period.</p>\n</td>\n<td>\n<p>Site processes does not allow\
    \ use of paper diary.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section 2.3.1.1, Coronavirus\
    \ Disease 2019; Section 10.5, COVID-19 Vaccine Risk Assessment</p>\n</td>\n<td>\n\
    <p>COVID-19 vaccination guidance added.</p>\n</td>\n<td>\n<p>To provide guidance\
    \ on potential risks identified and mitigation measures put in place regarding\
    \ the COVID-19\n        vaccination rollout.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section\
    \ 5.1, Inclusion criteria</p>\n</td>\n<td>\n<p>Inclusion criterion for confirmation\
    \ of diagnosis of WD changed to Leipzig score \u2265 4 and expanded to include\n\
    \        historical test results.</p>\n</td>\n<td>\n<p>To clarify the process\
    \ for confirming the score for patients who were diagnosed prior to the establishment\
    \ of\n        the 2012 European Association for the Study of Liver WD Clinical\
    \ Practice Guidelines.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section 5.2, Exclusion\
    \ criteria</p>\n</td>\n<td>\n<p>Exclusion criterion for drug screen revised to\
    \ state that cannabinoids will not be tested.</p>\n</td>\n<td>\n<ul>\n<li>\n<p>To\
    \ align with other ALXN1840 Phase 2 and Phase 3 study protocols which did not\
    \ reference this criterion</p>\n</li>\n<li>\n<p>Recreational use of cannabis use\
    \ is being decriminalized in many countries</p>\n</li>\n<li>\n<p>Medicinal use\
    \ of cannabis would potentially relieve symptoms of WD</p>\n</li>\n<li>\n<p>Recent\
    \ use of cannabis is not expected to alter copper or molybdenum balance</p>\n\
    </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section 5.2, Exclusion criteria</p>\n\
    </td>\n<td>\n<p>Exclusion criterion 11 revised to \u201CThe use of an experimental\
    \ or unapproved/unlicensed therapy at the same time\n        or within 90 days\
    \ or 5 half-lives, whichever is longer, prior to the Screening Visit.\u201D</p>\n\
    </td>\n<td>\n<p>For consistency across all ALXN1840 protocols.</p>\n</td>\n</tr>\n\
    <tr>\n<td>\n<p>Section 10.1.1, Regulatory and Ethical Considerations</p>\n</td>\n\
    <td>\n<p>Added: \u201CThe Investigator will notify the IRB/IEC of deviations from\
    \ the study protocol or GCP as defined by UK\n        legislation as a serious\
    \ breach or as required by IRB/IEC procedures.\u201D</p>\n</td>\n<td>\n<p>To align\
    \ with UK legislation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>All sections</p>\n</td>\n\
    <td>\n<p>Minor editorial updates and corrections</p>\n</td>\n<td>\n<p>For clarification,\
    \ and to ensure accuracy and consistency throughout the protocol</p>\n</td>\n\
    </tr>\n</table>\n<p><b>Amendment 3 (31 Aug 2021)</b></p>\n<p>This amendment was\
    \ considered to be substantial based on the criteria set forth in Article 10(a)\
    \ of Directive 2001/20/EC of the European Parliament and the Council of the European\
    \ Union, the US Food and Drug Administration's (FDA) regulation at 21 CFR part\
    \ 312.30(b), and any applicable local regulations.</p>\n<p><b>Overall Rationale\
    \ for the Amendment</b></p>\n<p>The main reason for preparation of this amendment\
    \ was to update the washout period for zinc. Additional changes are listed below.</p>\n\
    <p><b>Changes to the Protocol</b></p>\n<table class=\"table align-top table-bordered\"\
    >\n<tr>\n<th>Section # and Name</th>\n<th>Description of Change</th>\n<th>Brief\
    \ Rationale and/or Clarifications</th>\n</tr>\n<tr>\n<td><p>Section 1.3, Schedule\
    \ of Activities; Section 4.2, Scientific Rationale for Study Design; Section 5.2,\
    \ Exclusion Criteria</p></td>\n<td><p>Previous treatment with zinc changed to\
    \ 21 days prior to Day 1.</p></td>\n<td><p>To align with feasibility of study\
    \ participation.</p></td>\n</tr>\n<tr>\n<td><p>Section 4.1, Overall Design, Table\
    \ 4</p></td>\n<td><p>Deleted the Adaptive Protocol Feature 1 that allowed enrollment\
    \ of participants who had completed other ALXN1840 studies.</p></td>\n<td><p>To\
    \ remove contradiction of the exclusion for previous treatment with ALXN1840.</p></td>\n\
    </tr>\n<tr>\n<td><p>Section 6.7 Intervention after the End of Study</p></td>\n\
    <td><p>Updated the options for intervention after study completion to include\
    \ both therapy that was discontinued before enrollment and other standard of care\
    \ therapy.</p></td>\n<td><p>To clarify treatment options at end of study.</p></td>\n\
    </tr>\n</table></div>"
- - NCI_105
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Brewer GJ, Hill GM, Prasad AS, Cossack
    ZT. Biological roles of ionic zinc. Prog Clin Biol Res. 1983;129:35-51.</p>

    <p>Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric
    emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91(1):94-99.</p>

    <p>Czachor JD, Cherian MG, Koropatnick J. Reduction of copper and metallothionein
    in toxic milk mice by tetrathiomolybdate, but not deferiprone. J Inorg Biochem.
    2002;88(2):213-222. Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis
    of the turnover of intestinal epithelia in preclinical animal species and humans.
    Drug Metab Dispos. 2014;42(12):2016-2022.</p>

    <p>Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani
    G. Wilson''s disease in children: 37-year experience and revised King''s score
    for liver transplantation. Liver Transpl. 2005;11(4):441-448.</p>

    <p>EASL. European Association for the Study of Liver (EASL) Clinical Practice
    Guidelines: Wilson''s disease. J Hepatol. 2012;56(3):671-685.</p>

    <p>Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification
    of Wilson disease. Liver Int. 2003;23(3):139-142.</p>

    <p>Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RD. Treatment of Wilson''s disease
    with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci.
    1986;292(6):344-349. Komatsu Y, Sadakata I, Ogra Y, Suzuki KT. Excretion of copper
    complexed with thiomolybdate into the bile and blood in LEC rats. Chem Biol Interact.
    2000;124(3):217-231.</p>

    <p>Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW,
    Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized
    serum creatinine values in the modification of diet in renal disease study equation
    for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.</p>

    <p>Lowndes SA, Adams A, Timms A, et al. Phase I study of copper-binding agent
    ATN-224 in patients with advanced solid tumors. Clin Cancer Res. 2008;14(22):7526-7534.</p>

    <p>Mason J, Lamand M, Tressol JC, Mulryan G. Studies of the changes in systemic
    copper metabolism and excretion produced by the intravenous administration of
    trithiomolybdate in sheep. Br J Nutr. 1988;59(2):289-300.</p>

    <p>Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified
    assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40-47.</p>

    <p>Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate
    on copper-metabolism in rats. J Inorg Biochem. 1981;14(3):189-207.</p>

    <p>Ogra Y, Ohmichi M, Suzuki KT. Systemic dispositions of molybdenum and copper
    after tetrathiomolybdate injection in LEC rats. J Trace Elem Med Biol. 1995;9(3):165-169.</p>

    <p>Ogra Y, Chikusa H, Suzuki KT. Metabolic fate of the insoluble copper/tetrathiomolybdate
    complex formed in the liver of LEC rats with excess tetrathiomolybdate. J Inorg
    Biochem. 2000;78(2):123-128.</p>

    <p>Plitz T, Boyling L. Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate)
    in a rat model of Wilson disease. Xenobiotica. 2019;49(3):332-338.</p>

    <p>Scheinberg IH, Sternlieb I, Schilsky M, Stockert RJ. Penicillamine may detoxify
    copper in Wilson''s disease. Lancet. 1987;2(8550):95.</p>

    <p>Strickland GT, Blackwell RQ, Watten RH. Metabolic Studies in Wilson''s Disease.
    Evaluation of Efficacy of Chelation Therapy in Respect to Copper Balance. Am J
    Med. 1971;51(1):31-40. Walshe JM. Copper chelation in patients with Wilson''s
    disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
    Q J Med. 1973;42(167):441-452.</p>

    <p>Weiss K, Askari F, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in
    patients with Wilson''s disease: an open-label, multicentre, phase 2 study. Lancet
    Gastroenterol Hepatol. 2017;2(12):869-876.</p></div>'
mainTimeline:
- - Description
  - This is the main timeline for the study design.
  - description
  - Day -42 to -9
  - Day -21
  - Day -8, check in day
  - Day -7
  - null
  - Day -6 and -5
  - null
  - Day -4
  - Day -3
  - Day -2
  - Day -1
  - Day 1
  - Day 2
  - Day 3
  - Day 4
  - Day 5
  - Day 6
  - Day 7
  - Day 8
  - Day 9
  - Day 10
  - Day 11
  - Day 12
  - Day 13
  - Day 14
  - Day 15
  - Day 16
  - Day 17
  - Day 18
  - Day 19
  - Day 20
  - Day 21
  - Day 22
  - Day 23
  - Day 24
  - Day 25
  - Day 26
  - Day 27
  - Day 28
  - Day 29
  - Day 30
  - Day 31
  - Day 32
  - Day 33
  - Day 34
  - Day 35
  - Day 36
  - Day 37
  - Day 38
  - Day 39
  - Day 40
  - End Of Study
- - Condition
  - Potential subject identified
  - label
  - -42 to -9
  - '-21'
  - '-8'
  - '-7'
  - null
  - -6 through -5
  - null
  - '-4'
  - '-3'
  - '-2'
  - '-1'
  - '1'
  - '2'
  - '3'
  - '4'
  - '5'
  - '6'
  - '7'
  - '8'
  - '9'
  - '10'
  - '11'
  - '12'
  - '13'
  - '14'
  - '15'
  - '16'
  - '17'
  - '18'
  - '19'
  - '20'
  - '21'
  - '22'
  - '23'
  - '24'
  - '25'
  - '26'
  - '27'
  - '28'
  - '29'
  - '30'
  - '31'
  - '32'
  - '33'
  - '34'
  - '35'
  - '36'
  - '37'
  - '38'
  - '39'
  - '40'
  - EOS
- - null
  - null
  - type
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
  - Activity
- - null
  - null
  - default
  - ZINC
  - CHECK_IN
  - D-7
  - D-6-5_START
  - D-6-5
  - D-6-5_DECISION
  - D-4
  - D-3
  - D-2
  - D-1
  - D1
  - D2
  - D3
  - D4
  - D5
  - D6
  - D7
  - D8
  - D9
  - D10
  - D11
  - D12
  - D13
  - D14
  - D15
  - D16
  - D17
  - D18
  - D19
  - D20
  - D21
  - D22
  - D23
  - D24
  - D25
  - D26
  - D27
  - D28
  - D29
  - D30
  - D31
  - D32
  - D33
  - D34
  - D35
  - D36
  - D37
  - D38
  - D39
  - D40
  - EOS
  - null
- - null
  - null
  - condition
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - null
  - epoch
  - Screening
  - Screening
  - Check In
  - Check In
  - Check In
  - Check In
  - null
  - Check In
  - Check In
  - Check In
  - Check In
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Treatment
  - Follow-Up
- - null
  - null
  - encounter
  - E1
  - E2
  - E3
  - E4
  - null
  - E5
  - null
  - E6
  - E7
  - E8
  - E9
  - E10
  - E11
  - E12
  - E13
  - E14
  - E15
  - E16
  - E17
  - E18
  - E19
  - E20
  - E21
  - E22
  - E23
  - E24
  - E25
  - E26
  - E27
  - E28
  - E29
  - E30
  - E31
  - E32
  - E33
  - E34
  - E35
  - E36
  - E37
  - E38
  - E39
  - E40
  - E41
  - E42
  - E43
  - E44
  - E45
  - E46
  - E47
  - E48
  - E49
  - E50
- - Parent Activity
  - Child Activity
  - BC/Procedure/Timeline
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Informed consent
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Admit to unit
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Discharge from unitf
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
- - null
  - Outpatient visit or phone callg
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Inclusion/exclusion
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Discuss/document contraception
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
- - null
  - Follicle-stimulating hormone (post-menopausal females only)
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Alcohol test
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Urine drug screen
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - HIV, hepatitis B and C screen
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Medical history/demographicsi
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - WD history
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Prior WD treatment
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Physical examination
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
- - null
  - Heightl , weight, and BMI
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
- - null
  - Enrollment/inclusion
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Discontinue chelation therapy
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Discontinue zinc therapy
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - ALXN1840 15 mg/day
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - ALXN1840 30 mg/day
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
- - null
  - Study intervention compliancen
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - 'Blood sampling for PK: Plasma total Mo and PUF-Mo PD: Plasma total and PUF-Cu,
    LBC, ceruloplasmin, ceruloplasmin-bound Cu'
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
- - null
  - Chemistry, hematology, Coagulation
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - X
  - X
  - X
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - X
  - X
- - null
  - Urinalysis
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
- - null
  - Urine/serum pregnancy tests
  - null
  - X
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
- - null
  - Retained serum sample (safety)
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Vitals sign measurements
  - null
  - X
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
- - null
  - 12-lead ECG (triplicate)
  - null
  - X
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - null
  - X
- - null
  - Adverse events
  - null
  - X
  - null
  - X
  - X
  - null
  - X
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
- - null
  - Cu/Mo-controlled meals
  - null
  - null
  - null
  - null
  - X
  - null
  - X
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
- - null
  - Light exercise regimen
  - null
  - null
  - null
  - null
  - X
  - null
  - X
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
- - null
  - Urination and bowel movement monitoring, menstruation checks
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - 24-hour urine for Cu and Mo
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Feces for Cu and Mo
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
  - null
- - null
  - Concomitant medication and non-pharmacologic therapy/procedure
  - null
  - X
  - null
  - X
  - X
  - X
  - X
  - null
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
  - X
study:
- - studyTitle
  - null
  - null
  - null
  - null
  - null
  - null
- - studyVersion
  - '2'
  - null
  - null
  - null
  - null
  - null
- - studyType
  - null
  - null
  - null
  - null
  - null
  - null
- - studyPhase
  - Phase II Trial
  - null
  - null
  - null
  - null
  - null
- - studyAcronym
  - null
  - null
  - null
  - null
  - null
  - null
- - studyRationale
  - "<p>The principal aim of this exploratory study is to investigate the effects\
    \ of ALXN1840 on copper balance in participants with Wilson disease (WD). The\
    \ study will specifically evaluate the effects of 2 different ALXN1840 doses as\
    \ well as the duration of treatment on copper balance to further elucidate the\
    \ dose response of \u201Cdecoppering\u201D versus \u201Cmaintenance\u201D dose\
    \ in participants with WD.</p>\n<p>The secondary aim of the study is to characterize\
    \ the steady-state absorption, distribution, metabolism, and excretion (ADME;\
    \ mass balance) of total molybdenum which is a surrogate measure of ALXN1840 disposition\
    \ in participants with WD.</p>\n<p>ALXN1840 contains the active anion tetrathiomolybdate\
    \ and has been shown to cause negative copper balance when administered to healthy\
    \ animals as well as decopper the liver in animal models of WD. In Study WTX101-201,\
    \ which assessed the safety and efficacy of ALXN1840 in participants with WD,\
    \ ALXN1840 demonstrated enhanced copper control as measured by reduced plasma\
    \ non-ceruloplasmin-bound copper (NCC) corrected (NCCcorrected ) for the stable\
    \ tetrathiomolybdate- copper -albumin tripartite complex (TPC).</p>\n<p>Depletion\
    \ of copper by ALXN1840 has been shown to occur primarily through fecal elimination\
    \ in both healthy and WD animal models. In this study, copper balance will be\
    \ calculated as the difference between measured copper input in food and drink\
    \ and measured copper output in urine and feces. This method is classically considered\
    \ the most objective measure of decoppering ability with a decoppering agent able\
    \ to drive a net negative copper balance.</p>\n<p>As part of the secondary objective,\
    \ to confirm that ALXN1840 steady state is adequately characterized by the plasma\
    \ pharmacokinetics (PK), a molybdenum mass balance assessment will be performed\
    \ at predicted steady state for the 15 mg/day and 30 mg/day doses: if steady state\
    \ is achieved, molybdenum(out) will equal molybdenum(in). This approach may also\
    \ detect potential accumulation in the liver or other tissues of participants\
    \ with WD.</p>"
  - null
  - null
  - null
  - null
  - null
- - businessTherapeuticAreas
  - 'SPONSOR: PHARMA = Alexion'
  - null
  - null
  - null
  - null
  - null
- - briefTitle
  - Copper and Molybdenum Balance in Participants with Wilson Disease Treated with
    ALXN1840
  - null
  - null
  - null
  - null
  - null
- - officialTitle
  - A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants
    with Wilson Disease Treated with ALXN1840
  - null
  - null
  - null
  - null
  - null
- - publicTitle
  - null
  - null
  - null
  - null
  - null
  - null
- - scientificTitle
  - null
  - null
  - null
  - null
  - null
  - null
- - protocolVersion
  - '3.1'
  - null
  - null
  - null
  - null
  - null
- - protocolStatus
  - Final
  - null
  - null
  - null
  - null
  - null
- - spare
  - null
  - null
  - null
  - null
  - null
  - null
- - category
  - name
  - description
  - label
  - type
  - date
  - scopes
- - amendment
  - AMEND_DATE_A1
  - Amendment approval date
  - Protocol Approval
  - Sponsor Approval Date
  - 18/08/2020
  - Global
- - amendment
  - AMEND_DATE_A2
  - Amendment approval date
  - Protocol Approval
  - Sponsor Approval Date
  - 19/03/2021
  - Global
- - amendment
  - AMEND_DATE_A3
  - Amendment approval date
  - Protocol Approval
  - Sponsor Approval Date
  - 31/08/2021
  - Global
- - amendment
  - AMEND_DATE_A3-1
  - Amendment approval date
  - Protocol Approval
  - Sponsor Approval Date
  - 18/03/2022
  - 'Country: United States of America'
- - protocol_document
  - P_APPROVE_ORG
  - Original protocol approval date
  - Original Protocol
  - Sponsor Approval Date
  - 12/05/2020
  - Global
- - protocol_document
  - P_APPROVE_A1
  - Amendment 1 approval date
  - Amendment 1
  - Sponsor Approval Date
  - 18/08/2020
  - Global
- - protocol_document
  - P_APPROVE_A2
  - Amendment 2 approval date
  - Amendment 2
  - Sponsor Approval Date
  - 19/03/2021
  - Global
- - protocol_document
  - P_APPROVE_A3
  - Amendment 3 approval date
  - Amendment 3
  - Sponsor Approval Date
  - 31/08/2021
  - Global
- - protocol_document
  - P_APPROVE_A3-1
  - Amendment 3.1 approval date
  - Amendment 3.1
  - Sponsor Approval Date
  - 18/03/2022
  - 'Country: United States of America'
- - protocol_document
  - P_APPROVE_A3
  - Amendment 3 approval date
  - Amendment 3
  - Sponsor Approval Date
  - 31/08/2021
  - Global
- - protocol_document
  - P_APPROVE_A3-1
  - Amendment 3.1 approval date
  - Amendment 3.1
  - Sponsor Approval Date
  - 18/03/2022
  - 'Country: United States of America'
studyDesign:
- - studyDesignDescription
  - The main design for the study
  - null
  - null
  - null
- - therapeuticAreas
  - 'SNOMED: 88518009 = Wilson''s disease'
  - null
  - null
  - null
- - studyDesignRationale
  - '<p>The study is designed as an open-label exploratory study to provide a descriptive
    assessment of copper balance in participants with WD, the target population for
    ALXN1840 therapy. The study is being conducted as a repeat-dose study to assess
    the effect of duration of ALXN1840 treatment and the effects of intra-patient
    dose increase on copper and molybdenum balance in participants with WD. The intra-patient
    dose escalation schedule is similar to that employed in the current Phase 3 Study
    WTX101-301. The similar schedule was chosen to characterize the decoppering effects
    expected early with treatment. This study is designed to supplement the mechanism
    of action study in healthy participants (Study ALXN1840-HV-108). While healthy
    participants are expected to be adequate to assess the mechanism of action of
    ALXN1840, characterization of copper balance in the WD population will help to
    understand if there are differences in the magnitude of effect between the 2 populations
    as this may be important to understand the doses that may support a net neutral
    versus a net negative copper balance. Limited nonclinical data on copper elimination
    with tetrathiomolybdate suggested copper excretion may be at least maintained
    or increased with repeated dosing (refer to the current IB).</p>

    <p>Therefore, the duration of the study and multiple collection periods will better
    characterize the pattern of copper elimination over time. Such information may
    be helpful in understanding the decoppering and maintenance phases.</p>

    <p>As the study involves intensive diet control and sampling, the study is planned
    to be conducted in a small number of participants with WD who will be admitted
    to a CRU for 2 inpatient periods. Inpatient Period 1 includes a baseline and initial
    15 mg/day collection period during the accumulation phase followed by an Outpatient
    Period; Inpatient Period 2 with a second collection period to support analysis
    of copper balance at 15 mg/day steady state and a 30 mg/day accumulation and steady
    state.</p>

    <p>During the Outpatient Period, participants will be encouraged to remain on
    a copper-controlled diet; however, to avoid confounding, a diet equilibration
    period is included in each study period. Overall, collection periods are a minimum
    of 3 days and as long as 15 days (which will be subdivided for analyses). Collection
    periods of at least 3 days were used to help minimize the impact of day-to-day
    variability on measurements. In addition, the time period for analysis will take
    into consideration the average bowel transit of approximately 40 hours (male:
    33 hours; female: 47 hours) (Camilleri, 1986; Metcalf, 1987). Because the periods
    are of different lengths, the study will calculate mean daily copper balance.</p>

    <p>While the primary endpoint for the study is an assessment of net copper balance,
    measurement of a pretreatment copper baseline will be helpful to understand the
    magnitude of effect of ALXN1840. To assess the copper baseline during the Inpatient
    Run-in Period, participants will be discontinued from their chelator therapy for
    approximately 4 days prior to initiating ALXN1840. During this period, participants
    will be maintained on a copper-controlled diet to minimize risk to the participants.
    In the Phase 3 study ALXN1840-WD-301, participants discontinue their chelator
    approximately 48 hours prior to initiation of ALXN1840 without reported complications.
    Among participants who discontinue chelator due to intolerance or noncompliance,
    the time from chelator discontinuation to the onset or worsening of symptoms varies
    from as little as 1 or 2 weeks to as long as months or years (Scheinberg, 1987).
    To prevent confounding of the study results, participants must be off zinc therapy
    for a minimum of 21 days prior to Day 1 because zinc works through upregulation
    of metallothionein (MT) in enterocytes resulting in elevation of fecal copper
    excretion. Previously, reports in the literature suggest that it can take up to
    3 weeks or longer for zinc treatment to have an efficacious effect on copper balance
    (Brewer, 1983), so a delayed time to reversal of this effect could also occur.
    However, the physiologic turnover of human gastrointestinal epithelial cells is
    3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc on intestinal
    copper absorption is expected to be minimal 21 days after discontinuation of zinc.</p>

    <p>Following ALXN1840 administration, the active drug moiety tetrathiomolybdate
    rapidly binds copper to form TPC, mostly in the liver and blood, and presents
    as such in the systemic circulation. If TPC is not rapidly formed, tetrathiomolybdate
    spontaneously undergoes serial hydrolysis to form molybdate, the most common form
    of nutrient molybdenum, and is excreted in the urine. Total molybdenum concentration
    has been measured as a surrogate of ALXN1840 PK; however, total molybdenum concentration
    cannot distinguish whether the molybdenum is protein bound (mostly as TPC), free
    active drug as ALXN1840, intermediate hydrolysis products, or molybdate. To better
    characterize the amount of non-TPC-bound drug and its unbound degradation products,
    plasma PUF-molybdenum has also been measured, which represents the free parent
    drug (ALXN1840), short-lived intermediate hydrolysis products, and molybdate,
    which may have originated from the tetrathiomolybdate or from food intake as a
    micronutrient. Total molybdenum PK and free molybdenum PK serve as surrogate measures
    of ALXN1840 PK. To better characterize the ADME of ALXN1840, the PK of both total
    molybdenum and PUF-molybdenum will be characterized and described.</p>

    <p>This study is designed to provide an extensive assessment of copper and molybdenum
    balance over the first 40 days of treatment with ALXN1840 and support a more robust
    understanding of the effects of duration of treatment and dose of ALXN1840 on
    copper balance. Half-life estimates for total molybdenum in Study WTX101-201 were
    reported to be approximately 24 hours at steady state on Days 84 and 168, while
    in healthy participants, total molybdenum half-life was measured closer to 51
    hours. With a half-life within this range, the sample collection periods include
    assessment of copper and molybdenum balance both during accumulation and at steady
    state for both the 15 mg/day and 30 mg/day doses. The study will include both
    intake and output collection as well as PK and copper assessments (ie, ceruloplasmin-bound
    copper and labile bound copper [LBC]) to inform the relationship between balance
    measurements and copper and molybdenum levels in the blood.</p>

    <p>Finally, preclinical data from ALXN1840 ADME study suggest the potential for
    molybdenum accumulation in the liver of participants with WD; therefore, an assessment
    of molybdenum balance will help determine whether steady state has been reached
    as defined by a molybdenum balance of neutral during the collection period. Because
    molybdenum is a necessary micronutrient and serves as a cofactor for a number
    of enzymes and may exist in intracellular stores, small variations in molybdenum
    balance could be due to molybdate rather than ALXN1840.</p>'
  - null
  - null
  - null
- - studyDesignBlindingScheme
  - Open Label Study
  - null
  - null
  - null
- - trialIntentTypes
  - Cure Study
  - null
  - null
  - null
- - trialSubTypes
  - Efficacy Study, Safety Study, Pharmacokinetic Study
  - null
  - null
  - null
- - interventionModel
  - Single Group Study
  - null
  - null
  - null
- - masking
  - null
  - null
  - null
  - null
- - characteristics
  - ADAPTIVE
  - null
  - null
  - null
- - mainTimeline
  - mainTimeline
  - null
  - null
  - null
- - otherTimelines
  - null
  - null
  - null
  - null
- - studyType
  - Interventional Study
  - null
  - null
  - null
- - Epoch/Arms
  - Screening
  - Check In
  - Treatment
  - Follow-Up
- - 15mg-30mg
  - null
  - null
  - null
  - null
- - null
  - null
  - null
  - null
  - null
- - Epoch/Arms
  - Screening
  - Check In
  - Treatment
  - Follow-Up
- - Epoch/Arms
  - Screening
  - Check In
  - Treatment
  - Follow-Up
- - Epoch/Arms
  - Screening
  - Check In
  - Treatment
  - Follow-Up
- - Epoch/Arms
  - Screening
  - Check In
  - Treatment
  - Follow-Up
- - 15mg-30mg
  - null
  - null
  - null
  - null
studyDesignActivities:
- - Eligibility
  - Eligibility
  - Eligibility grouping activity
- - Informed consent
  - Informed consent
  - null
- - Admit to unit
  - Admit to unit
  - null
- - Discharge from unit
  - Discharge from unitf
  - null
- - Outpatient visit or phone call
  - Outpatient visit or phone callg
  - null
- - Inclusion/exclusion
  - Inclusion/exclusion
  - null
- - Discuss/document contraception
  - Discuss/document contraception
  - null
- - Follicle-stimulating hormone
  - Follicle-stimulating hormone (post-menopausal females only)
  - null
- - Alcohol test
  - Alcohol test
  - null
- - Urine drug screen
  - Urine drug screen
  - null
- - HIV, hepatitis B and C screen
  - HIV, hepatitis B and C screen
  - null
- - Study Administration
  - Study Administration
  - Study Administration grouping activity
- - Medical history/demographics
  - Medical history/demographicsi
  - null
- - WD history
  - WD history
  - null
- - Prior WD treatment
  - Prior WD treatment
  - null
- - Physical examination
  - Physical examination
  - null
- - Height, weight, and BMI
  - Heightl , weight, and BMI
  - null
- - Enrollment
  - Enrollment
  - Enrollment grouping activity
- - Enrollment/inclusion
  - Enrollment/inclusion
  - null
- - Discontinue chelation therapy
  - Discontinue chelation therapy
  - null
- - Discontinue zinc therapy
  - Discontinue zinc therapy
  - null
- - Administration of Study Intervention
  - Administration of Study Intervention
  - Administration of Study Intervention grouping activity
- - ALXN1840 15 mg/day
  - ALXN1840 15 mg/day
  - null
- - ALXN1840 30 mg/day
  - ALXN1840 30 mg/day
  - null
- - Study intervention compliance
  - Study intervention compliancen
  - null
- - PK/PD Analyses
  - PK/PD Analyses
  - PK/PD Analyses grouping activity
- - Blood sampling for PK and PD
  - 'Blood sampling for PK: Plasma total Mo and PUF-Mo PD: Plasma total and PUF-Cu,
    LBC, ceruloplasmin, ceruloplasmin-bound Cu'
  - null
- - Safety Assessments / Laboratory Analyses
  - Safety Assessments / Laboratory Analyses
  - Safety Assessments / Laboratory Analyses grouping activity
- - Chemistry, hematology, Coagulation
  - Chemistry, hematology, Coagulation
  - null
- - Urinalysis
  - Urinalysis
  - null
- - Urine/serum pregnancy tests
  - Urine/serum pregnancy tests
  - null
- - Retained serum sample (safety)
  - Retained serum sample (safety)
  - null
- - Vitals sign measurements
  - Vitals sign measurements
  - null
- - 12-lead ECG (triplicate)
  - 12-lead ECG (triplicate)
  - null
- - Adverse events
  - Adverse events
  - null
- - Balance assessments
  - Balance assessments
  - Balance assessments grouping activity
- - Cu/Mo-controlled meals
  - Cu/Mo-controlled meals
  - null
- - Light exercise regimen
  - Light exercise regimen
  - null
- - Urination and bowel movement monitoring, menstruation checks
  - Urination and bowel movement monitoring, menstruation checks
  - null
- - 24-hour urine for Cu and Mo
  - 24-hour urine for Cu and Mo
  - null
- - Feces for Cu and Mo
  - Feces for Cu and Mo
  - null
- - Other
  - Other
  - Other grouping activity
- - Concomitant medication and non-pharmacologic therapy/procedure
  - Concomitant medication and non-pharmacologic therapy/procedure
  - null
- - PK / PD Blood Sampling
  - 'Blood sampling for PK: Plasma total Mo and PUF-Mo PD: Plasma total and PUF-Cu,
    LBC, ceruloplasmin, ceruloplasmin-bound Cu'
  - null
studyDesignArms:
- - 15mg-30mg
  - Treatment with 15mg and then 30 mg
  - Treatment
  - Protocol Treatment Arm
  - Data collected from subjects
  - Data Generated Within Study
studyDesignContent:
- - NC_1
  - '0.'
  - Title Page
  - '<div xmlns="http://www.w3.org/1999/xhtml"><div class="container">

    <div class="row mt-5">

    <div class="col-md-10 offset-md-1 text-center">

    <p><b>TITLE PAGE</b></p>

    </div>

    </div>

    </div>

    <p><b>Protocol Title: </b><usdm:ref attribute="text" id="StudyTitle_2" klass="StudyTitle"></usdm:ref></p>

    <p><b>Protocol Number: </b><usdm:ref attribute="text" id="StudyIdentifier_1" klass="StudyIdentifier"></usdm:ref></p>

    <p><b>Amendment Number: </b>TBD</p>

    <p><b>Compound: </b>TBD</p>

    <p><b>Study Phase: </b><usdm:ref attribute="decode" id="Code_365" klass="Code"></usdm:ref></p>

    <p><b>Short Title: </b><usdm:ref attribute="text" id="StudyTitle_1" klass="StudyTitle"></usdm:ref></p>

    <p><b>Sponsor Name: </b><usdm:ref attribute="label" id="Organization_1" klass="Organization"></usdm:ref>,
    <usdm:ref attribute="text" id="Address_1" klass="Address"></usdm:ref></p>

    <p><b>Legal Registered Address:</b><usdm:ref attribute="label" id="Organization_1"
    klass="Organization"></usdm:ref>, <usdm:ref attribute="text" id="Address_1" klass="Address"></usdm:ref></p>

    <p><b>Regulatory Agency Identifier Number(s)</b></p>

    <p><usdm:ref attribute="text" id="StudyIdentifier_2" klass="StudyIdentifier"></usdm:ref>,
    <usdm:ref attribute="text" id="StudyIdentifier_3" klass="StudyIdentifier"></usdm:ref>,
    <usdm:ref attribute="text" id="StudyIdentifier_4" klass="StudyIdentifier"></usdm:ref></p>

    <b>Approval Date:</b>

    <p><b><usdm:ref attribute="label" id="GovernanceDate_1" klass="GovernanceDate"></usdm:ref>
    <usdm:ref attribute="dateValue" id="GovernanceDate_1" klass="GovernanceDate"></usdm:ref></b></p>

    <p><b>Amendment 1 18 Aug 2020</b></p>

    <p><b>Amendment 2 19 Mar 2021</b></p>

    <p><b>Amendment 3 31 Aug 2021</b></p>

    <p><b>Amendment 3.1 (US) 18 Mar 2022</b></p>

    <p><b>Sponsor Signatory:</b></p>

    <div class="container">

    <div class="row mt-5">

    <div class="col-md-6">

    <p>____________________________________</p>

    </div>

    <div class="col-md-6">

    <p>____________________________________</p>

    <p><b>Date</b></p>

    </div>

    </div>

    </div>

    <p><b>Medical Monitor Name and Contact Information can be found in the Study Contact
    List.</b></p>

    <div class="container">

    <div class="row mt-5">

    <div class="col-md-10 offset-md-1 text-center">

    <p>INVESTIGATOR''S AGREEMENT</p>

    </div>

    </div>

    </div>

    <p>I have read the study protocol amendment 3.1 and agree to conduct the study
    in accordance with this protocol, all applicable government regulations, the principles
    of the ICH E6 Guidelines for Good Clinical Practice, and the principles of the
    World Medical Association Declaration of Helsinki. I also agree to maintain the
    confidentiality of all information received or developed in connection with this
    protocol.</p>

    <p>____________________________________</p>

    <p>Printed Name of Investigator</p>

    <p>_____________________________________</p>

    <p>Signature of Investigator</p>

    <p>_______________</p>

    <p>Date</p>

    <p><b>PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE</b></p>

    <p><b>Amendment 3.1 (US), 18 Mar 2022</b></p>

    <p>This amendment is considered to be substantial based on the criteria set forth
    in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council
    of the European Union, the US Food and Drug Administration''s (FDA) regulation
    at 21 CFR part 312.30(b), and any applicable local regulations.</p>

    <p><b>Overall Rationale for the Amendment</b></p>

    <p>The main reason for preparation of this amendment was to clarify study procedures
    occurring across different sites in the US, so as to facilitate participant recruitment
    across different regions of the US, and to lessen inconvenience for participants
    without compromising the quality of the study.</p>

    <p><b>Changes to the Protocol</b></p>

    <table class="table align-top table-bordered">

    <tr>

    <th>Section # and Name</th>

    <th>Description of Change</th>

    <th>Brief Rationale and/or Clarifications</th>

    </tr>

    <tr>

    <td><p>Section 1.3 Schedule of Activities (SoA), Table 1</p></td>

    <td><p>Addition of text to the footnote to state that procedures specific to screening
    sites (only in the US) detailed in Section 8</p></td>

    <td><p>As per Section 8 (below).</p></td>

    </tr>

    <tr>

    <td><p>4.2 Scientific Rationale for Study Design</p></td>

    <td><p>Number of days changed from 30 days to 21 days in the following sentence:</p>

    <ul><li><p>However, the physiologic turnover of human gastrointestinal epithelial
    cells is 3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc
    on intestinal copper absorption is expected to be minimal <del>30</del> <ins>21</ins>
    days after discontinuation of zinc.</p></li></ul></td>

    <td><p>To align the number of days with the mention of zinc discontinuation elsewhere
    in the protocol.</p></td>

    </tr>

    <tr>

    <td><p>Section 8 Study Assessments and Procedures</p></td>

    <td><p>Addition of text applicable only to the US that details the possibility
    for sites in the US to only perform screening procedures and not any of the remaining
    study procedures.</p></td>

    <td><p>To facilitate participant recruitment across different regions of the US
    and to lessen inconvenience for participants without compromising the quality
    of the study.</p></td>

    </tr>

    </table></div>'
- - NC_2
  - '1.'
  - PROTOCOL SUMMARY
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_3
  - 1.1.
  - Synopsis
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Protocol Title: </b><usdm:ref\
    \ attribute=\"text\" id=\"StudyTitle_2\" klass=\"StudyTitle\"></usdm:ref>\n<p><b>Short\
    \ Title: </b><usdm:ref attribute=\"text\" id=\"StudyTitle_1\" klass=\"StudyTitle\"\
    ></usdm:ref></p>\n<p><b>Rationale: </b><usdm:ref attribute=\"rationale\" id=\"\
    StudyVersion_1\" klass=\"StudyVersion\"></usdm:ref></p>\n<p><b>Objectives and\
    \ Endpoints</b></p>\n<table \"=\"\" class=\"table align-top\">\n<tr>\n<th>Objectives</th>\n\
    <th>Endpoints</th>\n</tr>\n<tr>\n<td>\n<p><b>Primary</b></p>\n<p>\n<usdm:ref attribute=\"\
    text\" id=\"Objective_1\" klass=\"Objective\"></usdm:ref>\n</p>\n</td>\n<td>\n\
    <p>\n<usdm:ref attribute=\"text\" id=\"Endpoint_1\" klass=\"Endpoint\"></usdm:ref>\n\
    </p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Secondary</b></p>\n<p><usdm:ref attribute=\"\
    text\" id=\"Objective_2\" klass=\"Objective\"></usdm:ref></p>\n</td>\n<td>\n<p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_2\" klass=\"Endpoint\"></usdm:ref></p>\n</td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_3\" klass=\"Objective\"\
    ></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_3\" klass=\"\
    Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\"\
    \ id=\"Objective_4\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_4\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_5\" klass=\"Objective\"\
    ></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_5\" klass=\"\
    Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\"\
    \ id=\"Objective_6\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_6\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_7\" klass=\"Objective\"\
    ></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_7\" klass=\"\
    Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td>\n<p><b>Safety</b></p>\n<p><usdm:ref\
    \ attribute=\"text\" id=\"Objective_8\" klass=\"Objective\"></usdm:ref></p>\n\
    </td>\n<td>\n<p>Safety parameters:</p>\n<p><usdm:ref attribute=\"text\" id=\"\
    Endpoint_8\" klass=\"Endpoint\"></usdm:ref></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Exploratory</b></p>\n\
    <p><usdm:ref attribute=\"text\" id=\"Objective_9\" klass=\"Objective\"></usdm:ref></p>\n\
    </td>\n<td>\n<p><usdm:ref attribute=\"text\" id=\"Endpoint_9\" klass=\"Endpoint\"\
    ></usdm:ref></p>\n</td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"\
    Objective_10\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"\
    text\" id=\"Endpoint_10\" klass=\"Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n\
    <td><p><usdm:ref attribute=\"text\" id=\"Objective_11\" klass=\"Objective\"></usdm:ref></p></td>\n\
    <td><p><usdm:ref attribute=\"text\" id=\"Endpoint_11\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_12\" klass=\"\
    Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_12\"\
    \ klass=\"Endpoint\"></usdm:ref></p></td>\n</tr>\n<tr>\n<td><p><usdm:ref attribute=\"\
    text\" id=\"Objective_13\" klass=\"Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref\
    \ attribute=\"text\" id=\"Endpoint_13\" klass=\"Endpoint\"></usdm:ref></p></td>\n\
    </tr>\n<tr>\n<td><p><usdm:ref attribute=\"text\" id=\"Objective_14\" klass=\"\
    Objective\"></usdm:ref></p></td>\n<td><p><usdm:ref attribute=\"text\" id=\"Endpoint_14\"\
    \ klass=\"Endpoint\"></usdm:ref></p></td>\n</tr>\n</table>\n<p>Note: The accumulation\
    \ period refers to time from initiation of ALXN1840 (Day 1) to expected steady\
    \ state at Day 10, based on 5 times the half-life of 2 days.</p>\n<p><b>Overall\
    \ Design</b></p>\n<p>This is a single-arm, open-label, repeat-dose study to evaluate\
    \ the effects of ALXN1840 administration on copper balance in participants with\
    \ WD. The safety and tolerability of ALXN1840 in participants with WD will also\
    \ be assessed. ALXN1840 PK in plasma as measured via total molybdenum and plasma\
    \ ultrafiltrate (PUF) molybdenum will be determined after repeated dosing along\
    \ with total molybdenum mass balance at steady state.</p>\n<p><b>Disclosure Statement</b>:\
    \ This is an open-label, 3-period study with 1 arm.</p>\n<p><b>Number of Participants:</b></p>\n\
    <p>The sample size will be approximately 10 participants which will allow a general\
    \ characterization of copper balance in response to ALXN1840.</p>\n<p><b><u>Note</u>:</b>\
    \ \u201CEnrolled\u201D means all participants who sign the informed consent form\
    \ (ICF), are eligible for the study, and are registered on Day -7 when participants\
    \ are assigned a participant number.</p>\n<p><b>Intervention Groups and Duration:</b></p>\n\
    <p>Treatment-experienced (which includes standard of care therapies or ALXN1840)\
    \ and treatment-na\xEFve participants are eligible for this study. Following screening\
    \ and enrollment, participants will have a Run-in Period to support diet equilibration\
    \ (Day -7 through Day -5) and measurement of pretreatment copper and molybdenum\
    \ balance (Day -4 through Day -1). Following the Run-in Period, participants will\
    \ be administered ALXN1840 at 15 mg/day for a treatment period of approximately\
    \ 28 days followed by titration up to 30 mg/day on Day 29. Before titration to\
    \ 30 mg/day, the Safety Review Committee (SRC) will review available safety data\
    \ through Day 23 for each participant.</p>\n<p>Participants will have intake and\
    \ output collection periods from Day -4 through Day -1, from Day 1 through Day\
    \ 8 (initial 15 mg/day collection period), and Day 25 through Day 39. The collection\
    \ periods will support an assessment of both copper and molybdenum balance (as\
    \ a measure of ALXN1840 ADME) at the 15 mg/day and 30 mg/day doses and will allow\
    \ assessment of the effects of duration of treatment on copper elimination and\
    \ copper balance</p>\n<p>Participants may be discharged from the clinical research\
    \ unit (CRU) on Day 9 to return on Day 22 or Day 23 (predose); all procedures\
    \ will start on Day 23. To ensure flexibility, the Outpatient Period during Treatment\
    \ Period 1 may be extended up to an additional 14 days with Investigator approval.\
    \ In this situation, participants will be given additional investigational product\
    \ to support daily dosing throughout the Outpatient Period. In such cases, the\
    \ actual Outpatient Period</p>\n<p>duration will be recorded and the participant\
    \ will continue Inpatient Period 2 at Day 23. During the Outpatient Period, participants\
    \ will use SMS text messaging to confirm study intervention administration. At\
    \ the CRU's discretion, participants may remain in the CRU during the outpatient\
    \ period for safety or to maintain the integrity of the conduct of the study.</p>\n\
    <p><b>Safety Review Committee:</b></p>\n<p>A Safety Review Committee (SRC), composed\
    \ of a minimum of the Investigator, Alexion Medical Monitor, and Alexion Safety\
    \ Physician, will meet at the end of 15 mg/day dosing to confirm proceeding to\
    \ 30 mg/day and as necessary based on any emerging safety concerns.</p></p></div>"
- - NC_4
  - '1.2'
  - Schema
  - '<div xmlns="http://www.w3.org/1999/xhtml"><b>Figure 1: Study Schematic</b>

    <img alt="Alt text" src="data:image/png;base64,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'
- - NC_5
  - 1.3.
  - Schedule of Activities (SoA)
  - '<div xmlns="http://www.w3.org/1999/xhtml"><div class="page soa-page table-responsive"><p><b>Timeline:
    Main Timeline, Potential subject identified</b></p><table class="table table-bordered
    table-sm" style="width:100%"><tr><td><p class="soa-activity-text"></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_1" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_1" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_2" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_3" klass="StudyEpoch"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="StudyEpoch_4" klass="StudyEpoch"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="Encounter_1" klass="Encounter"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Encounter_2" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_3" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_4" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="Encounter_5" klass="Encounter"></usdm:ref></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_6" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_7" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_8" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_9" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_10" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_11" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_12" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_13" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_14" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_15" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_16" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_17" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_18" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_19" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_20" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_21" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_22" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_23" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_24" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_25" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_26" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_27" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_28" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_29" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_30" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_31" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_32" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_33" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_34" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_35" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_36" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_37" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_38" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_39" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_40" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_41" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_42" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_43" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_44" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_45" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_46" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_47" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_48" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_49" klass="Encounter"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="label" id="Encounter_50" klass="Encounter"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="label"
    id="Timing_1" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_2" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_3" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_4" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_5" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_6" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_7" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_8" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_9" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_10" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_11" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_12" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_13" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_14" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_15" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_16" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_17" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_18" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_19" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_20" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_21" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_22" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_23" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_24" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_25" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_26" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_27" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_28" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_29" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_30" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_31" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_32" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_33" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_34" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_35" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_36" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_37" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_38" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_39" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_40" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_41" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_42" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_43" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_44" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_45" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_46" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_47" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_48" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_49" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_50" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_51" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="label" id="Timing_52" klass="Timing"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"></p></td><td><p class="soa-body-text"><usdm:ref attribute="windowLabel"
    id="Timing_1" klass="Timing"></usdm:ref></p></td><td><p class="soa-body-text"><usdm:ref
    attribute="windowLabel" id="Timing_2" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_3" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_4" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_5" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_6" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_7" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_8" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_9" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_10" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_11" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_12" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_13" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_14" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_15" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_16" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_17" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_18" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_19" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_20" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_21" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_22" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_23" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_24" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_25" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_26" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_27" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_28" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_29" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_30" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_31" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_32" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_33" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_34" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_35" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_36" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_37" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_38" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_39" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_40" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_41" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_42" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_43" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_44" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_45" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_46" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_47" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_48" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_49" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_50" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_51" klass="Timing"></usdm:ref></p></td><td><p
    class="soa-body-text"><usdm:ref attribute="windowLabel" id="Timing_52" klass="Timing"></usdm:ref></p></td></tr><tr><td><p
    class="soa-activity-text"><usdm:ref attribute="label" id="Activity_1" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text">X</p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td></tr><tr><td><p class="soa-activity-text"><usdm:ref
    attribute="label" id="Activity_2" klass="Activity"></usdm:ref><sup>1</sup></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text">X</p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text">X</p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td></tr><tr><td><p class="soa-activity-text"><usdm:ref
    attribute="label" id="Activity_3" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text">X<sup>2</sup></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text">X<sup>3</sup></p></td><td><p class="soa-body-text"></p></td></tr><tr><td><p
    class="soa-activity-text"><usdm:ref attribute="label" id="Activity_4" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text">X<sup>4</sup></p></td><td><p class="soa-body-text">X<sup>5</sup></p></td><td><p
    class="soa-body-text">X<sup>6</sup></p></td><td><p class="soa-body-text">X<sup>7</sup></p></td><td><p
    class="soa-body-text">X<sup>8</sup></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td></tr><tr><td><p class="soa-activity-text"><usdm:ref
    attribute="label" id="Activity_5" klass="Activity"></usdm:ref></p></td><td><p
    class="soa-body-text">X</p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text">X</p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text">X</p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p class="soa-body-text"></p></td><td><p
    class="soa-body-text"></p></td><td><p cla'
- - NC_6
  - '2.'
  - INTRODUCTION
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>ALXN1840 (bis-choline tetrathiomolybdate;
    formerly known as WTX101) is a novel copper binding agent in development for the
    treatment of WD.</p></div>
- - NC_7
  - 2.1.
  - Study Rationale
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The principal aim of this exploratory\
    \ study is to investigate the effects of ALXN1840 on copper balance in participants\
    \ with WD. The study will specifically evaluate the effects of 2 different ALXN1840\
    \ dose levels as well as the duration of treatment on copper balance to further\
    \ elucidate the dose response of \u201Cdecoppering\u201D versus \u201Cmaintenance\u201D\
    \ dose in participants with WD.</p>\n<p>ALXN1840 contains the active anion tetrathiomolybdate\
    \ and has been shown to cause negative copper balance when administered to healthy\
    \ animals as well as decopper the liver in animal models of WD (Mills, 1981; Czachor,\
    \ 2002). In Study WTX101-201, which assessed the safety and efficacy of ALXN1840\
    \ in participants with WD, ALXN1840 demonstrated enhanced copper control as measured\
    \ by reduced plasma NCCcorrected for the stable tetrathiomolybdatecopper-albumin\
    \ TPC (Weiss, 2017).</p>\n<p>Depletion of copper by ALXN1840 has been shown to\
    \ occur primarily through fecal elimination in both healthy and WD animal models.\
    \ Sheep injected with 30 mg/day of tetrathiomolybdate for 5 days were shown to\
    \ have an elevation of fecal copper during the treatment period increasing from\
    \ a baseline of approximately 3 mg/day up to approximately 7 mg/day during the\
    \ treatment period, before returning to baseline concentrations (Mason, 1988).\
    \ Similarly, when Long-Evans Cinnamon (LEC) WD model rats were injected intraperitoneally\
    \ with a saline solution of tetrathiomolybdate at a dose of 10 mg/kg body weight\
    \ for 8 consecutive days, the amounts of both copper and molybdenum excreted into\
    \ the feces increased significantly (Ogra, 2000), which may suggest that copper\
    \ is excreted in a complex with tetrathiomolybdate into the feces. While fecal\
    \ copper increases with tetrathiomolybdate, the amount of copper excreted into\
    \ the urine decreased and that of molybdenum increased significantly during treatment\
    \ with tetrathiomolybdate. Molybdenum in the urine was molybdate which does not\
    \ bind copper (data on file). These findings are in line with other studies showing\
    \ enhanced biliary and/or fecal excretion of copper and molybdenum upon administration\
    \ of tetrathiomolybdate in rats and sheep (Komatsu, 2000; Ogra, 1995; Mason, 1988).</p>\n\
    <p>We hypothesize that repeated doses of ALXN1840 may drive a net negative copper\
    \ balance in participants with WD by increasing fecal excretion of copper. In\
    \ this study, copper balance will be calculated as the difference between measured\
    \ copper input in food and drink and measured copper output in urine and feces.\
    \ This method is classically considered the most objective measure of decoppering\
    \ ability with a decoppering agent able to drive a net negative copper balance\
    \ (Hill,1986; Strickland, 1971; Walshe, 1973). The purpose of this study is to\
    \ provide additional descriptive characterization of the effect of ALXN1840 on\
    \ copper balance in participants with WD. Further data obtained may help support\
    \ characterization of a \u201Cdecoppering\u201D versus \u201Cmaintenance\u201D\
    \ dose of ALXN1840, where a decoppering dose would be a dose sufficient to drive\
    \ a net negative copper balance and maintenance would support a more neutral copper\
    \ balance.</p>\n<p>The secondary aim of the study is to characterize the steady-state\
    \ ADME (mass balance) of total molybdenum as a surrogate measure of ALXN1840 disposition\
    \ in participants with WD. To confirm that steady state is adequately characterized\
    \ by the plasma PK, a molybdenum mass balance assessment will be performed on\
    \ Day 25 through Day 28 for the 15 mg/day dose and Day 36 through Day 39 for the\
    \ 30 mg/day dose: if steady state is achieved, molybdenum(out) will equal molybdenum(in).</p></div>"
- - NC_8
  - '2.2'
  - Background
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>ALXN1840 has been selected for\
    \ development in WD due to its improved stability properties over ammonium tetrathiomolybdate,\
    \ which has previously been studied in participants with WD and other indications.\
    \ Ammonium tetrathiomolybdate and bis-choline tetrathiomolybdate nonclinical and\
    \ clinical data reported to date support the efficacy and safety of ALXN1840.</p>\n\
    <p>ALXN1840 rapidly forms stable tetrathiomolybdate-copper-albumin TPCs, which\
    \ stabilize free copper leading to a reduction in the NCC concentrations after\
    \ correction for free copper bound to TPC (NCCcorrected ).</p>\n<p>Studies in\
    \ both healthy and WD animal models showed that treatment with tetrathiomolybdate\
    \ results in removal of copper from the liver. Tetrathiomolybdate administered\
    \ to healthy mice by intraperitoneal injection resulted in a dose-dependent reduction\
    \ in liver copper concentration over a treatment range of 0 - 6 mg/kg/day (human\
    \ equivalent dose [HED] by body surface area [BSA] scaling: 0 - 1 mg/kg/day).\
    \ The results of these studies indicated that only 30% \u2011 40% of copper remained\
    \ after 5 weeks of treatment. Similar liver decoppering (approximately 40% - 60%)\
    \ was also reported in toxic milk mice (a WD animal model) at 5 mg/kg/ day for\
    \ 14 days (HED by BSA scaling: 0.4 mg/kg/day; Mills, 1981; Czachor, 2002). In\
    \ LEC WD model rats, 25 mg/kg/day of ALXN1840 (HED by BSA scaling: 4 mg/kg/day)\
    \ administered by oral gavage for 10 days, resulted in an approximately 50% decrease\
    \ in liver copper concentration. Because ALXN1840 has been shown to have a similar\
    \ mechanism of action in healthy and WD animal models, a mechanism of action study\
    \ in healthy participants is being performed (Study ALXN1840-HV-108) to demonstrate\
    \ that ALXN1840 can result in a change from baseline in copper balance with repeat-dose\
    \ ALXN1840 (30 mg/day) treatment.</p>\n<p>In the Phase 2 proof-of-concept Study\
    \ WTX101-201 in participants with WD, ALXN1840 demonstrated a sustained control\
    \ of free copper as measured by NCCcorrected . Importantly, ALXN1840 treatment\
    \ resulted in improvements in disability and neurologic symptoms as measured by\
    \ the Unified Wilson Disease Rating Scale (UWDRS, Parts II and III) and stabilization\
    \ of liver function (Weiss, 2017). Treatment with ALXN1840 resulted in an acceptable\
    \ safety and tolerability profile when initiated at 15 mg daily with Investigator-driven,\
    \ individual participant titration of dose based on safety, NCCcorrected , and\
    \ symptoms.</p>\n<p>Following single-dose administration of 60 mg ALXN1840, total\
    \ molybdenum peaked at approximately 4.54 hours with a terminal elimination half-life\
    \ measured at approximately 51 hours. In Study WTX101-201, the PK of ALXN1840,\
    \ based on total molybdenum, indicated that exposure in participants with WD at\
    \ a dose of 30 mg appeared consistent with previous results from healthy participants.\
    \ The half-life was estimated to be approximately 24 hours at steady state on\
    \ Days 84 and 168 and was shorter than estimated in previous studies. Based on\
    \ a total molybdenum PK half-life of approximately 24 - 51 hours, total molybdenum\
    \ steady state may conservatively be reached within approximately 10 - 12 days.\
    \ Nevertheless, results (as</p>\n<p>measured by total molybdenum) obtained from\
    \ the ALXN1840 balance study in the LEC WD rat model suggested that approximately\
    \ 30% of a single dose of ALXN1840 remained in the liver by Day 7, indicating\
    \ the possibility of tissue accumulation, particularly in the setting of high\
    \ liver copper concentration (Plitz, 2019).</p>\n<p>If the half-life of ALXN1840\
    \ in liver were longer than that of the systemic compartment, the accumulation\
    \ may not be readily detected in the absence of a longer treatment period and\
    \ with characterization of the terminal elimination period. An alternative approach\
    \ to assessing steady state using total molybdenum PK is to assess whether the\
    \ total molybdenum intake is equal to the total molybdenum output; this approach\
    \ may detect any significant ongoing accumulation in the liver or other tissues.</p>\n\
    <p>Detailed descriptions of the chemistry, pharmacology, efficacy, and safety\
    \ of ALXN1840 are provided in the Investigator's Brochure (IB).</p></div>"
- - NC_9
  - '2.3'
  - Benefit-Risk Assessment
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Detailed information about the known
    and expected benefits, risks, and reasonably expected adverse events (AEs) of
    ALXN1840 are presented in the IB. Information about the known or potential risks
    and benefits are detailed in the following sections.</p></div>
- - NC_10
  - 2.3.1
  - Risk Assessment
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Details of the potential risks and
    mitigation strategy are provided in Table 3.</p>

    <p><b>Table 3: Potential Risks and Mitigation Strategy</b></p>

    <table "="" class="table align-top">

    <tr>

    <th>Potential Risk of Clinical Significance</th>

    <th>Summary of Data/Rationale for Risk</th>

    <th>Mitigation Strategy</th>

    </tr>

    <tr>

    <td colspan="3"><b>ALXN1840</b></td>

    </tr>

    <tr>

    <td><p>Dose-dependent elevations in transaminases (ALT and AST)</p></td>

    <td><p>Generally mild to moderate in severity, asymptomatic and reversible with
    dose adjustments were reported, usually after 3 - 6 weeks of treatment.</p>

    <p>Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in
    participants with WD; see the IB.</p></td>

    <td><p>Regular monitoring of liver function tests.</p>

    <p>Dose modification or discontinuation (Section 6.6).</p></td>

    </tr>

    <tr>

    <td><p>Anemia</p></td>

    <td><p>Anemia has been observed in participants with WD, attributed to overtreatment
    and resultant copper depletion; see the IB.</p></td>

    <td><p>Monitoring complete blood count. Dose modification or discontinuation (Section
    6.6).</p></td>

    </tr>

    <tr>

    <td><p>Low white blood cell count (leukopenia, bone marrow toxicity)</p></td>

    <td><p>Leukopenia and bone marrow toxicity (myelosuppression) have been observed
    in participants with WD, attributed to overtreatment and resultant copper depletion.
    Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in participants
    with WD; see the IB.</p></td>

    <td><p>Monitoring of complete blood count. Dose modification or discontinuation
    (Section 6.6).</p></td>

    </tr>

    <tr>

    <td><p>Neurological dysfunction</p></td>

    <td><p>Neurological worsening may occur due to copper mobilization. Peripheral
    neuropathy may be seen with over decoppering; however, symptoms such as myelosuppression
    is typically seen earlier.</p></td>

    <td><p>Regular monitoring for neurologic adverse events. Dose modification or
    discontinuation (Section 6.6).</p></td>

    <tr>

    <td colspan="3"><p><b>Study Procedures</b></p></td>

    </tr>

    <tr>

    <td><p>Risks associated with the study design and procedures</p></td>

    <td><p>Participants will undergo repeated blood draws to measure the PK of the
    study intervention and metabolism. Blood draws may result in ecchymosis, redness,
    and minor pain to the site. On rare occasion, infection or hrombophlebitis can
    occur.</p></td>

    <td><p>Blood draws are optimized for PK. A cannula may be placed to minimize needle
    sticks; however, a catheter may not be left in place for longer than 72 hours
    and should be flushed a minimum of every 8 hours.</p></td>

    </tr></tr></table>

    <p><small>Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase;
    IB = Investigator''s Brochure; PK = pharmacokinetics; WD = Wilson disease.</small></p></div>'
- - NC_11
  - 2.3.1.1
  - Coronavirus (SARS-CoV-2) Disease 2019
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>The COVID-19 pandemic is active at
    the time of this protocol amendment. Given this unique circumstance, specific
    consideration has been given to the potential risks and mitigation measures due
    to COVID-19 vaccine (see Section 10.5).</p></div>
- - NC_12
  - 2.3.2
  - Benefit Assessment
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The main objective of effective\
    \ WD treatment is to provide:</p>\n<ul>\n<li><p>Rapid and sustained control of\
    \ copper and mitigation of clinical symptoms of WD through the formation of a\
    \ stable tetrathiomolybdate-copper-albumin TPC. Copper control may prevent tissue\
    \ toxicity, including neurological deterioration that has been reported at the\
    \ initiation of treatment with chelators. This hypothesis is supported by results\
    \ from Study\u202FWTX101-201 in participants with WD (Weiss, 2017).</p></li>\n\
    <li><p>Improved compliance over current chelator therapy through improved tolerability\
    \ and the convenience of a\n implified dosing regimen (once daily) compared to\
    \ current therapeutic options (multiple daily dosing). </p></li>\n</ul>\n<p>Potential\
    \ benefits of study participation for participants include:</p>\n<ul>\n<li><p>Participation\
    \ in a clinical study increases the participant's understanding of the pathophysiology\
    \ and treatment of WD.</p></li>\n<li><p>Removal of total body copper as a definitive\
    \ treatment for WD.</p>\n<li><p>Participants in the study will contribute to improved\
    \ care for other participants with WD in the future.</p></li>\n<ul></ul></li></ul></div>"
- - NC_13
  - 2.3.3
  - Overall Benefit-Risk Conclusion
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Taking into account the measures
    implemented to minimize risk to participants in this study, the potential risks
    identified in association with ALXN1840 are justified by the anticipated benefits
    that may be afforded to participants with WD.</p></div>
- - NC_14
  - '3.'
  - OBJECTIVES AND ENDPOINTS
  - '<div xmlns="http://www.w3.org/1999/xhtml"><table "="" class="table align-top">

    <tr>

    <th>Objectives</th>

    <th>Endpoints</th>

    </tr>

    <tr>

    <td>

    <p><b>Primary</b></p>

    <p>

    <usdm:ref attribute="text" id="Objective_1" klass="Objective"></usdm:ref>

    </p>

    </td>

    <td>

    <p>

    <usdm:ref attribute="text" id="Endpoint_1" klass="Endpoint"></usdm:ref>

    </p>

    </td>

    </tr>

    <tr>

    <td>

    <p><b>Secondary</b></p>

    <p><usdm:ref attribute="text" id="Objective_2" klass="Objective"></usdm:ref></p>

    </td>

    <td>

    <p><usdm:ref attribute="text" id="Endpoint_2" klass="Endpoint"></usdm:ref></p>

    </td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_3" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_3" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_4" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_4" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_5" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_5" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_6" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_6" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_7" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_7" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td>

    <p><b>Safety</b></p>

    <p><usdm:ref attribute="text" id="Objective_8" klass="Objective"></usdm:ref></p>

    </td>

    <td>

    <p>Safety parameters:</p>

    <p><usdm:ref attribute="text" id="Endpoint_8" klass="Endpoint"></usdm:ref></p>

    </td>

    </tr>

    <tr>

    <td>

    <p><b>Exploratory</b></p>

    <p><usdm:ref attribute="text" id="Objective_9" klass="Objective"></usdm:ref></p>

    </td>

    <td>

    <p><usdm:ref attribute="text" id="Endpoint_9" klass="Endpoint"></usdm:ref></p>

    </td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_10" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_10" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_11" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_11" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_12" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_12" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_13" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_13" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    <tr>

    <td><p><usdm:ref attribute="text" id="Objective_14" klass="Objective"></usdm:ref></p></td>

    <td><p><usdm:ref attribute="text" id="Endpoint_14" klass="Endpoint"></usdm:ref></p></td>

    </tr>

    </table></div>'
- - NC_15
  - '4.'
  - STUDY DESIGN
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_16
  - '4.1'
  - Overall Design
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This study will be conducted as\
    \ an open-label, repeat-dose study to evaluate the effects of ALXN1840 on copper\
    \ balance in participants with WD.</p>\n<p>Treatment-experienced (which includes\
    \ standard of care therapies or ALXN1840) and treatment-na\xEFve participants\
    \ are eligible for this study. Eligible patients will be classified into one of\
    \ two cohorts:</p>\n<ul>\n<li><p>Cohort 1 (treatment experienced): Patients who\
    \ have received WD therapy for &gt; 28 days</p></li>\n<li><p>Cohort 2 (treatment\
    \ na\xEFve): Patients who have received WD therapy for \u2264 28 days</p></li>\n\
    </ul>\n<p>Following screening and enrollment, participants will check-in to the\
    \ CRU on Day -8 for the Run-in Period. The purpose of the Run-in Period is to\
    \ support diet equilibration (Day -7 through Day -5) and measure pretreatment\
    \ copper and molybdenum balance (Day -4 through Day -1). Participants will remain\
    \ on a copper/molybdenum-controlled diet throughout both the Inpatient Period\
    \ 1 (Day -8 to Day 9) and Inpatient Period 2 (Day 23 to Day 40). While not in\
    \ the CRU, participants will be encouraged to adhere to their usual copper-controlled\
    \ diet.</p>\n<p>Participants who are taking copper-chelating therapies (penicillamine\
    \ or trientine) at the time of enrollment will be discontinued from their decoppering\
    \ therapies starting on Day -4 to allow a baseline assessment of copper/molybdenum\
    \ balance prior to ALXN1840 treatment. On Day 1, participants will be initiated\
    \ on 15 mg/day of ALXN1840 for a treatment period of approximately 28 days followed\
    \ by titration up to 30 mg/day on Day 29. Before titration to 30 mg/day, the SRC\
    \ will review available safety data through Day 23 for each participant.</p>\n\
    <p>Participants will have intake and output collection periods from Day -4 through\
    \ Day -1, from Day 1 through Day 8, and Day 25 through Day 39. The collection\
    \ periods will support an assessment of both copper and molybdenum balance (as\
    \ a measure of ALXN1840 ADME) at the 15 mg and 30 mg doses and will allow assessment\
    \ of the effects of duration of treatment on copper elimination and copper balance.</p>\n\
    <p>Collection periods for feces and urine will vary in duration from 3 to 15 days\
    \ to support assessment of both copper and molybdenum balance before and at steady\
    \ state for both 15 mg and 30 mg. Equilibration periods on copper/molybdenum-controlled\
    \ diets will be a minimum of 48 hours. Copper balance will be calculated as the\
    \ mean daily copper balance over each of the 4 collection periods. The interpretation\
    \ of copper balance will be based on the criteria established by Hill,1986 when\
    \ undertaking copper balance studies with zinc treatment. For assessment of ALXN1840\
    \ effect on copper balance, the time period for analysis will take into consideration\
    \ the average bowel transit of approximately 40 hours (male: 33 hours; female:\
    \ 47 hours) (Camilleri, 1986; Metcalf, 1987).</p>\n<p>Throughout the inpatient\
    \ periods, participants will remain on a copper-controlled diet. Meal portions\
    \ will be weighed, and meal sizes will be appropriate to support male and female\
    \ caloric consumption. Participants will be encouraged to complete 100% of all\
    \ meals throughout the inpatient period to support quantification of copper and\
    \ molybdenum intake. If participants are unable to complete the full meal, the\
    \ uneaten portion will be weighed to allow calculation of meal fraction, and copper\
    \ and molybdenum intake will be adjusted based on the fractional intake of the\
    \ meal. In addition to food, fluid intake and type will be measured and recorded\
    \ each day. Samples of all meals and fluids will be sent for bioanalysis to support\
    \ accurate quantification of copper and molybdenum in fluids. In the event that\
    \ items cannot be accurately quantified, items may be balanced during pretreatment\
    \ period and post-treatment period to support the change from baseline assessment.</p>\n\
    <p>During the inpatient collection periods, daily urine will be pooled (24-hour\
    \ collection) with volumes recorded for each 24-hour period; participants will\
    \ be strongly encouraged to void within 2 hours of completion of each 24-hour\
    \ period (ie, dosing time). Stool samples will be individually collected and each\
    \ sample will include a collection date, time, and weight.</p>\n<p>Participants\
    \ may be discharged from the CRU on Day 9 and return on Day 22 or Day 23 (predose);\
    \ all procedures will start on Day 23. To ensure flexibility, the Outpatient Period\
    \ during Treatment Period 1 may be extended up to an additional 14 days with Investigator\
    \ approval. In this situation, participants will be given additional investigational\
    \ product to support daily dosing throughout the Outpatient Period. In such cases,\
    \ the actual Outpatient Period duration will be recorded and the participant will\
    \ continue Inpatient Period 2 at Day 23. During the Outpatient Period, participants\
    \ will use SMS text messaging to confirm study intervention administration. At\
    \ the CRU's discretion, participants may remain in the CRU during the outpatient\
    \ period for safety or to maintain the integrity of the conduct of the study.</p>\n\
    <p>Blood sampling for PK/pharmacodynamic (PD) will occur over the 24-hour dosing\
    \ period on Days 1, 25, 29, and 39. Predose PK samples will be collected at all\
    \ time points during the intake and output collection period to help characterize\
    \ PK during accumulation (Days 1 through 9 for 15 mg and Days 31 through 35 for\
    \ 30 mg) and at steady state (Days 25 through 28 for 15 mg and Days 36 through\
    \ 39 for 30 mg).</p>\n<p>This study incorporates the use of an adaptive design.\
    \ Adaptive features may be implemented at the discretion of the Investigator to\
    \ support conduct of the study. Such adaptive features do not require amendment\
    \ of the protocol. Adaptive features and their limits are described in Table 4.</p>\n\
    <p><b>Table 4. Adaptive Protocol Features</b></p>\n<table \"=\"\" class=\"table\
    \ align-top\">\n<tr>\n<th>Features</th>\n<th>Limits</th>\n</tr>\n<tr>\n<td><p>1.\
    \ Outpatient Period (Day 9 to Day 23) may be extended up to an additional 14 days\
    \ with Investigator approval with adequate supply of study intervention to support\
    \ daily dosing can be provided, and with record of exact duration of Outpatient\
    \ Period is recorded; participants will reinitiate the study on Day 23.</p></td>\n\
    <td><p>\u2022 Not &gt;14 days</p></td>\n</tr>\n<tr>\n<td><p>2. Participants may\
    \ be checked in on Day 22 rather than Day 23 at the Investigator</p></td>\n<td><p>\u2022\
    \ Check-in to clinical research unit allowed 1 day prior discretion.</p></td>\n\
    </tr>\n<tr>\n<td><p>3. In this study, dosing for ALXN1840 will be initiated at\
    \ 15 mg once daily for a minimum of 4 weeks, with an increase to 30 mg after 4\
    \ weeks, unless there are safety concerns that, in the opinion of the Investigator(s)\
    \ and/or \nAlexion, may place participants at undue risk, in which case, patients\
    \ may remain on the 15 mg/day dose for the duration of the study.</p></td>\n<td><p><p>\u2022\
    \ Dose range limit 15 mg every other day to 30 mg/day </p></p></td>\n</tr>\n<tr>\n\
    <td><p>4. The dose should be decreased or interrupted if any of the relevant Dose\
    \ Modification criteria are met (Table 7).</p></td>\n<td><p>\u2022 Dose range\
    \ limit 15 mg every other day to 30 mg/day</p></td>\n</tr>\n</table></div>"
- - NC_17
  - 4.2.
  - Scientific Rationale for Study Design
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The study is designed as an open-label
    exploratory study to provide a descriptive assessment of copper balance in participants
    with WD, the target population for ALXN1840 therapy. The study is being conducted
    as a repeat-dose study to assess the effect of duration of ALXN1840 treatment
    and the effects of intra-patient dose increase on copper and molybdenum balance
    in participants with WD. The intra-patient dose escalation schedule is similar
    to that employed in the current Phase 3 Study WTX101-301. The similar schedule
    was chosen to characterize the decoppering effects expected early with treatment.
    This study is designed to supplement the mechanism of action study in healthy
    participants (Study ALXN1840-HV-108). While healthy participants are expected
    to be adequate to assess the mechanism of action of ALXN1840, characterization
    of copper balance in the WD population will help to understand if there are differences
    in the magnitude of effect between the 2 populations as this may be important
    to understand the doses that may support a net neutral versus a net negative copper
    balance. Limited nonclinical data on copper elimination with tetrathiomolybdate
    suggested copper excretion may be at least maintained or increased with repeated
    dosing (refer to the current IB).</p>

    <p>Therefore, the duration of the study and multiple collection periods will better
    characterize the pattern of copper elimination over time. Such information may
    be helpful in understanding the decoppering and maintenance phases.</p>

    <p>As the study involves intensive diet control and sampling, the study is planned
    to be conducted in a small number of participants with WD who will be admitted
    to a CRU for 2 inpatient periods. Inpatient Period 1 includes a baseline and initial
    15 mg/day collection period during the accumulation phase followed by an Outpatient
    Period; Inpatient Period 2 with a second collection period to support analysis
    of copper balance at 15 mg/day steady state and a 30 mg/day accumulation and steady
    state.</p>

    <p>During the Outpatient Period, participants will be encouraged to remain on
    a copper-controlled diet; however, to avoid confounding, a diet equilibration
    period is included in each study period. Overall, collection periods are a minimum
    of 3 days and as long as 15 days (which will be subdivided for analyses). Collection
    periods of at least 3 days were used to help minimize the impact of day-to-day
    variability on measurements. In addition, the time period for analysis will take
    into consideration the average bowel transit of approximately 40 hours (male:
    33 hours; female: 47 hours) (Camilleri, 1986; Metcalf, 1987). Because the periods
    are of different lengths, the study will calculate mean daily copper balance.</p>

    <p>While the primary endpoint for the study is an assessment of net copper balance,
    measurement of a pretreatment copper baseline will be helpful to understand the
    magnitude of effect of ALXN1840. To assess the copper baseline during the Inpatient
    Run-in Period, participants will be discontinued from their chelator therapy for
    approximately 4 days prior to initiating ALXN1840. During this period, participants
    will be maintained on a copper-controlled diet to minimize risk to the participants.
    In the Phase 3 study ALXN1840-WD-301, participants discontinue their chelator
    approximately 48 hours prior to initiation of ALXN1840 without reported complications.
    Among participants who discontinue chelator due to intolerance or noncompliance,
    the time from chelator discontinuation to the onset or worsening of symptoms varies
    from as little as 1 or 2 weeks to as long as months or years (Scheinberg, 1987).
    To prevent confounding of the study results, participants must be off zinc therapy
    for a minimum of 21 days prior to Day 1 because zinc works through upregulation
    of metallothionein (MT) in enterocytes resulting in elevation of fecal copper
    excretion. Previously, reports in the literature suggest that it can take up to
    3 weeks or longer for zinc treatment to have an efficacious effect on copper balance
    (Brewer, 1983), so a delayed time to reversal of this effect could also occur.
    However, the physiologic turnover of human gastrointestinal epithelial cells is
    3 - 5 days (Darwich, 2014); therefore, the inhibitory effect of zinc on intestinal
    copper absorption is expected to be minimal 21 days after discontinuation of zinc.</p>

    <p>Following ALXN1840 administration, the active drug moiety tetrathiomolybdate
    rapidly binds copper to form TPC, mostly in the liver and blood, and presents
    as such in the systemic circulation. If TPC is not rapidly formed, tetrathiomolybdate
    spontaneously undergoes serial hydrolysis to form molybdate, the most common form
    of nutrient molybdenum, and is excreted in the urine. Total molybdenum concentration
    has been measured as a surrogate of ALXN1840 PK; however, total molybdenum concentration
    cannot distinguish whether the molybdenum is protein bound (mostly as TPC), free
    active drug as ALXN1840, intermediate hydrolysis products, or molybdate. To better
    characterize the amount of non-TPC-bound drug and its unbound degradation products,
    plasma PUF-molybdenum has also been measured, which represents the free parent
    drug (ALXN1840), short-lived intermediate hydrolysis products, and molybdate,
    which may have originated from the tetrathiomolybdate or from food intake as a
    micronutrient. Total molybdenum PK and free molybdenum PK serve as surrogate measures
    of ALXN1840 PK. To better characterize the ADME of ALXN1840, the PK of both total
    molybdenum and PUF-molybdenum will be characterized and described.</p>

    <p>This study is designed to provide an extensive assessment of copper and molybdenum
    balance over the first 40 days of treatment with ALXN1840 and support a more robust
    understanding of the effects of duration of treatment and dose of ALXN1840 on
    copper balance. Half-life estimates for total molybdenum in Study WTX101-201 were
    reported to be approximately 24 hours at steady state on Days 84 and 168, while
    in healthy participants, total molybdenum half-life was measured closer to 51
    hours. With a half-life within this range, the sample collection periods include
    assessment of copper and molybdenum balance both during accumulation and at steady
    state for both the 15 mg/day and 30 mg/day doses. The study will include both
    intake and output collection as well as PK and copper assessments (ie, ceruloplasmin-bound
    copper and labile bound copper [LBC]) to inform the relationship between balance
    measurements and copper and molybdenum levels in the blood.</p>

    <p>Finally, preclinical data from ALXN1840 ADME study suggest the potential for
    molybdenum accumulation in the liver of participants with WD; therefore, an assessment
    of molybdenum balance will help determine whether steady state has been reached
    as defined by a molybdenum balance of neutral during the collection period. Because
    molybdenum is a necessary micronutrient and serves as a cofactor for a number
    of enzymes and may exist in intracellular stores, small variations in molybdenum
    balance could be due to molybdate rather than ALXN1840.</p></div>'
- - NC_18
  - 4.2.1
  - Participant Input into Design
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Not applicable.</p></div>
- - NC_19
  - 4.3.
  - Justification for Dose
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>ALXN1840 at 60 mg single dose has
    been shown to have an adequate safety profile and be well-tolerated in healthy
    male and female participants in the Phase 1 bioavailability Studies WTX101-101
    and WTX101-102. In addition, preliminary data from Study WTX101-106 have also
    shown ALXN1840 to be well tolerated in healthy Japanese and non-Japanese male
    and female participants at a single dose of 15 mg or 60 mg. While no repeat-dose
    studies have been performed in healthy participants, bis-choline tetrathiomolybdate
    (ALXN1840) has been tested in a range of oncologic indications with a maximum
    tolerated dose of 300 mg/day (Lowndes, 2008).</p>

    <p>In the Phase 2 Study WTX101-201 conducted in participants with WD, the daily
    ALXN1840 doses were 15 mg for 6 (21%) participants, 30 mg for 13 (46%) participants,
    and 60 mg (32%) for 9 participants at Week 24 when the primary endpoint assessment
    was conducted, or at the last dose received for participants with early discontinuation.
    The 15 to 60 mg/day dose range has been demonstrated to be efficacious with a
    favorable safety profile in treating participants with WD (Weiss, 2017). Based
    on these Phase 2 study results, the ongoing Phase 3 Study WTX101-301 in participants
    with WD has been testing the efficacy and safety of ALXN1840 at a dose titration
    range from 15 mg to 60 mg daily with data to date supporting an acceptable safety
    profile.</p>

    <p>Similar to the Phase 2 study, in Study WTX101-301, participants are started
    at a dose of 15 mg/day and, after review of all safety information, participants
    may be titrated up to 30 mg/day after approximately 4 weeks. Based on the results
    of Study WTX101-201, doses ranging from 15 mg/day to 60 mg/day were adequate to
    significantly decrease non-ceruloplasmin corrected copper concentrations corrected
    for TPC (NCCcorrected ) and, in many cases, return the NCC to normal concentrations
    of copper control. Given the robust improvement in copper control, it is hypothesized
    that doses within the 15 to 30 mg/day range will be adequate to drive a net negative
    copper balance. The current study will explore copper balance in response to treatment
    with ALXN1840, with the purpose of informing the dose and dosing duration required
    to result in adequate copper elimination to drive a measurable net negative copper
    balance. Copper balance will be assessed for the 15 mg/day dose at the beginning
    and end of the 15 mg/day treatment period, and at the beginning of the 30 mg/day
    treatment period. Copper balance will be assessed for the 30 mg/day dose at Days
    31 through 35 and Days 36 through 39. The multiple collection periods will support
    assessment of duration of treatment and dose on copper elimination and overall
    copper balance.</p>

    <p>In this study, dosing for ALXN1840 will be initiated at 15 mg once daily for
    a minimum of 4 weeks, with an increase to 30 mg after 4 weeks, unless there are
    safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may
    place participants at undue risk, in which case, participants may remain on the
    15 mg/day dose for the duration of the study. Further dose adjustments will be
    made as appropriate.</p>

    <p>The dose should be decreased or interrupted if any of the relevant Dose Modification
    Criteria are met. Deviation from the dose modification guidelines must be agreed
    with the Alexion Medical Monitor.</p></div>'
- - NC_20
  - 4.4.
  - End of Study Definition
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>A participant is considered to have
    completed the study if he/she has completed all phases of the study including
    the last scheduled procedure shown in the Schedule of Activities (SoA). The end
    of the study is defined as the date the last participant completes the last visit
    shown in the SoA (Section 1.3).</p></div>
- - NC_21
  - '5.'
  - STUDY POPULATION
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Prospective approval of protocol
    deviations to recruitment and enrollment criteria, also known as protocol waivers
    or exemptions, is not permitted.</p></div>
- - NC_22
  - 5.1.
  - Inclusion Criteria
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><i>Age</i></p>\n<usdm:ref attribute=\"\
    identifier\" id=\"EligibilityCriterion_1\" klass=\"EligibilityCriterion\"></usdm:ref>\
    \ <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_1\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<i>Type of Participants and Disease Characteristics</i>\n<usdm:ref\
    \ attribute=\"identifier\" id=\"EligibilityCriterion_2\" klass=\"EligibilityCriterion\"\
    ></usdm:ref> <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_2\" klass=\"\
    EligibilityCriterionItem\"></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"\
    EligibilityCriterion_3\" klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref\
    \ attribute=\"text\" id=\"EligibilityCriterionItem_3\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_4\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_4\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_5\" klass=\"EligibilityCriterion\"\
    ></usdm:ref> <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_5\" klass=\"\
    EligibilityCriterionItem\"></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"\
    EligibilityCriterion_6\" klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref\
    \ attribute=\"text\" id=\"EligibilityCriterionItem_6\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_7\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_7\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_8\" klass=\"EligibilityCriterion\"\
    ></usdm:ref> <usdm:ref attribute=\"text\" id=\"EligibilityCriterionItem_8\" klass=\"\
    EligibilityCriterionItem\"></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"\
    EligibilityCriterion_9\" klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref\
    \ attribute=\"text\" id=\"EligibilityCriterionItem_9\" klass=\"EligibilityCriterionItem\"\
    ></usdm:ref>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_10\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_10\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <p><i>Sex</i></p>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_11\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_11\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <i>Informed Consent</i>\n<usdm:ref attribute=\"identifier\" id=\"EligibilityCriterion_12\"\
    \ klass=\"EligibilityCriterion\"></usdm:ref> <usdm:ref attribute=\"text\" id=\"\
    EligibilityCriterionItem_12\" klass=\"EligibilityCriterionItem\"></usdm:ref>\n\
    <p><b>5.2. Exclusion Criteria</b><span class=\"s22\"><b>x</b></span><span class=\"\
    s20\"><b>c</b></span><span class=\"s37\"><b>l</b></span><span class=\"s19\"><b>u</b></span><span\
    \ class=\"s20\"><b>s</b></span><span class=\"s37\"><b>i</b></span><span class=\"\
    s22\"><b>on</b></span> <span class=\"s21\"><b>C</b></span><span class=\"s20\"\
    ><b>r</b></span><span class=\"s37\"><b>it</b></span><span class=\"s20\"><b>er</b></span><span\
    \ class=\"s37\"><b>i</b></span><span class=\"s22\"><b>a</b></span>\n<i>Medical\
    \ Conditions</i></p>\n<p>1. Decompensated cirrhosis or model for end-stage liver\
    \ disease (MELD) score &gt; 13.</p>\n<p>2. Modified Nazer score &gt; 7 (Dhawan,\
    \ 2005).</p>\n<p>3. Clinically significant gastrointestinal bleed within past\
    \ 3 months.</p>\n<p>4. Alanine aminotransferase (ALT) &gt; 2 \xD7 upper limit\
    \ of normal (ULN).</p>\n<p>5. Marked neurological disease requiring assistance\
    \ with self-care or activities of daily life.</p>\n<p>6. Hemoglobin less than\
    \ lower limit of the reference range for age and sex.</p>\n<p>7. Active infection\
    \ with hepatitis B virus (positive hepatitis B surface antigen) or C virus \n\
    (participants with positive hepatitis C antibody result would require confirmation\
    \ of \nactive disease with a positive hepatitis C polymerase chain reaction test),\
    \ or seropositivity \nfor human immunodeficiency virus (HIV).</p>\n<p>ALXN1840-WD-204</p>\n\
    <p>8. History or presence of/significant history of or current cardiovascular,\
    \ respiratory, hepatic, \nrenal, gastrointestinal, endocrinological, hematological,\
    \ or neurological disorders, or \npsychiatric disorder that in the opinion of\
    \ the Investigator may constitute a risk when \ntaking the study intervention;\
    \ or may interfere with the interpretation of data. \n<i>Prior/Concomitant Therapy</i></p>\n\
    <p>9. Previous treatment with ALXN1840 or other form of tetrathiomolybdate within\
    \ 1 year prior \nto dosing.</p>\n<p>10. Previous treatment with zinc within 21\
    \ days prior to Day 1. \n<i>Prior/Concurrent Clinical Study Experience</i></p>\n\
    <p>11. The use of an experimental or unapproved/unlicensed therapy at the same\
    \ time or within 90 \ndays or 5 half-lives, whichever is longer, prior to the\
    \ Screening Visit. \n<i>Diagnostic Assessments</i></p>\n<p>12. Participants in\
    \ renal failure, defined as in end-stage renal disease on dialysis (chronic kidney\
    \ \ndisease [CKD] stage 5) or creatinine clearance &lt; 30 mL/min (Levey, 2006).\
    \ \n<i>Other Exclusions</i></p>\n<p>13. Pregnant (or females who are planning\
    \ to become pregnant) or breastfeeding females \n(women of childbearing potential\
    \ must have a negative serum pregnancy test result at \nscreening).</p>\n<p>14.\
    \ Known sensitivity to ALXN1840, ALXN1840 excipients (anhydrous dicalcium phosphate,\
    \ \nanhydrous sodium carbonate), or any of the ingredients contained in ALXN1840\
    \ or \nrelated compounds.</p>\n<p>15. In the opinion of the Investigator, the\
    \ participant and/or their legal guardian is likely to be \nnon-compliant or uncooperative\
    \ during the study.</p>\n<p>16. History of illicit drug abuse, history of significant\
    \ alcohol abuse within 1 year prior to the \nScreening Visit, or clinical evidence\
    \ of substance and/or alcohol abuse within the 2 years \nbefore screening. Alcohol\
    \ abuse is defined as regular weekly intake of more than 14 units \n(for both\
    \ males and females), using the following National Health Service (NHS) alcohol\
    \ \ntracker http://www.nhs.uk/Tools/Pages/drinks-tracker.aspx.</p>\n<p>17. Positive\
    \ urine drug toxicology screen at Screening or on Day -8 (cannabinoids will not\
    \ be \ntested).</p>\n<p>18. Alcohol consumption within 48 hours prior to study\
    \ intervention administration or positive \nalcohol breath test at screening or\
    \ on Day -8.</p>\n<p>19. Participants unwilling to consistently complete every\
    \ meal and tolerate a controlled, limited \nmenu for the duration of the study.</p></div>"
- - NC_23
  - '5.2'
  - Exclusion Criteria
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><i>Medical Conditions</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_13" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_13" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_14" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_14" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_15" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_15" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_16" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_16" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_17" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_17" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_18" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_18" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_19" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_19" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_20" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_20" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Prior/Concomitant Therapy</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_21" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_21" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_22" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_22" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Prior/Concurrent Clinical Study Experience</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_23" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_23" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Diagnostic Assessments</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_24" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_24" klass="EligibilityCriterionItem"></usdm:ref>

    <p><i>Other Exclusions</i></p>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_25" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_25" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_26" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_26" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_27" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_27" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_28" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_28" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_29" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_29" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_30" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_30" klass="EligibilityCriterionItem"></usdm:ref>

    <usdm:ref attribute="identifier" id="EligibilityCriterion_31" klass="EligibilityCriterion"></usdm:ref>
    <usdm:ref attribute="text" id="EligibilityCriterionItem_31" klass="EligibilityCriterionItem"></usdm:ref></div>'
- - NC_24
  - 5.3.
  - Lifestyle Considerations
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Participants must be able and\
    \ willing to adhere to the lifestyle restrictions detailed in Table 5.</p>\n<p><b>Table\
    \ 5: Participant Lifestyle Considerations</b></p>\n<table class=\"table align-top\"\
    >\n<tr>\n<th>Restrictions</th>\n<th>Timeframe Restriction Applies</th>\n<th>Restrictions\
    \ End</th>\n</tr>\n<tr>\n<td>\n<p><b>Food</b><br/>Participants will remain on\
    \ a copper/molybdenum-controlled diet. Standardized copper- and\n        molybdenum-controlled\
    \ meals will be provided. Male participants will receive larger meals than female\n\
    \        participants, with adequate meal size to ensure appropriate daily caloric\
    \ intake. If a participant is unable to\n        eat 100% of the food, the remaining\
    \ food will be weighed and reported in the CRF to support copper/molybdenum\n\
    \        determination as a fraction of the total meal. Participants will be expected\
    \ to fast overnight. During the\n        dosing period, participants will be administered\
    \ ALXN1840 with 240 mL of water each morning; participants must\n        remain\
    \ fasted for a least 2 hours after dose administration.</p>\n</td>\n<td>\n<p>Dietary\
    \ restrictions will remain in place during Inpatient Periods 1 and 2.</p>\n</td>\n\
    <td>\n<p>Participants may return to routine diet after completion of Day 40.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p><b>Fluids</b><br/>All participants will drink water\
    \ from the same large water bottle dispenser. There will be\n        no set maximum\
    \ volume of water that the participants must consume, but there will be a minimal\
    \ volume that they\n        must consume each day (1.5 L). The precise volume\
    \ that each participant consumes will be measured.</p>\n</td>\n<td>\n<p>Water\
    \ restrictions will remain in place during Inpatient Periods 1 and 2.</p>\n</td>\n\
    <td>\n<p>Participants may return to routine fluid intake after completion of Day\
    \ 40.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Alcohol</b></p>\n</td>\n<td>\n<p> 48\
    \ hours before check-in to the CRU (Day -8 and Day 22/23) and until discharge\
    \ on Day 40, and 48 hours before\n        each study Outpatient/Follow-up Visit.</p>\n\
    </td>\n<td>\n<p>Discharge from the CRU and completion of EOS Visit.</p>\n</td>\n\
    </tr>\n<tr>\n<td>\n<p><b>Physical activity</b><br/> Participants will carry out\
    \ daily scheduled light exercise. This is to help\n        encourage\n       \
    \ regular bowel movements and for health benefits to the participants.</p>\n<p>Participants\
    \ must refrain from strenuous activity for 24 hours prior to each study visit\
    \ for the duration of\n        the study.</p>\n</td>\n<td>\n<p>48 hours prior\
    \ to check-in to the CRU (Day -8 and Day 22/23) and until discharge on Day 40.</p>\n\
    </td>\n<td>\n<p>Restrictions end after completion of EOS Visit.</p>\n</td>\n</tr>\n\
    <tr>\n<td>\n<p><b>Concomitant medication</b><br/>\n        Concomitant medication\
    \ guidelines are as per Section 6.5.</p>\n<p>Note: If participants have a medical\
    \ need to take any new medication(s) prescribed to them by a doctor, they\n  \
    \      should follow the medical advice but inform the Investigator as soon as\
    \ possible afterwards. Investigator in\n        consultation with Alexion should\
    \ determine participant's continued suitability to remain in the study.</p>\n\
    </td>\n<td>\n<p>Signing of informed consent until EOS Visit.</p>\n</td>\n<td>\n\
    <p>Restrictions ends after completion of EOS Visit.</p>\n</td>\n</tr>\n<tr>\n\
    <td>\n<p><b>Nonprescription/over-the-counter medication</b><br/> Any nonprescription/over-the-counter\
    \ medication may be\n        taken under the direction of the Investigator. Over-the-counter\
    \ medications may be given if they are not\n        expected to impact the outcome\
    \ of the study. Acetaminophen should be limited to 1000 mg/day. Herbal remedies\n\
    \        must be discontinued at least 7 days prior to first admission until study\
    \ completion.</p>\n</td>\n<td>\n<p>Allowed under direction of Investigator.</p>\n\
    </td>\n<td>\n<p>After the EOS Visit.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>St John's\
    \ wort</b><br/>\n        Any herbal remedy or dietary supplement containing St\
    \ John's wort.</p>\n</td>\n<td>\n<p>2 weeks before the planned first study intervention\
    \ is administered.</p>\n</td>\n<td>\n<p>After EOS Visit.</p>\n</td>\n</tr>\n<tr>\n\
    <td>\n<p><b>Blood and plasma donation</b></p>\n</td>\n<td>\n<p>Blood donation\
    \ or blood loss in excess of 500 mL in the 60 days prior to screening (Section\
    \ 5.2).</p>\n</td>\n<td>\n<p>1 month after EOS Visit.</p>\n</td>\n</tr>\n<tr>\n\
    <td>\n<p><b>Contraception</b><br/>Participants must consistently and correctly\
    \ use one or more of the appropriate\n        contraceptive methods described\
    \ in Section 10.4.</p>\n</td>\n<td>\n<p>Start times for contraceptives vary according\
    \ to method used (see Section 5.1 [inclusion criteria]).</p>\n</td>\n<td>\n<p>See\
    \ Section 10.4.</p>\n</td>\n</tr>\n</table>\n<p><small>Abbreviations: CRF = case\
    \ report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule\
    \ of Activities.</small></p></div>"
- - NC_25
  - 5.4.
  - Screen Failures
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Screen failures are defined as participants
    who consent to participate in the clinical study but are not subsequently assigned
    to study intervention. A minimal set of screen failure information is required
    to ensure transparent reporting of screen failure participants to meet the Consolidated
    Standards of Reporting Trials (CONSORT) publishing requirements and to respond
    to queries from regulatory authorities. Minimal information includes demography,
    screen failure details (eg, failed eligibility criteria), and any AEs, including
    any serious adverse events (SAEs) and any related concomitant medication, occurring
    during the Screening Period.</p>

    <p>Individuals who do not meet the criteria for participation in this study (screen
    failure) due to a reason that is expected to resolve or has resolved may be rescreened
    based on discussion and agreement between the Investigator and the Medical Monitor.
    Rescreened participants are not required to reconsent as long as they have signed
    the latest version of the ICF.</p></div>'
- - NC_26
  - '6.'
  - STUDY INTERVENTION
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Study intervention is defined as
    any investigational intervention(s), marketed product(s), placebo, or medical
    device(s) intended to be administered to a study participant according to the
    study protocol.</p></div>
- - NC_27
  - 6.1.
  - Study Intervention(s) Administered
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Details of ALXN1840 administered\
    \ in the study are provided in Table 6.</p>\n<p><b>Table 6: Study Intervention\
    \ Dosage and Mode of Administration</b></p>\n<table class=\"table align-top\"\
    >\n<tr>\n<th>\n<p>Drug Name</p>\n</th>\n<td>\n<p>ALXN1840 (formerly WTX101)</p>\n\
    </td>\n</tr>\n<tr>\n<th>\n<p>Type</p>\n</th>\n<td>\n<p>Drug</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>Dose formulation</p>\n</th>\n<td>\n<p>Tablet</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>Unit dose strength(s)</p>\n</th>\n<td>\n<p>15 mg ALXN1840 containing\
    \ 7.8 mg of tetrathiomolybdic acid</p>\n</td>\n</tr>\n<tr>\n<th>\n<p>Dosage level(s)</p>\n\
    </th>\n<td>\n<p>Repeat doses of 15 mg/day or 30 mg/day (administered as 2 \xD7\
    \ 15 mg ALXN1840 tablets) for 40 days</p>\n</td>\n</tr>\n<tr>\n<th>\n<p>Route\
    \ of administration</p>\n</th>\n<td>\n<p>Oral</p>\n</td>\n</tr>\n<tr>\n<th>\n\
    <p>Use</p>\n</th>\n<td>\n<p> Experimental/study intervention</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>IMP and NIMP</p>\n</th>\n<td>\n<p>IMP</p>\n</td>\n</tr>\n<tr>\n\
    <th>\n<p>Sourcing</p>\n</th>\n<td>\n<p>Provided by Alexion</p>\n</td>\n</tr>\n\
    <tr>\n<th>\n<p>Packaging and labeling</p>\n</th>\n<td>\n<p>ALXN1840 will be provided\
    \ in treatment kits that will each have a unique identification number and be\
    \ packaged\n        and labelled in accordance with all applicable regulatory\
    \ requirements. At a minimum, the treatment kit label\n        will provide the\
    \ following information: Alexion study identification, batch number, directions\
    \ for use, required\n        storage conditions, caution statements (including\
    \ \u201CNew Drug-Limited by Federal Law to Investigational Use\u201D\n       \
    \ language), study identification, and expiry date.</p>\n</td>\n</tr>\n<tr>\n\
    <th>\n<p>Current/former name(s) or alias(es)</p>\n</th>\n<td>\n<p>bis-choline\
    \ tetrathiomolybdate</p>\n</td>\n</tr>\n</table>\n<p><small>Abbreviations: IMP\
    \ = investigational medicinal product; NIMP = noninvestigational medicinal product.</small></p></div>"
- - NC_28
  - 6.2.
  - Preparation / Handling / Storage / Accountability
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ol>\n<li>\n<p>The Investigator or\
    \ designee must confirm appropriate temperature conditions have been maintained\
    \ during transit\n      for all study intervention received and any discrepancies\
    \ are reported and resolved before use of the study\n      intervention.</p>\n\
    <ol type=\"a\">\n<li>\n<p>The ALXN1840 treatment kits should be stored at refrigerated\
    \ conditions, 2\xB0C to 8\xB0C (36\xB0F to 46\xB0F).</p>\n</li>\n</ol>\n</li>\n\
    <li>\n<p>Only participants enrolled in the study may receive the study intervention\
    \ and only\n      authorized site staff may supply or administer the study intervention.\
    \ All study\n      intervention must be stored in a secure, environmentally controlled,\
    \ and monitored\n      (manual or automated) area in accordance with the labeled\
    \ storage conditions with access\n      limited to the Investigator and authorized\
    \ site staff.</p>\n</li>\n<li>\n<p>Authorized site staff will instruct participants\
    \ on study intervention storage and how to\n      correctly dose themselves during\
    \ the Outpatient Period. A sufficient number of kits\n      should be dispensed\
    \ to the participant to cover the need until check-in for Treatment\n      Period\
    \ 2. Participants will return all unused study intervention and empty kits so\
    \ that\n      study drug compliance may be calculated.</p>\n</li>\n<li>\n<p>The\
    \ Investigator and/or qualified delegate (ie, pharmacist) is responsible for study\
    \ intervention accountability,\n      reconciliation, and record maintenance (ie,\
    \ receipt, reconciliation, and final disposition records).</p>\n<ol type=\"a\"\
    >\n<li>\n<p>This responsibility includes the reporting of any product complaints\
    \ to XXXXXXX within 1 business day. A\n          product complaint is\n      \
    \    defined as any written, electronic, or oral communication that alleges deficiencies\
    \ related to the identity,\n          quality, durability, reliability, usability,\
    \ safety, effectiveness, or performance of a product or clinical\n          study\
    \ material and/or its packaging components after it is has been released for distribution\
    \ to an end\n          customer that affects the performance of such product.</p>\n\
    </li>\n</ol>\n</li>\n<li>\n<p>Further guidance and information for the final disposition\
    \ of unused study interventions are provided in the\n      Pharmacy Manual.</p>\n\
    </li>\n</ol></div>"
- - NC_29
  - 6.3.
  - 'Measures to Minimize Bias: Randomization and Blinding'
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Blinding and randomization are not
    applicable. This is an open-label study in which all participants are expected
    to receive ALXN1840.</p></div>
- - NC_30
  - 6.4.
  - Study Intervention Compliance
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>While in the CRU, participants will
    receive study intervention directly from the Investigator or designee, under medical
    supervision. The date and time of each dose administered in the clinic will be
    recorded in the source documents and in the case report form (CRF) (if the CRF
    is not the source document). The dose of study intervention and study participant
    identification will be confirmed at the time of dosing by a member of the study
    site staff other than the person administering the study intervention.</p>

    <p>During the Outpatient Period, participants will use SMS text messaging to confirm
    study intervention administration. Compliance with ALXN1840 during the Outpatient
    Period will be assessed by means of tablet counts of used and partially used treatment
    kits returned to the site by the participant. Any deviation from the prescribed
    dosing regimen including extra doses, missed doses, and drug interruptions will
    be documented in the source documents and CRF.</p>

    <p>Reasons for not following study intervention administration as described in
    the protocol should be clearly recorded in the source documents.</p>

    <p>A record of the number of ALXN1840 tablets dispensed to and taken by each participant
    must be maintained and reconciled with study intervention and compliance records.
    Study intervention start and stop dates, including dates for drug delays and/or
    dose reductions will also be recorded in the CRF.</p></div>'
- - NC_31
  - 6.5.
  - Concomitant Therapy
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Any medication or vaccine (including
    over-the-counter or prescription medicines, vitamins, and/or herbal supplements),
    or other specific categories of interest, that the participant is receiving from
    14 days prior to study enrollment (Day -7) until the EOS Visit must be recorded
    along with:</p>

    <ul>

    <li><p>Reason for use</p></li>

    <li><p>Dates of administration including start and end dates</p></li>

    <li><p>Dosage information including dose and frequency</p></li>

    </ul>

    <p>The Medical Monitor should be contacted if there are any questions regarding
    concomitant or prior therapy.</p>

    <p>Medications specific for WD taken at any time prior to the study will also
    be recorded, including ALXN1840 received in a previous clinical study (clinical
    study number and subject ID should be noted).</p></div>'
- - NC_32
  - 6.5.1
  - Allowed Medicine and Therapy
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Paracetamol/acetaminophen\
    \ at doses of a maximum 1000 mg per day is permitted for use \nas an exception\
    \ with the approval of the Investigator.</p></li>\n<li><p>As per the ALXN1840\
    \ IB, in this study, Investigators should use caution in the \ncoadministration\
    \ of drugs known to be substrates of cytochromes 2C9 and 2B6 (CYP2C9 \nand CYP2B6).\
    \ Common substrates of CYP2C9 include ibuprofen, which is permitted in \nthis\
    \ study. The Investigator must use ibuprofen with caution during the conduct of\
    \ the \nstudy, and the ibuprofen dose must not exceed 1200 mg in any 24-hour period.\
    \ Ibuprofen \nmay only be used with approval of the Investigator.</p></li>\n<li><p>Concomitant\
    \ procedures are not allowed unless medically indicated and/or permitted by \n\
    Alexion or the Investigator or delegate.</p></li>\n<li><p>Concomitant medications\
    \ may be used during the study if deemed medically indicated by \nthe Investigator.\
    \ The Investigator or designee will notify Alexion of any AEs requiring \nadministration\
    \ of prescription medication(s) while on study.</p></li>\n</ul></div>"
- - NC_33
  - 6.5.2
  - Disallowed Medicine and Therapy
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Participants must abstain from taking
    prescription medications within 14 days or 5 half-lives (whichever is longer)
    of Day -7 or nonprescription drugs (including vitamins and dietary or herbal supplements)
    within 7 days or 5 half-lives (whichever is longer) before Day -7 and until completion
    of the follow-up visit, except as described in Section 6.5.1.</p></div>
- - NC_34
  - 6.6.
  - Dose Modification
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Participants will be initiated\
    \ on ALXN1840 at 15 mg once daily and increased to 30 mg once daily on Day 29.\
    \ Specific criteria for dose reduction, temporary interruption of dosing, or restriction\
    \ of dose increases of ALXN1840 are detailed in Table 7. Repeat testing of parameters\
    \ meeting dose modification criteria should follow the instructions in Table 7.\
    \ Results from nonscheduled safety laboratory assessments must be recorded in\
    \ the CRF.</p>\n<p>Alexion should be notified within 24 hours of any laboratory,\
    \ vital sign, electrocardiogram (ECG) abnormality, or AE that are considered of\
    \ clinical concern by the Investigator. Investigators must notify Alexion immediately\
    \ of study intervention discontinuation. The decision to discontinue study intervention\
    \ should not be delayed for causality assessment.</p>\n<p><b>Table 7: ALXN1840\
    \ Dose Modifications for Individual Participants</b></p>\n<table class=\"table\
    \ align-top\">\n<tr>\n<th>Test</th>\n<th>Result</th>\n<th>Conditions</th>\n<th>Action\
    \ with ALXN1840 Dosing</th>\n<th>Changes in Safety Monitoring<sup>a</sup></th>\n\
    <th>Rechallenge<sup>b,c,d</sup></th>\n</tr>\n<tr>\n<td rowspan=\"4\">\n<p>ALT\
    \ </p>\n</td>\n<td>\n<p>&gt;5\xD7 \u2191 from baseline</p>\n</td>\n<td>\n<p>ALT\
    \ above reference range at baseline</p>\n</td>\n<td>Temporary interruption </td>\n\
    <td>\n<p>Contact participant within 48 hours to arrange repeat testing (weekly\
    \ repeat testing)</p>\n</td>\n<td>\n<p>At 15 mg QOD when ALT &lt; 2 \xD7 \u2191\
    \ from baseline.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt; 5 \xD7 ULN</p>\n</td>\n\
    <td>\n<p>ALT within reference range at baseline</p>\n</td>\n<td>\n<p>Temporary\
    \ interruption</p>\n</td>\n<td>\n<p>Contact participant within 48 hours to arrange\
    \ repeat testing (weekly repeat testing)</p>\n</td>\n<td>\n<p>At 15 mg QOD when\
    \ ALT &lt; 2 \xD7 ULN.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;2\xD7 \u2191 from\
    \ baseline&lt;&lt; /p&gt;\n    </p></td>\n<td>\n<p>ALT above reference range at\
    \ baseline</p>\n</td>\n<td>\n<p>Reduce dose to previous dose level if up-titration\
    \ has occurred or reduce dose to 15 mg QOD if on 15 mg QD. No\n        further\
    \ dose \u2191 until resolution of abnormality.</p>\n</td>\n<td>\n<p>Weekly repeat\
    \ testing</p>\n</td>\n<td>\n<p>Not applicable.</p>\n</td>\n</tr>\n<tr>\n<td>\n\
    <p>&gt; 2 \xD7 ULN</p>\n</td>\n<td>\n<p>ALT within reference range at baseline</p>\n\
    </td>\n<td>\n<p>Reduce dose to previous dose level if up-titration has occurred\
    \ or reduce dose to 15 mg QOD if on 15 mg QD. No\n        further dose \u2191\
    \ until resolution of abnormality.</p>\n</td>\n<td>\n<p>Weekly repeat testing\
    \ </p>\n</td>\n<td>\n<p>Not applicable.</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"\
    2\">\n<p>Hemoglobin</p>\n</td>\n<td>\n<p>&lt; 8 g/dL in the absence of bleeding</p>\n\
    </td>\n<td>\n<p>None</p>\n</td>\n<td>\n<p>Temporary interruption </p>\n</td>\n\
    <td>\n<p>Weekly repeat testing </p>\n</td>\n<td>\n<p>At 15 mg QOD when hemoglobin\
    \ and other hematology parameters (neutrophils and platelets) are at baseline\n\
    \        concentration.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt; 30% \u2193 from\
    \ baseline</p>\n</td>\n<td>\n<p>None</p>\n</td>\n<td>\n<p>Reduce dose to previous\
    \ dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15\
    \ mg QD. No\n        further dose \u2191 until resolution of abnormality.</p>\n\
    </td>\n<td>\n<p>Weekly repeat testing</p>\n</td>\n<td>\n<p>Not applicable.</p>\n\
    </td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p>Platelets</p>\n</td>\n<td>\n<p>&lt;\
    \ 30,000 \xB5L</p>\n</td>\n<td>\n<p>None</p>\n</td>\n<td>\n<p>Temporary interruption</p>\n\
    </td>\n<td>\n<p>Weekly repeat testing</p>\n</td>\n<td>\n<p>At 15 mg QOD when platelets\
    \ and other hematology parameters (neutrophils and hemoglobin) are at baseline\n\
    \        concentration.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt; 30% \u2193 from\
    \ baseline</p>\n</td>\n<td>\n<p>Platelets below reference range at baseline</p>\n\
    </td>\n<td>\n<p>Reduce dose to previous dose level if up-titration has occurred\
    \ or reduce dose to 15 mg QOD if on 15 mg QD. No\n        further dose \u2191\
    \ until resolution of abnormality.</p>\n</td>\n<td>\n<p>Weekly repeat testing\
    \ </p>\n</td>\n<td>\n<p>Not applicable.</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"\
    2\">\n<p>Neutrophils</p>\n</td>\n<td>\n<p>&lt; 1.0 \xD7 103 /\xB5L</p>\n</td>\n\
    <td>\n<p>None</p>\n</td>\n<td>\n<p>Temporary interruption</p>\n</td>\n<td>\n<p>Weekly\
    \ repeat testing</p>\n</td>\n<td>\n<p>At 15 mg QOD when neutrophils and other\
    \ hematology parameters (hemoglobin and platelets) are at baseline\n        concentration.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>&gt; 30% \u2193 from baseline</p>\n</td>\n<td>\n\
    <p>Neutrophils below reference range at baseline</p>\n</td>\n<td>\n<p>Reduce dose\
    \ to previous dose level if up-titration has occurred or reduce dose to 15 mg\
    \ QOD if on 15 mg QD. No\n        further dose \u2191 until resolution of abnormality.</p>\n\
    </td>\n<td>\n<p>Weekly repeat testing</p>\n</td>\n<td>\n<p>Not applicable.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Bilirubin</p>\n</td>\n<td>\n<p>&gt; 2 \xD7 ULN</p>\n\
    </td>\n<td>\n<p>Accompanied by ALT &gt; 3 \xD7 ULN, indicative of liver injury</p>\n\
    </td>\n<td>\n<p>Temporary interruption</p>\n</td>\n<td>\n<p>Weekly repeat testing</p>\n\
    </td>\n<td>\n<p>At 15 mg QOD or less frequent, when bilirubin is below ULN. Rechallenge\
    \ under these conditions requires\n        approval of the Alexion Medical Monitor.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Neurological assessment</p>\n</td>\n<td colspan=\"\
    2\">\n<p>Evidence of neurologic worsening by AEs or by neurologic physical exam\
    \ assessment</p>\n</td>\n<td>\n<p>Investigator and Alexion Medical Monitor will\
    \ evaluate the need for dose modification (interruption, increase\n        or\
    \ decrease) based on copper control parameters and relevant clinical data. Rationale\
    \ for dosing decision must\n        be documented in study record and reevaluated\
    \ at the next study visit.</p>\n</td>\n<td>\n<p>All neurologic worsening should\
    \ be documented as AEs and followed up until study completion or resolution of\n\
    \        symptoms.</p>\n</td>\n<td>\n<p>Discuss with the Alexion Medical Monitor.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Psychiatric assessment</p>\n</td>\n<td colspan=\"\
    2\">\n<p>Evidence of clinically significant acute psychiatric worsening which\
    \ may include but not limited to\n        suicidality, acute depression, or psychosis.</p>\n\
    </td>\n<td>\n<p>Investigator and Alexion Medical Monitor will evaluate the need\
    \ for dose modification (interruption, increase\n        or decrease) based on\
    \ copper control parameters and relevant clinical data. Rationale for dosing decision\
    \ must\n        be documented in study record and reevaluated at the next study\
    \ visit.</p>\n</td>\n<td>\n<p>Worsening psychiatric symptoms will be documented\
    \ as adverse events in the eCRF and will be followed until\n        completion\
    \ of the study or resolution of symptoms.</p>\n</td>\n<td>\n<p>Discuss with the\
    \ Alexion Medical Monitor.</p>\n</td>\n</tr>\n</table>\n<p><sup>a</sup> For changes\
    \ in safety monitoring, weekly repeat testing for laboratory parameters can be\
    \ completed by a home healthcare nurse if a routine study visit is not scheduled\
    \ during this time period.</p>\n<p><sup>b</sup> A maximum of 3 rechallenges will\
    \ be allowed. \n<p><sup>c</sup> For rechallenges, participants who were on 15\
    \ mg QOD should be rechallenged at the 15 mg QOD dose.</p>\n<p><sup>d</sup> The\
    \ Investigator, in consultation with the Medical Monitor, may change dose and\
    \ dose frequency in participants who require rechallenge.</p>\n<p><small>Abbreviations:\
    \ AEs = adverse event; ALT = alanine aminotransferase; eCRF = electronic case\
    \ report form; QD = once daily; QOD = every other day; ULN = upper limit of normal.</small></p></p></div>"
- - NC_35
  - 6.7.
  - Intervention After the End of the Study
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Following completion of both inpatient
    periods of the study (ie, Day 40), participants will either:</p>

    <ul>

    <li><p>transition to therapy that was discontinued before enrollment, or</p></li>

    <li><p>transition to other standard of care therapy as directed by the treating
    physician, or</p></li>

    <li><p>at the discretion of the treating physician, consider and request continuation
    of ALXN1840 treatment permissible under local regulations for preapproval access.
    </p></li>

    </ul>

    All participants should return to the CRU for the EOS Visit on Day 54 (+/- 2 days).</div>'
- - NC_36
  - '7.'
  - DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_37
  - 7.1.
  - Discontinuation of Study Intervention
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>In rare instances, it may be necessary
    for a participant to permanently discontinue (definitive discontinuation) the
    study intervention. If the study intervention is definitively discontinued, the
    participant should remain in the study to be evaluated for safety follow-up. See
    the Schedule of Activities (SoA, Section 1.3) for data to be collected at the
    time of discontinuation of study intervention and follow-up and for any further
    evaluations that need to be completed.</p>

    <p>Discontinuation of study intervention for abnormal liver function should be
    considered by the Investigator when a participant meets one of the conditions
    outlined in the Dose Modification criteria (Section 6.6) or if the Investigator
    believes that it is in best interest of the participant.</p>

    <p>If a clinically significant finding is identified (including, but not limited
    to changes from baseline in QT interval corrected using Fridericia''s formula
    [QTcF]) after enrollment, the Investigator or qualified designee will determine
    if the participant can continue in the study and if any change in participant
    management is needed. This review of the ECG printed at the time of collection
    must be documented. Any new clinically relevant finding should be reported as
    an AE.</p>

    <p>Participants must be considered for discontinuation from study intervention
    if any of the following occur during the study:</p>

    <ul>

    <li><p>Serious hypersensitivity reaction;</p></li>

    <li><p>Severe uncontrolled infection;</p></li>

    <li><p>Use of disallowed medication;</p></li>

    <li><p>Pregnancy or planned pregnancy (see Section 8.2.6); or</p></li>

    <li><p>Alexion or the Investigator deems it is necessary for the participant.</p></li>

    </ul>

    <p>See the SoA (Table 1) for samples and data to be collected at the time of study
    intervention discontinuation and follow-up and for any further evaluations that
    need to be completed.</p></div>'
- - NC_38
  - 7.2.
  - Participant Discontinuation/Withdrawal From the Study
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>All efforts should be made to ensure participants are willing to comply
    with study participation prior to conducting the screening procedures. The study
    staff should notify Alexion and their site monitor of all study withdrawals as
    soon as possible. The reason for participant discontinuation must be recorded
    in the source documents and CRF.</p></li>

    <li><p>A participant may withdraw from the study at any time at his/her own request,
    or may be withdrawn at any time at the discretion of the Investigator for safety,
    behavioral, compliance, or administrative reasons.</p></li>

    <li><p>At the time of discontinuation from the study, if possible, an early discontinuation
    visit should be conducted, as shown in the SoA. See SoA (Section 1.3) for data
    to be collected at the time of study discontinuation and follow-up and for any
    further evaluations that need to be completed.</p></li>

    <li><p>The participant will be permanently discontinued both from the study intervention
    and from the study at that time.</p></li>

    <li><p>If the participant withdraws consent for disclosure of future information,
    Alexion may retain and continue to use any data collected before such a withdrawal
    of consent.</p></li>

    <li><p>If a participant withdraws from the study, he/she may request destruction
    of any samples taken and not tested, and the Investigator must document this in
    the site study records. </p></li></ul></div>'
- - NC_39
  - '7.3'
  - Lost to Follow-up
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A participant will be considered\
    \ lost to follow-up if he or she repeatedly fails to return for scheduled visits\
    \ and is unable to be contacted by the study site.</p>\n<p>The following actions\
    \ must be taken if a participant fails to return to the clinic for a required\
    \ study visit:</p>\n<ul>\n<li><p>\u2022 The site must attempt to contact the participant\
    \ and reschedule the missed visit as soon as possible and counsel the participant\
    \ on the importance of maintaining the assigned visit schedule and ascertain whether\
    \ or not the participant wishes to and/or should continue in the study.</p></li>\n\
    <li><p>Before a participant is deemed lost to follow-up, the Investigator or designee\
    \ must make every effort to regain contact with the participant (where possible,\
    \ 3 telephone calls and, if necessary, a certified letter to the participant's\
    \ last known mailing address or local equivalent methods). These contact attempts\
    \ should be documented in the participant's medical record.</p></li>\n<li><p>Should\
    \ the participant continue to be unreachable, he/she will be considered to have\
    \ withdrawn from the study.</p></li>\n</ul>\n<p>Discontinuation of specific sites\
    \ or of the study as a whole are handled as part of Section 10.1.8.</p></div>"
- - NC_40
  - '8.'
  - STUDY ASSESSMENTS AND PROCEDURES
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Study procedures and\
    \ their timing are summarized in the SoA (Section 1.3). Protocol waivers or exemptions\
    \ are not allowed.</p></li>\n<li><p>Immediate safety concerns should be discussed\
    \ with Alexion immediately upon occurrence or awareness to determine if the participant\
    \ should continue or discontinue study intervention.</p></li>\n<li><p>Adherence\
    \ to the study design requirements, including those specified in the SoA, is essential\
    \ and required for study conduct.</p></li>\n<li><p>All screening evaluations must\
    \ be completed and reviewed to confirm that potential participants meet all eligibility\
    \ criteria. The Investigator will maintain a screening log to record details of\
    \ all participants screened and to confirm eligibility or record reasons for screening\
    \ failure, as applicable.</p></li>\n<li><p>The following only applies to sites\
    \ in the US.</p>\n<ul type=\"a\">\n<li><p>In the US only, it is permissible for\
    \ study visits for individual participants to occur at more than 1 site. Some\
    \ sites may perform screening procedures only and not any of the remaining study\
    \ procedures. These sites will be known as \u201Cscreening sites\u201D. The procedures\
    \ performed at screening sites are defined in the Screening column (Study Days\
    \ -42 to -9 and -21) of the SoA (Section 1.3). Following the completion of screening\
    \ procedures at a screening site, eligible participants will be transferred to\
    \ the CRU, where the remaining study procedures and visits will occur. Site-to-site\
    \ transfer of the participant will be documented accordingly.</p></li>\n</ul>\n\
    </li></ul></div>"
- - NC_41
  - 8.1.
  - Efficacy Assessments
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Copper and Molybdenum Balance
    Measurements</b></p>

    <p>Copper and molybdenum balance measurements will be made on all intake (ie,
    investigational agent, food and fluids) and all output (urine and feces) from
    participants as indicated in the SoA. The copper and molybdenum concentration
    of each sample will be determined by inductively coupled plasma mass spectrometry
    (ICP-MS). Copper and molybdenum content of all intake and output will be calculated
    based on the volume or weight of intake and output and the concentration of representative
    samples.</p>

    <p><b>8.1.1.1. Food and Fluid Collection for Copper and Molybdenum Concentrations</b></p>

    <p>Samples of all meal and fluid batches will be collected and analyzed for measurement
    of copper and molybdenum content. A minimum of 3 complete portions/meals from
    each food and liquid batch will be sent for analysis. All participants will drink
    water from the same large water bottle dispenser. Samples of water from this dispenser
    will be collected and analyzed for copper and molybdenum content.</p>

    <p>Samples will be collected, stored and shipped as detailed in the Laboratory
    Manual. All sample handling procedures will be documented in detail in the Laboratory
    Manual. Copper and</p>

    <p>ALXN1840-WD-204</p>

    <p>molybdenum concentration of each food sample (ng/g) and each fluid sample (ng/mL)
    sample will be determined by ICP-MS.</p>

    <p><b>8.1.1.2 . Urine Collection for Measurement of Copper and Molybdenum content</b></p>

    <p>Urine samples to measure copper and molybdenum content will be collected periodically
    as described in the SoA (Table 1). Samples will be collected, stored and shipped
    as detailed in the Laboratory Manual. For each 24-hour collection period, urine
    will be pooled for analysis and volumes will be recorded. All sample handling
    procedures will be documented in detail as described in the Laboratory Manual.
    Copper and molybdenum concentration (ng/mL) of each 24-hour urine sample will
    be determined by ICP-MS.</p>

    <p><b>8.1.1.3 . Fecal Collection for Measurement of Copper and Molybdenum Content</b></p>

    <p>Fecal samples to measure copper and molybdenum content will be collected periodically
    as described in the SoA (Table 1). Samples will be collected, stored, and shipped
    as detailed in the Laboratory Manual. Fecal samples will be individually collected,
    weighed, and stored. The weight and time of each bowel movement will be recorded.
    All sample handling procedures will be documented in detail in the Laboratory
    Manual. Copper and molybdenum concentration (ng/g) of each stool sample will be
    determined by ICP-MS; each sample will be analyzed using a minimum of technical
    triplicates.</p></div>'
- - NC_42
  - 8.1.1
  - Copper and Molybdenum Balance Measurements
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Copper and molybdenum balance measurements
    will be made on all intake (ie, investigational agent, food and fluids) and all
    output (urine and feces) from participants as indicated in the SoA. The copper
    and molybdenum concentration of each sample will be determined by inductively
    coupled plasma mass spectrometry (ICP-MS). Copper and molybdenum content of all
    intake and output will be calculated based on the volume or weight of intake and
    output and the concentration of representative samples.</p></div>
- - NC_43
  - 8.1.1.1
  - Food and Fluid Collection for Copper and Molybdenum Concentrations
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Samples of all meal and fluid batches
    will be collected and analyzed for measurement of copper and molybdenum content.
    A minimum of 3 complete portions/meals from each food and liquid batch will be
    sent for analysis. All participants will drink water from the same large water
    bottle dispenser. Samples of water from this dispenser will be collected and analyzed
    for copper and molybdenum content.</p>

    <p>Samples will be collected, stored and shipped as detailed in the Laboratory
    Manual. All sample handling procedures will be documented in detail in the Laboratory
    Manual. Copper and molybdenum concentration of each food sample (ng/g) and each
    fluid sample (ng/mL) sample will be determined by ICP-MS.</p></div>'
- - NC_44
  - 8.1.1.2
  - Urine Collection for Measurement of Copper and Molybdenum content
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Urine samples to measure copper and
    molybdenum content will be collected periodically as described in the SoA (Table
    1). Samples will be collected, stored and shipped as detailed in the Laboratory
    Manual. For each 24-hour collection period, urine will be pooled for analysis
    and volumes will be recorded. All sample handling procedures will be documented
    in detail as described in the Laboratory Manual. Copper and molybdenum concentration
    (ng/mL) of each 24-hour urine sample will be determined by ICP-MS.</p></div>
- - NC_45
  - 8.1.1.3
  - Fecal Collection for Measurement of Copper and Molybdenum Content
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Fecal samples to measure copper and
    molybdenum content will be collected periodically as described in the SoA (Table
    1). Samples will be collected, stored, and shipped as detailed in the Laboratory
    Manual. Fecal samples will be individually collected, weighed, and stored. The
    weight and time of each bowel movement will be recorded. All sample handling procedures
    will be documented in detail in the Laboratory Manual. Copper and molybdenum concentration
    (ng/g) of each stool sample will be determined by ICP-MS; each sample will be
    analyzed using a minimum of technical triplicates.</p></div>
- - NC_46
  - 8.2.
  - Safety Assessments
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Planned time points for all safety
    assessments are provided in the SoA (Section 1.3).</p>

    <p>When multiple procedures are scheduled to occur at the same time, the following
    order of events should be strictly adhered to whenever possible: ECG, vital signs,
    blood sampling, study intervention administration, and meal.</p>

    <p>Pharmacokinetic collection should occur as close as possible to the scheduled
    time.</p>

    <p>All routine safety laboratory samples should be drawn following a minimum of
    8 hours fasting.</p></div>'
- - NC_47
  - 8.2.1
  - Physical Examinations
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li><p>A complete physical examination\
    \ will include, at a minimum, assessments of the \ncardiovascular, respiratory,\
    \ gastrointestinal, and neurological systems. Height (at \nScreening only) and\
    \ weight (as per the SoA for physical examinations) will also be \nmeasured and\
    \ recorded. A symptom-driven physical examination may be performed at \nother\
    \ times, at the Principal Investigator's discretion. </p></li></ul></div>"
- - NC_48
  - 8.2.2
  - Vital Signs
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Body temperature, heart\
    \ rate, respiratory rate, and systolic and diastolic blood pressure (mm Hg) will\
    \ be assessed using consistent methods and equipment to allow comparability and\
    \ reproducibility throughout the study.</p></li>\n<li><p>\u2022 Blood pressure\
    \ and heart rate measurements will be assessed with a completely automated device.\
    \ Manual techniques will be used only if an automated device is not available.</p></li>\n\
    <li><p>\u2022 Blood pressure and heart rate measurements should be preceded by\
    \ at least 5 minutes of rest for the participant in a quiet setting without distractions\
    \ (eg, television, cell phones). Ideally, the same arm for each participant should\
    \ be used for measurements.</p></li>\n<li><p>\u2022 Vital signs will be measured\
    \ in a supine position after 5 minutes rest and will include temperature, systolic\
    \ and diastolic blood pressure, and heart rate. Vital signs will consist of a\
    \ single pulse and blood pressure measurement. If vital signs are abnormal as\
    \ defined by inclusion/ exclusion criteria, 2 additional vital signs measurements\
    \ will be made. The average of the 3 vital signs measurements will be recorded\
    \ in the CRF and used to determine participant eligibility. The average of the\
    \ blood pressure readings will be recorded in the CRF. </p></li>\n</ul></div>"
- - NC_49
  - 8.2.3
  - Electrocardiograms
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>\u2022 Triplicate 12-lead\
    \ ECGs will be conducted as outlined in the SoA (see Section 1.3) to obtain heart\
    \ rate, PR, QRS, QT, and QTc intervals. Refer to Section 7 for QTc withdrawal\
    \ criteria and any additional QTc readings that may be necessary. As with vital\
    \ signs, if ECG interval measurements are abnormal, an additional triplicate will\
    \ be performed and recorded in the CRF. </p></li></ul>\n</div>"
- - NC_50
  - 8.2.4
  - Clinical Safety Laboratory Assessments
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>\u2022 See Section 10.2\
    \ for the list of clinical laboratory tests to be performed and to the SoA (Section\
    \ 1.3) for the timing and frequency.</p></li>\n<li><p>\u2022 The Investigator\
    \ must review the laboratory report, document this review, and record any clinically\
    \ relevant changes occurring during the study in the AE section of the CRF. The\
    \ laboratory reports must be filed with the source documents. Clinically significant\
    \ laboratory values are those deemed by the Investigator to be clinically significant\
    \ resulting in further evaluation or treatment or those associated with an AE\
    \ or clinical \nsigns or symptoms.</p></li>\n<li><p>\u2022 All laboratory tests\
    \ with values considered abnormal and clinically significant during participation\
    \ in the study or after the last dose of study intervention should be repeated\
    \ until the values return to normal or baseline or are no longer considered clinically\
    \ significant by the Investigator or Medical Monitor.</p>\n<ul>\n<li><p>If such\
    \ values do not return to normal/baseline within a period of time judged reasonable\
    \ by the Investigator, the etiology should be identified, and Alexion notified.</p></li>\n\
    <li><p>All protocol-required laboratory assessments, as defined in Section 10.2,\
    \ must be conducted in accordance with the laboratory manual and the SoA.</p></li>\n\
    <li><p>All laboratory values from non-protocol-specified laboratory assessments\
    \ must also be recorded in the CRF.</p></li>\n</ul></li></ul></div>"
- - NC_51
  - 8.2.4.1
  - Bowel and Urine Monitoring
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Participant's bowel movements and
    urination will be monitored by the clinical staff. The clinical staff will record
    in the CRF each time a fecal and urine sample is collected. All urine and feces
    must be collected from Day -4 through Day -1, Day 1 through Day 8, Day 25 through
    Day 39.</p></div>
- - NC_52
  - 8.2.4.2
  - Intake Monitoring
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>To support accurate quantification
    of copper/molybdenum intake, each participant's intake including both food and
    fluids will be monitored and recorded. Following each standardized meal, the clinical
    staff will record 100% completion of each meal including all liquids. If a participant
    is unable to eat 100% of the food for a given meal, the remaining food will be
    weighed and reported in the CRF to support accurate determination of copper/molybdenum
    as a fraction of the total meal. Similarly, if participants do not complete 100%
    of non-water fluids with meal, the remaining volume will be measured and recorded
    in the CRF. In the case of water intake, the staff will record daily water volume
    intake in the CRF.</p></div>
- - NC_53
  - 8.2.5
  - Suicidal Ideation and Behavior Risk Monitoring
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Suicidal ideation and behavioral
    changes will be recorded as adverse events and may, at the discretion of the Investigator,
    result in withdrawal of the participation from the study and urgent referral for
    psychiatric treatment.</p></div>
- - NC_54
  - 8.2.6
  - Pregnancy
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Pregnancy data from\
    \ female participants and female spouses/partners of male participants \nwill\
    \ be collected from the signing of the ICF and at the time points specified in\
    \ the SoA. \nAny female participant who becomes pregnant while participating in\
    \ the study will be \ndiscontinued from the study intervention. If a pregnancy\
    \ is reported, the Investigator must \nimmediately inform Alexion within 24 hours\
    \ of awareness of the pregnancy and follow \nthe procedures outlined in Section\
    \ 10.4.</p></li>\n<li><p>For all Alexion products, both in development or post\
    \ approval, exposure during \npregnancy must be recorded and the pregnancy followed,\
    \ until the outcome of the \npregnancy is known (ie, spontaneous miscarriage,\
    \ elective termination, normal birth, or \ncongenital abnormality), even if the\
    \ participant discontinues the study intervention or \nwithdraws from the study.\
    \ The corresponding infant must be followed for 3 months \npostpartum.</p></li>\n\
    <li><p>Pregnancy is not considered as an AE (Section 10.4) unless there is a suspicion\
    \ that the \nstudy intervention may have interfered with the effectiveness of\
    \ a contraceptive \nmedication. However, complications of pregnancy and abnormal\
    \ outcomes of pregnancy \nare AEs and may meet the criteria for an SAE (eg, ectopic\
    \ pregnancy, spontaneous \nabortion, intrauterine fetal demise, neonatal death,\
    \ or congenital anomaly) (Section 8.3). \nElective abortions without complications\
    \ should not be reported as AEs.</p></li>\n</ul></div>"
- - NC_55
  - 8.3.
  - Adverse Events and Serious Adverse Events
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The definitions of AEs and SAEs
    can be found in Section 10.3.</p>

    <p>All AEs will be reported to the Investigator or qualified designee by the participant
    (or, when appropriate, by a caregiver, surrogate, or the participant''s legally
    authorized representative).</p>

    <p>The Investigator and any qualified designees are responsible for detecting,
    documenting, and recording events that meet the definition of an AE or SAE and
    remain responsible for following up AEs that are serious, considered related to
    the study intervention or study procedures, or that caused the participant to
    discontinue the study intervention (see Section 7).</p>

    <p>Procedures for recording, evaluating, follow-up, and reporting AEs and SAEs
    are outlined in Section 10.3.</p></div>'
- - NC_56
  - 8.3.1
  - Time Period and Frequency for Collecting AE and SAE Information
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>All AEs and SAEs will be collected
    from the signing of the ICF until the EOS Visit.</p>

    <p>All SAEs will be recorded and reported to Alexion or the designee immediately
    and under no circumstance should this exceed 24 hours, as indicated in Section
    10.3. The Investigator will submit any updated SAE data to Alexion within 24 hours
    of it being available.</p>

    <p>Investigators are not obligated to actively seek AE or SAE data after conclusion
    of the study participation. However, if the Investigator learns of any SAE, including
    a death, at any time after a participant has been discharged from the study, and
    he/she considers the event to be reasonably related to the study intervention
    or study participation, the Investigator must promptly notify Alexion.</p></div>'
- - NC_57
  - 8.3.2
  - Method of Detecting AEs and SAEs
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The method of recording, evaluating,
    and assessing causality of AE and SAE and the procedures for completing and transmitting
    SAE reports are provided in Section 10.3.</p>

    <p>Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended
    and non-leading verbal questioning of the participant is the preferred method
    to inquire about AE occurrences.</p></div>'
- - NC_58
  - 8.3.3
  - Follow-up of AEs and SAEs
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>After the initial AE/SAE report,
    the Investigator is required to proactively follow up on each participant at subsequent
    visits/contacts. All SAEs will be followed up until resolution, stabilization,
    the event is otherwise explained, or the participant is lost to follow-up (as
    defined in Section 7.3). Further information on follow-up procedures is provided
    in Section 10.3.</p></div>
- - NC_59
  - 8.3.4
  - Regulatory Reporting Requirements for SAEs
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Prompt notification\
    \ of an SAE by the Investigator to Alexion is essential so that legal obligations\
    \ and ethical responsibilities toward the safety of participants and the safety\
    \ of a study intervention under clinical investigation are met.</p></li>\n<li><p>Alexion\
    \ has a legal responsibility to notify both the local regulatory authority and\
    \ other regulatory agencies about the safety of a study intervention under clinical\
    \ investigation. Alexion will comply with country-specific regulatory requirements\
    \ relating to safety reporting to the regulatory authority, Institutional Review\
    \ Boards (IRBs)/ Independent Ethics Committees (IECs), and Investigators.</p></li>\n\
    <li><p>Suspected unexpected serious adverse reactions (SUSARs) must be reported\
    \ according to local regulatory requirements and Alexion policy and forwarded\
    \ to Investigators as necessary.</p></li>\n<li><p>An Investigator who receives\
    \ an Investigator safety report describing an SAE or other \nspecific safety information\
    \ (eg, summary or listing of SAEs) from Alexion will review and then file it along\
    \ with the IB and will notify the IRB/IEC, if appropriate according to local requirements.\
    \ </p></li>\n</ul></div>"
- - NC_60
  - 8.3.5
  - Adverse Events of Special Interest
  - <div xmlns="http://www.w3.org/1999/xhtml">There are no adverse events of special
    interest for this study.</div>
- - NC_61
  - 8.3.6
  - Retained and Biobanked Sample
  - <div xmlns="http://www.w3.org/1999/xhtml">A single biobanked serum sample will
    be collected predose from each participant to serve as a retained sample during
    the study. Samples will remain on site and will be discarded following the completion
    of the clinical study report. The sample will not be used for genetic testing
    (see Section 8.7).</div>
- - NC_62
  - '8.4'
  - Treatment of Overdose
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For this study, any dose of ALXN1840\
    \ greater than that specified in the protocol will be considered an overdose.\
    \ </p>\n<p>Alexion does not recommend specific treatment for an overdose. </p>\n\
    <p>Overdoses are medication errors that are not considered AEs unless there is\
    \ an untoward medical occurrence resulting from the overdose. </p>\n<p>In the\
    \ event of an overdose or suspected overdose, the Investigator/treating physician\
    \ should:</p>\n<ol>\n<li><p>Contact the Medical Monitor immediately.</p></li>\n\
    <li><p>Closely monitor the participant for any AE/SAE.</p></li>\n<li><p>Obtain\
    \ a plasma sample for PK analysis if requested by the Medical Monitor (determined\
    \ \non a case-by-case basis).</p></li>\n<li><p>Document the quantity of the excess\
    \ dose as well as the duration of the overdose in the CRF.</p></li>\n</ol>\n<p>Decisions\
    \ regarding dose interruptions or modifications will be made by the Investigator\
    \ in consultation with the Medical Monitor based on the clinical evaluation of\
    \ the participant.</p></div>"
- - NC_63
  - '8.5'
  - Pharmacokinetics
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>Whole blood samples\
    \ will be collected for the measurement of plasma concentrations of total molybdenum\
    \ and PUF-molybdenum as specified in the SoA (Table 1) via ICP-MS. Samples collected\
    \ within \xB1\u202F10% or 30 min, whichever is less, of the scheduled time will\
    \ not be considered a protocol deviation.</p></li>\n<li><p>Instructions for the\
    \ collection and handling of biological samples will be provided by Alexion. The\
    \ actual date and time (24-hour clock time) of each sample will be recorded.</p></li>\n\
    <li><p>Total molybdenum and PUF-molybdenum are surrogate measures of ALXN1840\
    \ and concentrations will be used to evaluate the PK of ALXN1840. Samples collected\
    \ for analyses of plasma concentrations may also be used to evaluate safety aspects\
    \ related to concerns arising during or after the study.</p></li>\n<li><p>Excess/additional\
    \ samples may be stored for up to 5 years and used for PD and/or diagnostic biomarker\
    \ development and research to understand the pathways associated with the mechanism\
    \ of action of ALXN1840. These samples will not be used for genetic analyses (ie,\
    \ RNA or DNA analyses).</p></li>\n<li><p>Genetic analyses will not be performed\
    \ on these whole blood samples. Participant confidentiality will be maintained.</p></li>\n\
    <li><p>See also Section 8.1.1 for details of molybdenum measured in food, drinks,\
    \ urine, and \nfeces.</p></li>\n</ul></div>"
- - NC_64
  - 8.6.
  - Pharmacodynamics
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Plasma total and PUF-copper, ceruloplasmin,
    ceruloplasmin-bound copper, and LBC will be assessed during the study.</p>

    <p>Blood samples will be collected as described in the SoA (Table 1) for plasma
    isolation as per the Laboratory Manual. Plasma samples will be used for ICP-MS
    measurement of total copper and PUF-copper, ceruloplasmin, ceruloplasmin-bound
    copper, and non-ceruloplasmin-bound copper measured via PUF-copper, and/or LBC,
    or assessed via NCC/NCCcorrected methods at the time points indicated in the SoA
    (Table 1).</p></div>'
- - NC_65
  - 8.7.
  - Genetics
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Genetics will not be evaluated in
    this study.</p></div>
- - NC_66
  - 8.8.
  - Biomarkers
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Please see Section 8.6 for details
    of total copper and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and
    non-ceruloplasmin-bound copper as measured via PUF-copper, and/or LBC, or assessed
    via NCC/NCCcorrected methods, and Section 8.1.1 for details of copper measured
    in food, drink, urine, and feces.</p></div>
- - NC_67
  - 8.9.
  - Immunogenicity Assessments
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Not applicable.</p></div>
- - NC_68
  - 8.10.
  - Health Economics Data and/or Medical Resource Utilization
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Health economic and medical resource
    utilization parameters are not evaluated in this study.</p></div>
- - NC_69
  - '9.'
  - STATISTICAL CONSIDERATIONS
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><b>9.1.1. Primary Hypothesis</b></p>

    <p>ALXN1840-WD-204</p>

    <p>As this study is an exploratory study, no formal hypothesis testing is being
    conducted. Study results will be summarized using descriptive statistics.</p></div>'
- - NC_70
  - '9.1'
  - Statistical Hypotheses
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p><b>9.1.1. Primary Hypothesis</b></p>

    <p>ALXN1840-WD-204</p>

    <p>As this study is an exploratory study, no formal hypothesis testing is being
    conducted. Study results will be summarized using descriptive statistics.</p></div>'
- - NC_71
  - 9.1.1
  - Primary Hypothesis
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>As this study is an exploratory study,
    no formal hypothesis testing is being conducted. Study results will be summarized
    using descriptive statistics.</p></div>
- - NC_72
  - 9.2.
  - Sample Size Determination
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>The sample size will be approximately
    10 participants which will allow a general characterization of copper balance
    in response to ALXN1840.</p></div>
- - NC_73
  - 9.3.
  - Populations for Analyses
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The population sets used for analysis
    are defined Table 8.</p>

    <p><b>Table 8: Populations for Analysis</b></p>

    <table class="table align-top">

    <tr>

    <td><p>Screened</p></td><td><p>All participants who sign the ICF.</p></td>

    </tr>

    <tr>

    <td><p>Enrolled</p></td><td><p>All participants who sign the ICF, are eligible
    for the study, and are registered on Day -7 when participants are assigned a participant
    number.</p></td>

    </tr>

    <tr>

    <td><p>Safety Analysis Set</p></td><td><p>All participants who receive at least
    1 dose of ALXN1840 treatment</p></td>

    </tr>

    <tr>

    <td><p>Full Analysis Set</p></td><td><p>All participants who receive at least
    1 dose of ALXN1840 treatment.</p></td>

    </tr>

    <tr>

    <td><p>Per Protocol Set</p></td><td><p>All participants who received at least
    1 dose of ALXN1840, had Baseline and all post Baseline values of copper intake
    (in food and drink) and copper output (in feces and urine), and were 100% compliant
    with study drug dosing. Participants with major protocol deviations that are likely
    to impact the primary endpoint analysis will be excluded from the Per Protocol
    (PP) Set. Major protocol deviations, and the PP Set, will be defined, documented,
    and agreed within Alexion prior to database lock.</p></td>

    </tr>

    <tr>

    <td><p>Pharmacokinetic/Pharmacodynamic Analysis Set</p></td>

    <td><p>All participants who have sufficient plasma samples to enable the calculation
    of PK parameters and provide PK/PD profiles.</p></td>

    </tr>

    </table>

    <p><small>Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK
    = pharmacokinetic.</small></p></div>'
- - NC_74
  - 9.4.
  - Statistical Analyses
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Statistical methods described\
    \ in this section will be further elaborated in a separate Statistical Analysis\
    \ Plan (SAP). Summary statistics will be computed and displayed by visit where\
    \ applicable and will be presented by cohort (treatment experienced/treatment\
    \ na\xEFve), and overall Descriptive statistics for continuous variables will\
    \ minimally include the number of participants, mean, standard deviation, minimum,\
    \ median, and maximum. For categorical variables, frequencies, and percentages\
    \ will be presented. Graphical displays will be provided as appropriate.</p>\n\
    <p>Analyses will be performed using the SAS\xAE software Version 9.4 or higher.</p></div>"
- - NC_75
  - 9.4.1
  - Primary Analysis
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The primary objective of this study
    is to demonstrate a net negative copper balance with daily repeat-dose ALXN1840
    treatment (15 mg and 30 mg) in participants with WD.</p>

    <p>The primary analysis will be performed using the Full Analysis Set. Average
    daily copper balance and molybdenum balance will be calculated over the following
    periods:</p>

    <ol>

    <li><p>Day -4 through Day -1 representing predose baseline</p></li>

    <li><p>Days 1 through 8 representing the ALXN1840 15 mg/day accumulation period
    </p></li>

    <li><p>Days 25 through 28 representing the ALXN1840 15 mg/day steady-state period</p></li>

    <li><p>Days 31 through 35, representing the ALXN1840 30 mg/day accumulation period
    </p></li>

    <li><p>Days 36 through 39 representing the ALXN1840 30 mg/day steady-state period</p></li>

    </ol>

    <p>As ALXN1840 is expected to increase copper excretion through fecal excretion,
    copper in stool will be critical for determining copper balance. Because stools
    can be irregular, assessment of copper and molybdenum balance will only include
    data up to the day of the final bowel movement. For example, for the period Day
    1 through Day 8, if the final bowel movement occurs on Day 7, average daily copper
    balance for the Day 1 through Day 8 period will only include data from Day 1 through
    Day 7.</p>

    <p>In the case of the 15 mg/day steady-state period (ie, Day 25 through Day 28),
    stool data collected on Days 29 - 30 samples may be used if needed to support
    assessments for the 15 mg/day dose. Use of these stool data (as needed) are consistent
    with an approximately 2-day gastrointestinal transit time.</p>

    <p>In the case of stool irregularity, and to support assessment of copper output
    over time, bowel movement copper and molybdenum outputs may be averaged over the
    days between bowel movement (or start of study) to ensure an approximate value
    for each 24-hour period.</p></div>'
- - NC_76
  - 9.4.2
  - Secondary Analyses
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Secondary analyses will be performed
    using the Full Analysis Set. The secondary continuous endpoints (including copper
    balance, molybdenum balance, and 24-hour urine excretion of copper and molybdenum)
    will be analyzed using the same methods described for the primary analysis.</p></div>
- - NC_77
  - 9.4.3
  - Safety Analysis
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Safety analyses will be performed
    using the Safety Analysis Set.</p>

    <p>Safety analyses will include all AEs, ECGs, clinical laboratory data, physical
    examinations, and vital sign measurements using descriptive statistics.</p>

    <p>No inferential statistical analyses are planned for the safety parameters of
    this study. The incidence of AEs and SAEs will be summarized by System Organ Class
    and Preferred Term for each treatment and overall, and by relationship to study
    intervention. Adverse events will also be summarized by treatment and overall
    by severity. Serious AEs and AEs resulting in withdrawal from the study will be
    listed. Participants having multiple AEs within a category (eg, overall, System
    Organ Class, Preferred Term) will be counted once in that category. For severity
    tables, a participant''s most severe event within a category will be counted.</p>

    <p>Changes from baseline in vital sign measurements and laboratory assessments
    (eg, chemistry, hematology, coagulation, and urinalysis) will be summarized by
    treatment. Laboratory parameter values will be graded according to the National
    Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Shift
    tables by treatment will be produced for these laboratory</p>

    <p>ALXN1840-WD-204</p>

    <p>parameters. These tables will summarize the number of participants with each
    baseline grade relative to the reference ranges and changes to the worst highest
    grade assessed post dose during the study.</p>

    <p>Electrocardiogram parameters will be measured at the specified time points
    as per the SoA (Table 1), including heart rate, PR, RR, QRS, QT, and QTcF intervals.
    The average of the triplicate ECG readings at the time points collected will be
    calculated, and changes from pretreatment baseline values will be assessed by
    each treatment.</p>

    <p>All concomitant medications will be coded and summarized using the World Health
    Organization (WHO) Drug Dictionary.</p></div>'
- - NC_78
  - 9.4.4
  - Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For PK, PD, and biomarker endpoints,\
    \ analyses will be performed using the PK/PD Analysis Set. The following plasma\
    \ PK parameters will be calculated for total molybdenum and PUF molybdenum (as\
    \ surrogate measures of ALXN1840 PK) using noncompartmental methods with Phoenix\xAE\
    \ WinNonlin\xAE (Certara USA Inc., Princeton, New Jersey) Version 8.0 or higher\
    \ or SAS Version 9.3 or higher (SAS Institute Inc., Cary, North Carolina), as\
    \ applicable. Calculations will be based on the actual sampling times recorded\
    \ during the study.</p>\n<ul>\n<li><p>Time delay between the time of dosing and\
    \ time of appearance of molybdenum concentration (Tlag ) in plasma</p></li>\n\
    <li><p>Maximum observed concentration ( Cmax )</p></li>\n<li><p>Time to maximum\
    \ concentration (tmax )</p></li>\n<li><p>Trough (predose) concentration observed\
    \ at the start of the dosing interval (Ctrough )</p></li>\n<li><p>Area under the\
    \ plasma concentration versus time curve (AUC) from time 0 to the last quantifiable\
    \ concentration (AUCt )</p></li>\n<li><p>AUC over the dosing interval (AUCtau\
    \ )</p></li>\n<li><p>Accumulation ratio (AR) calculated as:</p>\n<p>For 15 mg/day:</p>\n\
    <p>\u2212 C<sub>max,Day25</sub>/C<sub>max,Day1</sub></p>\n<p>\u2212 C<sub>trough,Day26</sub>\
    \ /Ctrough,Day2</p>\n<p>\u2212 AUC<sub>tau,Day25</sub> /AUC<sub> tau,Day1</sub></p>\n\
    <p>For 30 mg/day:</p>\n<p>\u2212 C<sub>max,Day39 </sub>/C <sub>max,Day29,adjusted\
    \ </sub></p>\n<p>\u2212 C<sub>trough,Day40</sub> /C <sub>trough,Day30,adjusted\
    \ </sub></p>\n<p>\u2212 AUC<sub>tau,Day39 </sub>/AUC <sub>tau,Day29,adjusted </sub></p>\n\
    <p>Note: total molybdenum and PUF molybdenum concentration-time profiles on Day\
    \ 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr)\
    \ and subtracted from the observed Day 29 concentration-time profiles after the\
    \ first 30 mg</p>\n<p>ALXN1840 dose for the estimation of the C <sub>max,Day29,adjusted</sub>\
    \ , C <sub>trough,Day30,adjusted</sub> , and AUC <sub>tau,Day29,adjusted</sub>\
    \ .</p></li>\n<li><p>Apparent terminal phase elimination rate constant (\u03BB\
    <sub>z</sub> )</p></li>\n<li><p>Terminal elimination half-life (t<sub>\xBD</sub>\
    \ )</p></li>\n<li><p>Apparent total body clearance (CL/F) of ALXN1840 from plasma</p></li>\n\
    <li><p>Apparent volume of distribution (V<sub>d</sub> /F).</p></li>\n</ul>\n<p>Additional\
    \ plasma PK parameters may be calculated if deemed appropriate.</p>\n<p>Plasma\
    \ concentrations of total molybdenum and PUF molybdenum vs. time data will be\
    \ presented in a data listing by participant. Plasma concentration data will be\
    \ summarized separately by analyte and time point for each treatment by day using\
    \ the following descriptive statistics: number of participants, arithmetic mean,\
    \ geometric mean (GM), SD, coefficient of variation (CV), GMCV, median, minimum,\
    \ and maximum. Mean plasma concentration versus scheduled time profiles will be\
    \ presented in figures on both linear and semilogarithmic scales. Individual plasma\
    \ concentration versus actual time profiles will be presented similarly.</p>\n\
    <p>Pharmacokinetic parameters derived from plasma concentrations of total molybdenum\
    \ and PUF molybdenum will be presented in data listings and summarized separately\
    \ using the following descriptive statistics: number of participants, arithmetic\
    \ mean, GM, SD, arithmetic CV, GMCV, median, minimum, and maximum. Geometric mean\
    \ and geometric CV will be presented for Cmax and AUCs only.</p>\n<p>For PD (total\
    \ and PUF copper and LBC) and biomarker endpoints (ceruloplasmin, ceruloplasmin-bound\
    \ copper), concentration-time data will be listed and summarized with descriptive\
    \ statistics and plotted. The same analyses will be conducted on the absolute\
    \ and percent changes from baseline of these concentration-time data.</p></div>"
- - NC_79
  - 9.5.
  - Interim Analyses
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Marketing Authorisation Application(s)
    may be submitted before all patients complete the Treatment Periods; therefore,
    interim analyses of safety and efficacy data may be performed to support these
    submissions. These analyses will be descriptive only; they will not include formal
    hypothesis testing and will not be used to adapt the study. Full details will
    be provided in the SAP.</p></div>
- - NC_80
  - 9.6.
  - Data Monitoring Committee
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>There will not be a Data Monitoring
    Committee, but provision is included for an SRC (Section 9.7).</p></div>
- - NC_81
  - 9.7.
  - Safety Review Committee (SRC)
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>A SRC, composed of a minimum of the
    Investigator, Alexion Medical Monitor, and Alexion Safety Physician, will meet
    at the end of 15 mg/day dosing to confirm proceeding to 30 mg/day and as necessary
    based on any emerging safety concerns as described in Section 6.6.</p></div>
- - NC_82
  - '10.'
  - SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_83
  - 10.1.
  - Regulatory, Ethical, and Study Oversight Considerations
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_84
  - 10.1.1
  - Regulatory and Ethical Considerations
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>This study will be conducted\
    \ in accordance with the protocol and with the following:</p>\n<p>\u2212 Consensus\
    \ ethical principles derived from international guidelines including the Declaration\
    \ of Helsinki and Council for International Organizations of Medical Sciences\
    \ (CIOMS) International Ethical Guidelines</p>\n<p>\u2212 Applicable International\
    \ Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines </p>\n\
    <p>\u2212 Applicable laws and regulations </p></li>\n<li><p>The protocol, protocol\
    \ substantial amendments, ICF, IB, and other relevant documents (eg, advertisements)\
    \ must be submitted to an IRB/IEC by the Investigator and reviewed and approved\
    \ by the IRB/IEC before the study is initiated.</p></li>\n<li><p>Any substantial\
    \ amendments to the protocol will require IRB/IEC approval before implementation\
    \ of changes made to the study design, except for changes necessary to eliminate\
    \ an immediate hazard to study participants.</p></li>\n<li><p>The Investigator\
    \ will notify the IRB/IEC of deviations from the study protocol or GCP as defined\
    \ by UK legislation as a serious breach or as required by IRB/IEC procedures.</p></li>\n\
    <li><p>The Investigator will be responsible for the following:</p>\n<p>\u2212\
    \ Providing written summaries of the status of the study to the IRB/IEC annually\
    \ or more frequently in accordance with the requirements, policies, and procedures\
    \ established by the IRB/IEC</p>\n<p>\u2212 Notifying the IRB/IEC of SAEs or other\
    \ significant safety findings as required by IRB/IEC procedures</p>\n<p>\u2212\
    \ Providing oversight of the conduct of the study at the site and adherence to\
    \ requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC,\
    \ Directive 2001/20/EC, European regulation 536/2014 for clinical studies (if\
    \ applicable), and all other applicable local regulations</p></li>\n</ul></div>"
- - NC_85
  - 10.1.2
  - Financial Disclosure
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Investigators and Subinvestigators
    will provide Alexion with sufficient, accurate financial information as requested
    to allow Alexion to submit complete and accurate financial certification or disclosure
    statements to the appropriate regulatory authorities. Investigators are responsible
    for providing information on financial interests during the course of the study
    and for 1 year after completion of the study.</p></div>
- - NC_86
  - 10.1.3
  - Informed Consent Process
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>It is the responsibility of the Investigator to obtain signed (written
    or electronic signature) informed consent from all study participants prior to
    any study-related procedures including screening assessments.</p></li>

    <li><p>The Investigator or his/her representative will explain the nature of the
    study (including but not limited to the objectives, potential benefits and risks,
    inconveniences, and the participant''s rights and responsibilities) to the participant
    or his/her legally authorized representative, defined according to local and country
    regulations where the study is taking place, and answer all questions regarding
    the study.</p></li>

    <li><p>Participants must be informed that their participation is voluntary. Participants
    or their legally authorized representative will be required to sign a statement
    of informed consent or a certified translation if applicable, that meets the requirements
    of 21 CFR 50, local regulations, EU General Data Protection Regulation (GDPR),
    ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements,
    where applicable, and the IRB/IEC or study center.</p></li>

    <li><p>The medical record must include a statement that signed (written or electronic)
    informed consent was obtained before the participant was screened in the study
    and the date the written consent was obtained. The authorized person obtaining
    the informed consent must also sign the ICF/ICFs.</p></li>

    <li><p>Participants must be reconsented to the most current version of the ICF/ICFs
    during their participation in the study.</p></li>

    <li><p>A copy of the signed (written or electronic) informed consent documentation
    (ie, a complete set of participant information sheets and fully executed signature
    pages) must be provided to the participant or the participant''s legally authorized
    representative, as applicable. This document may require translation into the
    local language. Signed (written or electronic) consent [or assent] forms must
    remain in each participant''s study file and must be available for verification
    at any time.</p></li>

    </ul>

    <p>The ICF will contain a separate section that addresses the use of remaining
    mandatory samples for optional exploratory research. The Investigator or authorized
    designee will explain to each participant or their legally authorized representative
    the objectives of the exploratory research. If sharing exploratory research results
    with the Investigator is not planned, the ICF should mention it. Participants
    or their legally authorized representative will be told that they are free to
    refuse to participate and may withdraw their consent at any time and for any reason
    during the storage period. A separate signature will be required to document a
    participant''s agreement to allow any remaining specimens to be used for exploratory
    research. Participants who decline to participate in this optional research will
    not provide this separate signature.</p></div>'
- - NC_87
  - 10.1.4
  - Data Protection
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>Participants will be assigned a unique identifier by Alexion. Any participant
    records or datasets that are transferred to Alexion will contain the identifier
    only; participant names or any information which would make the participant identifiable
    will not be transferred.</p></li>

    <li><p>Participants must be informed that their personal study-related data will
    be used by Alexion in accordance with local data protection law. The level of
    disclosure must also be explained to the participants who will be required to
    give consent for their data to be used as described in the informed consent.</p></li>

    <li><p>Participants must be informed that their medical records may be examined
    by Clinical Quality Assurance auditors or other authorized personnel appointed
    by Alexion, appropriate IRB/IEC members, and inspectors from regulatory authorities.</p></li>

    </ul></div>'
- - NC_88
  - 10.1.5
  - Dissemination of Clinical Study Data
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>Study-related information and study
    results may be posted on publicly accessible clinical study databases (eg, www.clinicaltrials.gov
    or www.clinicaltrialsregister.eu), as appropriate, and in accordance with national,
    regional, and local regulations.</p></div>
- - NC_89
  - 10.1.6
  - Data Quality Assurance
  - '<div xmlns="http://www.w3.org/1999/xhtml"><ul>

    <li><p>All participant data relating to the study will be recorded on printed
    or electronic CRF unless transmitted to Alexion or designee electronically (eg,
    laboratory data). The Investigator is responsible for verifying that data entries
    are accurate and correct by physically or electronically signing the CRF.</p></li>

    <li><p>The Investigator must maintain accurate documentation (source data) that
    supports the information entered in the CRF.</p></li>

    <li><p>The Investigator must permit study-related monitoring, audits, IRB/IEC
    review, and regulatory agency inspections and provide direct access to source
    data documents.</p></li>

    <li><p>Alexion or designee is responsible for the data management of this study
    including quality checking of the data.</p></li>

    <li><p>Study monitors will perform ongoing source data verification to confirm
    that data entered into the CRF by authorized site personnel are accurate, complete,
    and verifiable from source documents; that the safety and rights of participants
    are being protected; and that the study is being conducted in accordance with
    the currently approved protocol and any other study agreements, ICH GCP, and all
    applicable regulatory requirements.</p></li>

    <li><p>Records and documents, including signed ICFs, pertaining to the conduct
    of this study must be retained by the Investigator for a minimum of 25 years after
    study completion, unless local regulations or institutional policies require a
    longer retention period. No records may be destroyed during the retention period
    without the written approval of Alexion. No records may be transferred to another
    location or party without written notification to Alexion.</p></li>

    </ul></div>'
- - NC_90
  - 10.1.7
  - Source Documents
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Source documents provide evidence
    for the existence of the participant and substantiate the integrity of the data
    collected. The Investigator or designee will prepare and maintain adequate</p>

    <p>and accurate source documents (eg, medical records, ECGs, AE and concomitant
    medication reporting, raw data collection forms) designed to record all observations
    and other pertinent data for each participant.</p>

    <p>Data reported on the CRF that are transcribed from source documents must be
    consistent with the source documents or the discrepancies must be explained. The
    Investigator may need to request previous medical records or transfer records,
    depending on the study. Also, current medical records must be available. Source
    documents are filed at the Investigator''s site.</p></div>'
- - NC_91
  - 10.1.8
  - Study and Site Start and Closure
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>The study start date is the date
    on which the first participant is consented.</p>

    <p>Alexion reserves the right to close the study site or terminate the study at
    any time for any reason at the sole discretion of Alexion. Study sites will be
    closed after the study is completed or following the decision to close or terminate
    the study. A study site is considered closed when all participants have completed
    the end of study or early discontinuation visit, all data have been collected
    and entered into electronic data capture (EDC) system, all required documents
    and study supplies have been collected, and a study-site closure visit has been
    performed.</p>

    <p>The Investigator may initiate study-site closure at any time, provided there
    is reasonable cause and sufficient notice is given in advance of the intended
    termination.</p>

    <p>Reasons for the early closure of a study site by Alexion or Investigator may
    include but are not limited to:</p>

    <ul>

    <li><p>Failure of the Investigator to comply with the protocol, the requirements
    of the IRB/IEC or local health authorities, Alexion''s procedures, or GCP guidelines</p></li>

    <li><p>Inadequate recruitment of participants by the Investigator</p></li>

    <li><p>Discontinuation of further study intervention development</p></li>

    </ul>

    <p>If the study is prematurely terminated or suspended, Alexion shall promptly
    inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract
    research organization(s) used in the study of the reason for termination or suspension,
    as specified by the applicable regulatory requirements. The Investigator shall
    promptly inform the participant and should assure appropriate participant therapy
    and/or follow-up.</p></div>'
- - NC_92
  - 10.1.9
  - Publication Policy
  - <div xmlns="http://www.w3.org/1999/xhtml"><p>The full terms regarding publication
    of the results of this study are outlined in the applicable Clinical Study Agreement.</p></div>
- - NC_93
  - 10.2.
  - Clinical Laboratory Tests
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul>\n<li><p>The tests detailed in\
    \ Table 9 will be performed by the local laboratory.</p></li>\n<li><p>Protocol-specific\
    \ requirements for inclusion or exclusion of participants are detailed in Section\
    \ 5.</p></li>\n<li><p>Additional tests may be performed at any time during the\
    \ study as determined necessary by the Investigator or required by local regulations.</p></li>\n\
    <li><p>Pregnancy testing: Women of childbearing potential should only be enrolled\
    \ after a negative serum pregnancy test result at Screening. Additional urine\
    \ pregnancy testing will be standard for the protocol unless serum testing is\
    \ required by site policies, local regulation, or IRB/IEC and should be performed\
    \ per the time points specified in the SoA (Section 1.3). Screening pregnancy\
    \ criteria are detailed in Section 5.1.</p></li>\n</ul>\n<p><b>Table 9: Protocol-Required\
    \ Safety Laboratory Assessments</b></p>\n<table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td colspan=\"2\"><p><b>Clinical Chemistry</b></p></td>\n</tr>\n<tr>\n\
    <td><p>\n<p>Blood urea nitrogen (BUN) &amp; <usdm:ref attribute=\"label\" id=\"\
    BiomedicalConcept_10\" klass=\"BiomedicalConcept\"></usdm:ref></p>\n</p></td><td><p>Alanine\
    \ aminotransferase</p></td>\n</tr>\n<tr>\n<td><p>Potassium</p></td><td><p>Alkaline\
    \ phosphatase</p></td>\n</tr>\n<tr>\n<td><p>Creatinine</p></td><td><p>Urea</p></td>\n\
    </tr>\n<tr>\n<td><p>Creatine kinase</p></td><td><p>Magnesium</p></td>\n</tr>\n\
    <tr>\n<td><p>Sodium</p></td><td><p>Iron</p></td>\n</tr>\n<tr>\n<td><p>Chloride</p></td><td><p>Zinc</p></td>\n\
    </tr>\n<tr>\n<td><p>Potassium</p></td><td><p>Total and direct bilirubin</p></td>\n\
    </tr>\n<tr>\n<td><p>Glucose</p></td><td><p>Total protein</p></td>\n</tr>\n<tr>\n\
    <td><p>Total carbon dioxide</p></td><td><p>Albumin</p></td>\n</tr>\n<tr>\n<td><p>Aspartate\
    \ aminotransferase</p></td><td><p>Calcium</p></td>\n</tr>\n<tr>\n<td><p>Gamma\
    \ glutamyltransferase</p></td><td><p>Phosphate</p></td>\n</tr>\n<tr>\n<td colspan=\"\
    2\"><p><b>Hematology</b></p></td>\n</tr>\n<tr>\n<td><p>Hematocrit</p></td><td><p>Red\
    \ blood cell count<sup>a</sup></p></td>\n</tr>\n<tr>\n<td><p>Platelets</p></td><td><p>Mean\
    \ corpuscular volume</p></td>\n</tr>\n<tr>\n<td><p>White blood cell count</p></td><td><p>Mean\
    \ cell hemoglobin concentration</p></td>\n</tr>\n<tr>\n<td><p>Mean cell hemoglobin</p></td><td><p>Lymphocytes</p></td>\n\
    </tr>\n<tr>\n<td><p>Neutrophils</p></td><td><p>Eosinophils</p></td>\n</tr>\n<tr>\n\
    <td><p>Monocytes</p></td><td><p>Prothrombin time</p></td>\n</tr>\n<tr>\n<td><p>Basophils</p></td><td><p>International\
    \ normalized ratio</p></td>\n</tr>\n<tr>\n<td><p>Hemoglobin</p></td><td><p>Partial\
    \ thromboplastin time</p></td>\n</tr>\n<tr>\n<td colspan=\"2\"><p><b>Urinalysis</b></p></td>\n\
    </tr>\n<tr>\n<td><p>Bilirubin</p></td><td><p>Blood</p></td>\n</tr>\n<tr>\n<td><p>Glucose</p></td><td><p>Ketones</p></td>\n\
    </tr>\n<tr>\n<td><p>Leukocytes</p></td><td><p>Microscopy</p></td>\n</tr>\n<tr>\n\
    <td><p>Nitrite</p></td><td><p>pH</p></td>\n</tr>\n<tr>\n<td><p>Protein</p></td><td><p>Specific\
    \ gravity</p></td>\n</tr>\n<tr>\n<td><p>Urobilinogen</p></td><td><p>Red blood\
    \ cells</p></td>\n</tr>\n<tr>\n<td><p>Bacteria</p></td><td><p></p></td>\n</tr>\n\
    <tr>\n<td colspan=\"2\"><p><b>Other Tests</b></p></td>\n</tr>\n<tr>\n<td><p>HIV,\
    \ hepatitis B, and hepatitis C screen</p></td><td><p>Total copper and total molybdenum</p></td>\n\
    </tr>\n<tr>\n<td><p>Ceruloplasmin (serum and plasma)</p></td><td><p>PUF-molybdenum\
    \ and PUF-copper</p></td>\n</tr>\n<tr>\n<td><p>Ceruloplasmin-bound copper</p></td><td><p>Labile\
    \ bound copper</p></td>\n</tr>\n<tr>\n<td><p>24-hour urine copper and molybdenum</p></td><td><p>Serum\
    \ and urine pregnancy test</p></td>\n</tr>\n<tr>\n<td><p>Urine drug screen</p></td><td><p></p></td>\n\
    </tr>\n</table>\n<p><sup>a</sup> Including nucleated red blood cells.</p>\n<p><small>Details\
    \ of liver chemistry stopping criteria and required actions and follow-up assessments\
    \ after liver stopping or monitoring event are given in Section 6.6 . All events\
    \ of alanine aminotransferase (ALT) \u2265 3 \xD7 upper limit of normal (ULN)\
    \ and bilirubin \u2265 2 \xD7 ULN (&gt; 35% direct bilirubin) or ALT \u2265 3\
    \ \xD7 ULN and international normalized ratio (INR) &gt; 1.5, if INR measured\
    \ which may indicate severe liver injury (possible Hy's Law), must be reported\
    \ as an SAE (excluding studies of hepatic impairment or cirrhosis).</small></p>\n\
    <p><small>Abbreviations: HIV= human immunodeficiency virus; PUF = plasma ultrafiltrate;\
    \ SAE = serious adverse event.</small></p>\n<p>Investigators must document their\
    \ review of each laboratory safety report.</p></div>"
- - NC_94
  - 10.3.
  - "Adverse Events: Definitions and Procedures for Recording, \nEvaluating, Follow-up,\
    \ and Reporting"
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_95
  - 10.3.1
  - Definition of AE
  - '<div xmlns="http://www.w3.org/1999/xhtml"><table class="table align-top table-bordered">

    <tr>

    <td><p><b>AE Definition</b></p></td>

    </tr>

    <tr>

    <td>

    <ul>

    <li><p>An AE is any untoward medical occurrence in a participant, temporally associated
    with the use of study intervention, whether or not considered related to the study
    intervention.</p></li>

    <li><p>Note: An AE can therefore be any unfavorable and unintended sign (including
    an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally
    associated with the use of study intervention .</p></li>

    </ul>

    </td>

    </tr>

    </table>

    <table class="table align-top table-bordered">

    <tr>

    <td><p><b>Events Meeting the AE Definition</b></p></td>

    </tr>

    <tr>

    <td>

    <ul>

    <li><p>Any abnormal laboratory test results (hematology, clinical chemistry, or
    urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs
    measurements), including those that worsen from baseline, considered clinically
    significant in the medical and scientific judgment of the Investigator (ie, not
    related to progression of underlying disease).</p></li>

    <li><p>Exacerbation of a chronic or intermittent pre-existing condition including
    either an increase in frequency and/or intensity of the condition.</p></li>

    <li><p>New conditions detected or diagnosed after study intervention administration
    even though it may have been present before the start of the study.</p></li>

    <li><p>Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.</p></li>

    <li><p>Signs, symptoms, or the clinical sequelae of a suspected overdose of either
    study intervention or a concomitant medication. Overdose per se will not be reported
    as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming
    intent. Such overdoses should be reported regardless of sequelae.</p></li>

    </ul>

    </td>

    </tr>

    </table>

    <table class="table align-top table-bordered">

    <tr>

    <td><p><b>Events Meeting the AE Definition</b></p></td>

    </tr>

    <tr>

    <td>

    <ul>

    <li><p>Medical or surgical procedure (eg, endoscopy, appendectomy): The condition
    that leads to the procedure is the AE. Situations in which an untoward medical
    occurrence did not occur (eg, hospitalization for elective surgery if planned
    before the signing the ICF, admissions for social reasons or for convenience).</p></li>

    <li><p>Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s)
    present or detected at the start of the study that do not worsen.</p></li>

    <li><p>A medication error (including intentional misuse, abuse, and overdose of
    the product) or use other than what is defined in the protocol is not considered
    an AE unless there is an untoward medical occurrence as a result of a medication
    error.</p></li>

    <li><p>Cases of pregnancy that occur during maternal or paternal exposure to study
    intervention are to be reported within 24 hours of Investigator/site awareness.
    Data on fetal outcome and breastfeeding will be collected for regulatory reporting
    and safety evaluation.</p></li>

    <li><p>Any clinically significant abnormal laboratory findings or other abnormal
    safety assessments which are associated with the underlying disease, unless judged
    by the Investigator to be more severe than expected for the participant''s condition.</p></li>

    <li><p>The disease/disorder being studied or expected progression, signs, or symptoms
    of the disease/disorder being studied, unless more severe than expected for the
    participant''s condition.</p></li>

    <li><p>Situations in which an untoward medical occurrence did not occur (social
    and/or convenience admission to a hospital).</p></li>

    </ul>

    </td>

    </tr>

    </table></div>'
- - NC_96
  - 10.3.2
  - Definition of SAE
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>If an event is not an AE per definition\
    \ above, then it cannot be an SAE even if serious conditions are met (eg, hospitalization\
    \ for signs/symptoms of the disease under study, death due to progression of disease).</p>\n\
    <table class=\"table align-top table-bordered\">\n<tr>\n<td><p><b>An SAE is defined\
    \ as any untoward medical occurrence that, at any dose:</b></p></td>\n</tr>\n\
    <tr>\n<td>\n<p><b>1. Results in death</b></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>2.\
    \ Is life-threatening</b></p>\n<p>The term \u201Clife-threatening\u201D in the\
    \ definition of \u201Cserious\u201D refers to an event in which the participant\
    \ was at risk of death at the time of the event. It does not refer to an event,\
    \ which hypothetically might have caused death, if it was more severe.</p>\n</td>\n\
    </tr>\n<tr>\n<td>\n<p><b>3. Requires inpatient hospitalization or prolongation\
    \ of existing hospitalization</b></p>\n<p>In general, hospitalization signifies\
    \ that the participant has been detained (usually involving at least an overnight\
    \ stay) at the hospital or emergency ward for observation and/or treatment that\
    \ would not have been appropriate in the physician's office or outpatient setting.\
    \ Complications that occur during hospitalization are AEs. If a complication prolongs\
    \ hospitalization or fulfills any other serious criteria, the event is serious.\
    \ When in doubt as to whether \u201Chospitalization\u201D occurred or was necessary,\
    \ the AE should be considered serious.</p>\n<p>Hospitalization for elective treatment\
    \ of a pre-existing condition that did not worsen from baseline is not considered\
    \ an AE.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>4. Results in persistent disability/incapacity</b></p>\n\
    <ul>\n<li><p>The term disability means a substantial disruption of a person's\
    \ ability to conduct normal life functions.</p></li>\n<li><p>This definition is\
    \ not intended to include experiences of relatively minor medical significance\
    \ such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental\
    \ trauma (eg, sprained ankle) which may interfere with or prevent everyday life\
    \ functions but do not constitute a substantial disruption.</p></li>\n</ul>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p><b>5. Is a congenital anomaly/birth defect</b></p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p><b>6. Other situations:</b></p>\n<ul>\n<li><p>Medical\
    \ or scientific judgment should be exercised in deciding whether SAE reporting\
    \ is appropriate in other situations such as important medical events that may\
    \ not be immediately life-threatening or result in death or hospitalization but\
    \ may jeopardize the participant or may require medical or surgical intervention\
    \ to prevent one of the other outcomes listed in the above definition. These events\
    \ should usually be considered serious.</p></li>\n<li><p>Examples of such events\
    \ include invasive or malignant cancers, intensive treatment in an emergency room\
    \ or at home for allergic bronchospasm, blood dyscrasias or convulsions that do\
    \ not result in hospitalization, or development of drug dependency or drug abuse.</p></li>\n\
    </ul>\n</td>\n</tr>\n</table>\n<table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b>A suspected unexpected serious adverse reaction (SUSAR) is\
    \ defined as:</b></p></td>\n</tr>\n<tr>\n<td>\n<p>A serious event that is not\
    \ listed in the Reference Safety Information of the Investigator's Brochure and\
    \ that the Investigator or Sponsor identifies as related to investigational product\
    \ or procedure. United States Title 21 CFR 312.32 and European Union Clinical\
    \ Trial Directive 2001/20/EC and the associated detailed guidances or national\
    \ regulatory requirements in participating countries require the reporting of\
    \ SUSARs. Alexion has procedures that will be followed for the recording and expedited\
    \ reporting of SUSARs that are consistent with global regulations and the associated\
    \ detailed guidances. Suspected unexpected serious adverse reactions will be reported\
    \ to the national competent authority and IRBs/IECs where applicable.</p>\n</td>\n\
    </tr>\n</table></div>"
- - NC_97
  - 10.3.3
  - Recording and Follow-Up of AE and/or SAE
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b>Recording of AE and/or SAE</b></p></td>\n</tr>\n<tr>\n<td>\n\
    <ul>\n<li><p>When an AE/SAE occurs, it is the responsibility of the Investigator\
    \ to review all documentation (eg, hospital progress notes, laboratory reports,\
    \ and diagnostics reports) related to the event.</p></li>\n<li><p>The Investigator\
    \ will then record all relevant AE/SAE information in the CRF.</p></li>\n<li><p>It\
    \ is not acceptable for the Investigator to send photocopies of the participant's\
    \ medical records to Alexion in lieu of completion of the AE/SAE CRF page.</p></li>\n\
    </ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><b>Recording of AE and/or SAE</b></p>\n<ul>\n\
    <li><p>There may be instances when copies of medical records for certain cases\
    \ are requested by Alexion. In this case, all participant identifiers, with the\
    \ exception of the participant number, will be redacted on the copies of the medical\
    \ records before submission to Alexion.</p></li>\n<li><p>The Investigator will\
    \ attempt to establish a diagnosis of the event based on signs, symptoms, and/or\
    \ other clinical information. Whenever possible, the diagnosis (not the individual\
    \ signs/symptoms) will be documented as the AE/SAE.</p></li>\n</ul></td>\n</tr>\n\
    <tr>\n<td>\n<p><b>Assessment of Severity</b> </p>\nThe Investigator will make\
    \ an assessment of severity for each AE and SAE reported during the study and\
    \ assign it to one of the following categories from National Cancer Institute\
    \ CTCAE v5.0, published 27 Nov 2017:\n<ul>\n<li><p>Grade 1: Mild (awareness of\
    \ sign or symptom, but easily tolerated)</p></li>\n<li><p>Grade 2: Moderate (discomfort\
    \ sufficient to cause interference with normal activities)</p></li>\n<li><p>Grade\
    \ 3: Severe (incapacitating, with inability to perform normal activities)</p></li>\n\
    <li><p>Grade 4: Life-threatening</p></li>\n<li><p>Grade 5: Fatal</p></li>\n</ul>\n\
    </td>\n</tr>\n</table>\n<table class=\"table align-top table-bordered\">\n<tr>\n\
    <td>\n<p><b>Assessment of Causality</b></p>\n</td>\n</tr>\n<tr>\n<td>\n<ul>\n\
    <li>\n<p>The Investigator is obligated to assess the relationship between the\
    \ study intervention and each occurrence\n            of each AE or SAE. An nvestigator\
    \ causality assessment must be provided for all AEs (both nonserious and\n   \
    \         serious). This assessment must be recorded in the CRF and on any additional\
    \ forms, as appropriate. The\n            definitions for the causality assessments\
    \ are as follows:</p>\n<ul>\n<li><p>Not related: There is no reasonable possibility\
    \ the study intervention caused the AE.</p></li>\n<ul>\n<li><p>The AE has a more\
    \ likely alternative etiology; it may be due to underlying or concurrent illness,\
    \ complications, concurrent treatments, or effects of another concurrent drug.</p></li>\n\
    <li><p>The event does not follow a reasonable temporal relationship to administration\
    \ of the study intervention.</p></li>\n</ul>\n<li><p>Related: There is a reasonable\
    \ possibility the study intervention caused the AE.</p></li>\n<ul>\n<li><p>The\
    \ AE has a temporal relationship to the administration of the study intervention.</p></li>\n\
    <li><p>The event does not have a likely alternative etiology.</p></li>\n<li><p>The\
    \ event corresponds with the known pharmaceutical profile of the study intervention.</p></li>\n\
    <li><p>There is improvement on discontinuation and/or reappearance on rechallenge.</p></li>\n\
    </ul>\n</ul>\n</li>\n<li><p>The Investigator will use clinical judgment to determine\
    \ the relationship.</p></li>\n<li><p>Alternative causes, such as underlying disease(s),\
    \ concomitant therapy, and other risk factors, as well as\n        the  temporal\
    \ relationship of the event to study intervention administration will be considered\
    \ and investigated.</p></li>\n<li><p>The Investigator will also consult the IB\
    \ and/or Product Information, for marketed products, in his/her\n        assessment.</p></li>\n\
    <li><p>For each AE/SAE, the Investigator <b>must</b> document in the medical notes\
    \ that he/she has reviewed the\n        AE/SAE and has provided an assessment\
    \ of causality.</p></li>\n<li><p>There may be situations in which an SAE has occurred,\
    \ and the Investigator has minimal information to\n        include in the initial\
    \ report to Alexion. However, it is very important that the Investigator always\
    \ make an\n        assessment of causality for every event before the initial\
    \ transmission of the SAE data to Alexion.</p></li>\n<li><p>The Investigator may\
    \ change his/her opinion of causality in light of follow-up information and send\
    \ an SAE\n        follow-up report with the updated causality assessment.</p></li>\n\
    <li><p>The causality assessment is one of the criteria used when determining regulatory\
    \ reporting requirements.</p></li>\n</ul>\n</td>\n</tr>\n</table>\n<table class=\"\
    table align-top table-bordered\">\n<tr>\n<td><p><b>Follow-up of AEs and SAEs</b></p></td>\n\
    </tr>\n<tr>\n<td>\n<ul>\n<li><p>The Investigator is obligated to perform or arrange\
    \ for the conduct of supplemental measurements and/or evaluations as medically\
    \ indicated or as requested by Alexion to elucidate the nature and/or causality\
    \ of the AE or SAE as fully as possible. This may include additional laboratory\
    \ tests or investigations, histopathological examinations, or consultation with\
    \ other health care professionals.</p></li>\n<li><p>If a participant dies during\
    \ participation in the study or during a recognized follow-up period, the Investigator\
    \ will provide Alexion with a copy of any post-mortem findings including histopathology.</p></li>\n\
    <li><p>New or updated information will be recorded in the originally completed\
    \ CRF.</p></li>\n<li><p>The Investigator will submit any updated SAE data to Alexion\
    \ within 24 hours of receipt of the information. </p></li>\n<ul>\n</ul></ul></td>\n\
    </tr></table></div>"
- - NC_98
  - 10.3.4
  - Reporting of SAEs
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b><b>SAE Reporting to Alexion via Paper Safety Reporting Form</b></b></p></td>\n\
    </tr>\n<tr>\n<td>\n<ul>\n<li><p>All SAEs will be recorded and reported to Alexion\
    \ or designee immediately and within 24 hours awareness.</p></li>\n<li><p>All\
    \ SAEs will be reported using the Safety Reporting Form and submitted to Alexion\
    \ GDS. The Investigator must complete, sign, and date the SAE pages, verify the\
    \ accuracy of the information recorded on the SAE pages with the corresponding\
    \ source documents, and send a copy via email or facsimile to the contact information\
    \ provided below: </p></li>\n<p>\u2212 Email: XXXXXXX or Fax: XXXXXX</p>\n<li><p>Additional\
    \ follow-up information, if required or available, should be entered into the\
    \ CRF and sent to Alexion GDS within 24 hours of the Investigator or study site\
    \ staff becoming aware of this additional information via the reporting process\
    \ outlined above.</p></li>\n<li><p>For all SAEs, the Investigator must provide\
    \ the following:</p></li>\n<p>\u2212 Appropriate and requested follow-up information\
    \ in the time frame detailed above </p>\n<p>\u2212 Causality of the SAE(s) </p>\n\
    <p>\u2212 Treatment of/intervention for the SAE(s) </p>\n<p>\u2212 Outcome of\
    \ the SAE(s) </p>\n<p>\u2212 Medical records and laboratory/diagnostic information</p>\n\
    <li><p>All paper forms and follow-up information submitted to Alexion GDS must\
    \ be accompanied by a cover page signed by the Investigator.</p></li>\n<li><p>Paper\
    \ source documents and/or reports should be kept in the appropriate section of\
    \ the study file .</p></li>\n</ul>\n</td>\n</tr>\n</table></div>"
- - NC_99
  - 10.4.
  - Contraceptive Guidance and Collection of Pregnancy Information
  - <div xmlns="http://www.w3.org/1999/xhtml"></div>
- - NC_100
  - 10.4.1
  - Definitions and Contraceptive Guidance
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"table align-top table-bordered\"\
    >\n<tr>\n<td><p><b>CONTRACEPTIVES<sup>a</sup> ALLOWED DURING THE STUDY INCLUDE:\
    \ Highly Effective Methodsb That Have Low User Dependency</b></p></td>\n</tr>\n\
    <tr>\n<td><ul><li><p>Implantable progestogen-only hormone contraception associated\
    \ with inhibition of ovulationc</p></li></ul></td>\n</tr>\n<tr>\n<td><ul><li><p>Intrauterine\
    \ device (IUD): female participants with a copper-containing IUD are excluded\
    \ from study</p></li></ul></td>\n</tr>\n<tr>\n<td><ul><li><p>Intrauterine hormone-releasing\
    \ system (IUS)c</p></li></ul></td>\n</tr>\n<tr>\n<td><ul><li><p>Bilateral tubal\
    \ occlusion</p></li></ul></td>\n</tr>\n<tr>\n<td><p><ul><li>Vasectomized partner\
    \ </li></ul></p>\n<ul><li><p>Vasectomy is a highly effective contraceptive method\
    \ provided that the partner is the sole sexual partner of the woman of childbearing\
    \ potential and the absence of sperm has been confirmed. If not, an additional\
    \ highly effective method of contraception should be used. Spermatogenesis cycle\
    \ is approximately 90 days.</p></li></ul></td>\n</tr>\n<tr>\n<td><p><b>Highly\
    \ Effective Methods<sup>b</sup> That Are User Dependent</b></p></td>\n</tr>\n\
    <tr>\n<td><ul><li><p>Combined (estrogen- and progestogen-containing) hormonal\
    \ contraception associated with inhibition of ovulation </p></li>\n<ul>\n<li><p>Oral</p></li>\n\
    <li><p>Injectable </p></li>\n<li><p>Intravaginal </p></li>\n<li><p>Transdermal</p></li>\n\
    </ul></ul>\n</td></tr>\n<tr>\n<td><ul><li><p>Progestogen-only hormone contraception\
    \ associated with inhibition of ovulation<sup>c</sup></p>\n<ul>\n<li><p>Oral</p></li>\n\
    <li><p>Injectable </p></li>\n</ul></li></ul>\n</td></tr>\n<tr>\n<td><ul><li><p>Sexual\
    \ abstinence </p>\n<ul>\n<li><p>Sexual abstinence is considered a highly effective\
    \ method only if defined as refraining from heterosexual intercourse during the\
    \ entire period of risk associated with the study intervention. The reliability\
    \ of sexual abstinence needs to be evaluated in relation to the duration of the\
    \ study and the preferred and usual lifestyle of the participant.</p>\n</li></ul></li></ul>\n\
    </td></tr>\n<tr>\n<td><p>Female participants of non-childbearing potential are\
    \ exempt from contraception requirements. Non-childbearing potential for female\
    \ participants is defined as any of the following:</p>\n<ul>\n<li><p>Prior to\
    \ first menses</p>\n<li><p>Postmenopausal, as documented by amenorrhea for at\
    \ least 1 year prior to the Day 1 visit and follicle stimulating hormone serum\
    \ levels consistent with postmenopausal status</p>\n<li><p>Permanent sterilization\
    \ at least 6 weeks prior to the Day 1 visit:</p>\n<li><p>Hysteroscopic sterilization</p>\n\
    <li><p>Bilateral tubal ligation or bilateral salpingectomy </p>\n<li><p>Hysterectomy\
    \ </p>\n<li><p>Bilateral oophorectomy</p>\n</li></li></li></li></li></li></li></ul>\n\
    </td>\n</tr></table>\n<p><small>Note: Periodic abstinence (calendar, symptothermal,\
    \ post-ovulation methods), withdrawal (coitus interruptus), spermicides only,\
    \ and lactational amenorrhea method (LAM) are not acceptable methods of contraception\
    \ for this study. Male condom and female condom should not be used together (due\
    \ to risk of failure with friction).</small></p>\n<p><small><sup>a</sup>Contraceptive\
    \ use by men or women should be consistent with local regulations regarding the\
    \ use of contraceptive \nmethods for those participating in clinical studies.</small></p>\n\
    <p><small><sup>b</sup>Failure rate of &lt; 1% per year when used consistently\
    \ and correctly. Typical use failure rates differ from those when used consistently\
    \ and correctly.</small></p>\n<p><small><sup>c</sup>If locally required, in accordance\
    \ with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive\
    \ methods are limited to those which inhibit ovulation as the primary mode of\
    \ action.</small></p></div>"
- - NC_101
  - 10.4.2
  - Collection of Pregnancy Information
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>If a female participant or a male\
    \ participant's female spouse/partner becomes pregnant after the first dose of\
    \ ALXN1840 through 3 months after the end of systemic exposure of the study intervention,\
    \ the Investigator must submit the \u201CPregnancy/Breastfeeding Reporting and\
    \ Outcome Form\u201D to Alexion Global Drug Safety (GDS) via fax or email (see\
    \ Section 10.3 for contact information). When the outcome of the pregnancy becomes\
    \ known, the form should be updated and submitted to Alexion GDS. If additional\
    \ follow-up is required, the Investigator will be requested to provide the information.</p>\n\
    <p>Exposure of an infant to an Alexion product during breastfeeding must also\
    \ be reported (via the \u201CPregnancy/Breastfeeding Reporting and Outcome Form\u201D\
    ) and any AEs experienced by the infant must be reported to Alexion GDS or designee\
    \ via email or facsimile (see Section 10.3 for contact information).</p></div>"
- - NC_102
  - 10.5.
  - COVID-19 Vaccine Risk Assessment
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>ALXN1840-WD-204</p>\n<p>To date,\
    \ following a review of the limited available COVID-19 vaccine data (eg, Pfizer/BioNTech,\
    \ Moderna, AstraZeneca), it is unlikely that the immune response to a COVID-19\
    \ vaccine will be diminished with concomitant ALXN1840 administration, based on\
    \ ALXN1840's mechanism of action. There is currently no information available\
    \ evaluating the safety or efficacy of COVID-19 vaccines in participants treated\
    \ with ALXN1840.</p>\n<p>Local and national guidelines should be consulted for\
    \ recommendations related to COVID-19 vaccination. Alexion suggests that participants\
    \ complete vaccination series before study participation, if feasible. The decision\
    \ to allow COVID-19 vaccinated participants to continue in the study should be\
    \ made by the investigator on a participant-by-participant basis.</p>\n<p>The\
    \ potential risks identified and mitigation measures put in place in light of\
    \ the COVID-19 vaccination rollout are provided in Table 10.</p>\n<p><b>Table\
    \ 10: Potential Risks and Mitigation Measures due to COVID-19 Vaccine</b></p>\n\
    <table class=\"table align-top table-bordered\">\n<tr>\n<td><p><b>Risks category</b></p></td><td><p>\
    \ Summary of Data/ Rationale for Risk</p></td><td><p><b>Mitigation Strategy</b></p></td>\n\
    </tr>\n<tr>\n<td <p=\"\" colspan=\"3\"><b>Potential risks</b></td>\n</tr>\n<tr>\n\
    <td><p>Data quality and integrity</p></td>\n<td><p>Missing data due to appointments\
    \ for COVID-19 vaccination or side effects of COVID-19 vaccine may impact study\
    \ visit schedules and \nincrease missed visits and/or participant study discontinuations,\
    \ inadvertently resulting in missing data (eg, for protocol-specified procedures)./p&gt;</p></td>\n\
    <td><p>It will be important to capture specific information in the eCRF that explains\
    \ the reason the data is missing (eg, missed study visits due to appointments\
    \ for COVID-19 vaccination or side effects of COVID-19 vaccine).</p></td>\n</tr></table>\n\
    <p><small>Abbreviation: COVID-19 = coronavirus disease 2019.</small></p></div>"
- - NC_103
  - 10.6.
  - Abbreviations
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A list of abbreviations and terms\
    \ used in this study protocol is provided in Table 11.</p>\n<p><b>Table 11: List\
    \ of Abbreviations and Definitions of Terms</b></p>\n<table class=\"table align-top\
    \ table-bordered\">\n<tr><th><p>Abbreviation</p></th><th><p>Definition</p></th></tr>\n\
    <tr><td><p>\u03BBz</p></td><td><p>apparent terminal-phase elimination rate constant</p></td></tr>\n\
    <tr><td><p>ADME</p></td><td><p>absorption, distribution, metabolism, and excretion</p></td></tr>\n\
    <tr><td><p>AE</p></td><td><p>adverse event</p></td></tr>\n<tr><td><p>ALT</p></td><td><p>alanine\
    \ aminotransferase</p></td></tr>\n<tr><td><p>AST</p></td><td><p>aspartate aminotransferase</p></td></tr>\n\
    <tr><td><p>AUC</p></td><td><p>area under the plasma concentration versus time\
    \ curve</p></td></tr>\n<tr><td><p>AUCt</p></td><td><p>area under the plasma concentration\
    \ versus time curve from time 0 to the last quantifiable concentration</p></td></tr>\n\
    <tr><td><p>AUC</p></td><td><p>area under the plasma concentration versus time\
    \ curve from zero to infinity</p></td></tr>\n<tr><td><p>BSA</p></td><td><p>body\
    \ surface area</p></td></tr>\n<tr><td><p>CFR</p></td><td><p>Code of Federal Regulations</p></td></tr>\n\
    <tr><td><p>CIOMS</p></td><td><p>Council for International Organizations of Medical\
    \ Sciences</p></td></tr>\n<tr><td><p>CKD</p></td><td><p>chronic kidney disease</p></td></tr>\n\
    <tr><td><p>CL/F</p></td><td><p>apparent total body clearance</p></td></tr>\n<tr><td><p>Cmax</p></td><td><p>maximum\
    \ observed concentration</p></td></tr>\n<tr><td><p>CONSORT</p></td><td><p>Consolidated\
    \ Standards of Reporting Trials</p></td></tr>\n<tr><td><p>COVID-19</p></td><td><p>Coronavirus\
    \ disease</p></td></tr>\n<tr><td><p>CRF</p></td><td><p>case report form</p></td></tr>\n\
    <tr><td><p>CRU</p></td><td><p>clinical research unit</p></td></tr>\n<tr><td><p>CTCAE</p></td><td><p>Common\
    \ Terminology Criteria for Adverse Events</p></td></tr>\n<tr><td><p>CYP</p></td><td><p>cytochrome\
    \ P450</p></td></tr>\n<tr><td><p>CYP2C9/2B6</p></td><td><p>cytochromes 2C9 and\
    \ 2B6</p></td></tr>\n<tr><td><p>EDC</p></td><td><p>electronic data capture</p></td></tr>\n\
    <tr><td><p>EOS</p></td><td><p>End of Study</p></td></tr>\n<tr><td><p>GCP</p></td><td><p>Good\
    \ Clinical Practice</p></td></tr>\n<tr><td><p>GDPR</p></td><td><p>General Data\
    \ Protection Regulation</p></td></tr>\n<tr><td><p>GDS</p></td><td><p>Global Drug\
    \ Safety</p></td></tr>\n<tr><td><p>HED</p></td><td><p>human equivalent dose</p></td></tr>\n\
    <tr><td><p>HIPAA</p></td><td><p>Health Insurance Portability and Accountability\
    \ Act</p></td></tr>\n<tr><td><p>HIV</p></td><td><p>human immunodeficiency virus</p></td></tr>\n\
    <tr><td><p>IB</p></td><td><p>Investigator's Brochure</p></td></tr>\n<tr><td><p>ICH</p></td><td><p>International\
    \ Council for Harmonisation</p></td></tr>\n<tr><td><p>ICF</p></td><td><p>informed\
    \ consent form</p></td></tr>\n<tr><td><p>ICP-MS</p></td><td><p>inductively coupled\
    \ plasma mass spectrometry</p></td></tr>\n<tr><td><p>IEC</p></td><td><p>Independent\
    \ Ethics Committee</p></td></tr>\n<tr><td><p>IRB</p></td><td><p>Institutional\
    \ Review Board</p></td></tr>\n<tr><td><p>IUD</p></td><td><p>intrauterine device</p></td></tr>\n\
    <tr><td><p>IUS</p></td><td><p>intrauterine hormone-releasing system</p></td></tr>\n\
    <tr><td><p>LBC</p></td><td><p>labile bound copper</p></td></tr>\n<tr><td><p>LEC</p></td><td><p>Long-Evans\
    \ Cinnamon</p></td></tr>\n<tr><td><p>MELD</p></td><td><p>model for end-stage liver\
    \ disease</p></td></tr>\n<tr><td><p>MT</p></td><td><p>metallothionein</p></td></tr>\n\
    <tr><td><p>NCC</p></td><td><p>non-ceruloplasmin-bound copper</p></td></tr>\n<tr><td><p>NCCcorrected</p></td><td><p>corrected\
    \ NCC</p></td></tr>\n<tr><td><p>NHS</p></td><td><p>National Health Service</p></td></tr>\n\
    <tr><td><p>PD</p></td><td><p>pharmacodynamic</p></td></tr>\n<tr><td><p>PK</p></td><td><p>pharmacokinetic(s)</p></td></tr>\n\
    <tr><td><p>PUF</p></td><td><p>plasma ultrafiltrate</p></td></tr>\n<tr><td><p>QTcF</p></td><td><p>QT\
    \ interval corrected for heart rate using Fridericia's formula</p></td></tr>\n\
    <tr><td><p>SAE</p></td><td><p>serious adverse event</p></td></tr>\n<tr><td><p>SAP</p></td><td><p>Statistical\
    \ Analysis Plan</p></td></tr>\n<tr><td><p>SoA</p></td><td><p>Schedule of Activities</p></td></tr>\n\
    <tr><td><p>SRC</p></td><td><p>Safety Review Committee</p></td></tr>\n<tr><td><p>SUSAR</p></td><td><p>suspected\
    \ unexpected serious adverse reaction</p></td></tr>\n<tr><td><p>TEAE</p></td><td><p>treatment-emergent\
    \ adverse event</p></td></tr>\n<tr><td><p>t\xBD</p></td><td><p>terminal elimination\
    \ half-life</p></td></tr>\n<tr><td><p>Tlag</p></td><td><p> time delay between\
    \ the time of dosing and time of appearance of molybdenum concentration</p></td></tr>\n\
    <tr><td><p>tmax</p></td><td><p>time to maximum concentration</p></td></tr>\n<tr><td><p>TPC</p></td><td><p>tripartite\
    \ complex</p></td></tr>\n<tr><td><p>TTM</p></td><td><p>tetrathiomolybdate</p></td></tr>\n\
    <tr><td><p>ULN</p></td><td><p>upper limit of normal</p></td></tr>\n<tr><td><p>UWDRS</p></td><td><p>Unified\
    \ Wilson Disease Rating Scale</p></td></tr>\n<tr><td><p>Vd /F</p></td><td><p>apparent\
    \ volume of distribution</p></td></tr>\n<tr><td><p>WD</p></td><td><p>Wilson disease</p></td></tr>\n\
    <tr><td><p>WHO</p></td><td><p>World Health Organization</p></td></tr>\n</table></div>"
- - NC_104
  - 10.7.
  - Protocol Amendment History
  - "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The Protocol Amendment Summary\
    \ of Changes Table for the current amendment is located directly before the Table\
    \ of Contents.</p>\n<table class=\"table align-top table-bordered\">\n<tr>\n<th\
    \ colspan=\"2\"><p>DOCUMENT HISTORY</p></th>\n</tr>\n<tr>\n<th><p>Document</p></th><th><p>Date</p></th>\n\
    </tr>\n<tr>\n<td><p>Original Protocol</p></td><td><p>12 May 2020</p></td>\n</tr>\n\
    <tr>\n<td><p>Amendment 1</p></td><td><p>18 Aug 2020</p></td>\n</tr>\n<tr>\n<td><p>Amendment\
    \ 2</p></td><td><p>19 Mar 2021</p></td>\n</tr>\n<tr>\n<td><p>Amendment 3</p></td><td><p>31\
    \ Aug 2021</p></td>\n</tr>\n<tr>\n<td><p>Amendment 3.1 (US)</p></td><td><p>18\
    \ Mar 2022</p></td>\n</tr>\n</table>\n<p><b>Amendment 1 (18 Aug 2020)</b></p>\n\
    <p>This amendment was considered to be substantial based on the criteria set forth\
    \ in Article 10(a) of Directive 2001/20/EC of the European Parliament and the\
    \ Council of the European Union.</p>\n<p><b>Overall Rationale for the Amendment</b></p>\n\
    <p>The main reason for preparation of this amendment was to update procedures\
    \ outlined in the Schedule of Activities, remove contradictory text on the reporting\
    \ of serious adverse events, and add details of an interim analysis. Additional,\
    \ minor changes are included in the table below.</p>\n<p><b>Changes to the Protocol</b></p>\n\
    <table class=\"table align-top table-bordered\">\n<tr>\n<th>Section # and Name</th><th>Description\
    \ of Change</th><th>Brief Rationale and/or Clarifications</th>\n</tr>\n<tr>\n\
    <td><p>Section 1.3, Schedule of Activities, Section 4.1, Overall Design, Section\
    \ 6.4, Study Intervention Compliance</p></td>\n<td><p>Procedures updated include\
    \ Wilson disease history and treatment; study intervention compliance during outpatient\
    \ period captured with study dosing diary; light exercise.</p></td>\n<td><p>Data\
    \ collected for analysis of patient population and study intervention compliance,\
    \ and to compare endpoints with other ALXN1840 studies.</p></td>\n</tr>\n<tr>\n\
    <td><p>Section 2, Introduction Section 2.2, Background</p></td>\n<td><p>Removal\
    \ of text relating to primary biliary cholangitis.</p></td>\n<td><p>To reflect\
    \ that development of ALXN1840 is for Wilson disease.</p></td>\n</tr>\n<tr>\n\
    <td><p>Section 6.7, Intervention After the End of Study</p></td>\n<td><p>Text\
    \ updated regarding access to study intervention after the end of study.</p></td>\n\
    <td><p>To clarify the option for study intervention access at the end of study.</p></td>\n\
    </tr>\n<tr>\n<td><p>Section 9.3, Populations for Analysis</p></td>\n<td><p>Definition\
    \ of the Per Protocol set was updated.</p></td>\n<td><p>To align the definition\
    \ with the Statistical Analysis Plan.</p></td>\n</tr>\n<tr>\n<td><p>Section 9.5,\
    \ Interim Analyses</p></td>\n<td><p> Text pertaining to an interim analysis was\
    \ added.</p></td>\n<td><p>Interim data may support Marketing Authorisation Application(s).</p></td>\n\
    </tr>\n<tr>\n<td><p>Section 10.3.2, Definition of SAE</p></td>\n<td><p> Definition\
    \ of SUSAR was added.</p></td>\n<td><p>To align with current Alexion approved\
    \ language</p></td>\n</tr>\n<tr>\n<td><p>Section 10.3.4, Reporting of SAEs </p></td>\n\
    <td><p>Removal of contradictory text on SAE reporting via an electronic data collection\
    \ tool.</p></td>\n<td><p>SAE reporting will be via a paper safety reporting form.</p></td>\n\
    </tr>\n<tr>\n<td><p>All </p></td>\n<td><p>Minor editorial updates and corrections</p></td>\n\
    <td><p>For clarification, and to ensure accuracy and consistency throughout the\
    \ protocol</p></td>\n</tr></table>\n<p><b>Amendment 2 (19 Mar 2021)</b></p>\n\
    <p>This amendment was considered to be substantial based on the criteria set forth\
    \ in Article 10(a) of Directive 2001/20/EC of the European Parliament and the\
    \ Council of the European Union.</p>\n<p><b>Overall Rationale for the Amendment</b></p>\n\
    <p>The main reason for preparation of this amendment was to revise the exclusion\
    \ criterion for a urine drug screen. Changes implemented via Administrative Letter\
    \ 1 and Administrative Letter 2, as well as COVID vaccination guidance, have also\
    \ been incorporated.</p>\n<p><b>Changes to the Protocol</b></p>\n<table class=\"\
    table align-top table-bordered\">\n<tr>\n<th>Section # and Name</th>\n<th>Description\
    \ of Change</th>\n<th>Brief Rationale and/or Clarifications</th>\n</tr>\n<tr>\n\
    <td>\n<p>Section 1.1, Synopsis; Section 9.2, Sample Size Determination</p>\n</td>\n\
    <td>\n<p>The number of participants changed from \u201Cup to 10\u201D to \u201C\
    approximately 10\u201D.</p>\n</td>\n<td>\n<p>Clarification of sample size.</p>\n\
    </td>\n</tr>\n<tr>\n<td>\n<p>Section 1.1, Synopsis; Section 1.2, Schema; Section\
    \ 1.3, Schedule of Activities; Section 4.1, Overall Design;\n        Section 6.4,\
    \ Study Intervention Compliance</p>\n</td>\n<td>\n<p>SMS text messaging will replace\
    \ the dosing diary as the method of confirming treatment compliance during the\n\
    \        outpatient period.</p>\n</td>\n<td>\n<p>Site processes does not allow\
    \ use of paper diary.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section 2.3.1.1, Coronavirus\
    \ Disease 2019; Section 10.5, COVID-19 Vaccine Risk Assessment</p>\n</td>\n<td>\n\
    <p>COVID-19 vaccination guidance added.</p>\n</td>\n<td>\n<p>To provide guidance\
    \ on potential risks identified and mitigation measures put in place regarding\
    \ the COVID-19\n        vaccination rollout.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section\
    \ 5.1, Inclusion criteria</p>\n</td>\n<td>\n<p>Inclusion criterion for confirmation\
    \ of diagnosis of WD changed to Leipzig score \u2265 4 and expanded to include\n\
    \        historical test results.</p>\n</td>\n<td>\n<p>To clarify the process\
    \ for confirming the score for patients who were diagnosed prior to the establishment\
    \ of\n        the 2012 European Association for the Study of Liver WD Clinical\
    \ Practice Guidelines.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section 5.2, Exclusion\
    \ criteria</p>\n</td>\n<td>\n<p>Exclusion criterion for drug screen revised to\
    \ state that cannabinoids will not be tested.</p>\n</td>\n<td>\n<ul>\n<li>\n<p>To\
    \ align with other ALXN1840 Phase 2 and Phase 3 study protocols which did not\
    \ reference this criterion</p>\n</li>\n<li>\n<p>Recreational use of cannabis use\
    \ is being decriminalized in many countries</p>\n</li>\n<li>\n<p>Medicinal use\
    \ of cannabis would potentially relieve symptoms of WD</p>\n</li>\n<li>\n<p>Recent\
    \ use of cannabis is not expected to alter copper or molybdenum balance</p>\n\
    </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>Section 5.2, Exclusion criteria</p>\n\
    </td>\n<td>\n<p>Exclusion criterion 11 revised to \u201CThe use of an experimental\
    \ or unapproved/unlicensed therapy at the same time\n        or within 90 days\
    \ or 5 half-lives, whichever is longer, prior to the Screening Visit.\u201D</p>\n\
    </td>\n<td>\n<p>For consistency across all ALXN1840 protocols.</p>\n</td>\n</tr>\n\
    <tr>\n<td>\n<p>Section 10.1.1, Regulatory and Ethical Considerations</p>\n</td>\n\
    <td>\n<p>Added: \u201CThe Investigator will notify the IRB/IEC of deviations from\
    \ the study protocol or GCP as defined by UK\n        legislation as a serious\
    \ breach or as required by IRB/IEC procedures.\u201D</p>\n</td>\n<td>\n<p>To align\
    \ with UK legislation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>All sections</p>\n</td>\n\
    <td>\n<p>Minor editorial updates and corrections</p>\n</td>\n<td>\n<p>For clarification,\
    \ and to ensure accuracy and consistency throughout the protocol</p>\n</td>\n\
    </tr>\n</table>\n<p><b>Amendment 3 (31 Aug 2021)</b></p>\n<p>This amendment was\
    \ considered to be substantial based on the criteria set forth in Article 10(a)\
    \ of Directive 2001/20/EC of the European Parliament and the Council of the European\
    \ Union, the US Food and Drug Administration's (FDA) regulation at 21 CFR part\
    \ 312.30(b), and any applicable local regulations.</p>\n<p><b>Overall Rationale\
    \ for the Amendment</b></p>\n<p>The main reason for preparation of this amendment\
    \ was to update the washout period for zinc. Additional changes are listed below.</p>\n\
    <p><b>Changes to the Protocol</b></p>\n<table class=\"table align-top table-bordered\"\
    >\n<tr>\n<th>Section # and Name</th>\n<th>Description of Change</th>\n<th>Brief\
    \ Rationale and/or Clarifications</th>\n</tr>\n<tr>\n<td><p>Section 1.3, Schedule\
    \ of Activities; Section 4.2, Scientific Rationale for Study Design; Section 5.2,\
    \ Exclusion Criteria</p></td>\n<td><p>Previous treatment with zinc changed to\
    \ 21 days prior to Day 1.</p></td>\n<td><p>To align with feasibility of study\
    \ participation.</p></td>\n</tr>\n<tr>\n<td><p>Section 4.1, Overall Design, Table\
    \ 4</p></td>\n<td><p>Deleted the Adaptive Protocol Feature 1 that allowed enrollment\
    \ of participants who had completed other ALXN1840 studies.</p></td>\n<td><p>To\
    \ remove contradiction of the exclusion for previous treatment with ALXN1840.</p></td>\n\
    </tr>\n<tr>\n<td><p>Section 6.7 Intervention after the End of Study</p></td>\n\
    <td><p>Updated the options for intervention after study completion to include\
    \ both therapy that was discontinued before enrollment and other standard of care\
    \ therapy.</p></td>\n<td><p>To clarify treatment options at end of study.</p></td>\n\
    </tr>\n</table></div>"
- - NC_105
  - '11.'
  - REFERENCES
  - '<div xmlns="http://www.w3.org/1999/xhtml"><p>Brewer GJ, Hill GM, Prasad AS, Cossack
    ZT. Biological roles of ionic zinc. Prog Clin Biol Res. 1983;129:35-51.</p>

    <p>Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric
    emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91(1):94-99.</p>

    <p>Czachor JD, Cherian MG, Koropatnick J. Reduction of copper and metallothionein
    in toxic milk mice by tetrathiomolybdate, but not deferiprone. J Inorg Biochem.
    2002;88(2):213-222. Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis
    of the turnover of intestinal epithelia in preclinical animal species and humans.
    Drug Metab Dispos. 2014;42(12):2016-2022.</p>

    <p>Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani
    G. Wilson''s disease in children: 37-year experience and revised King''s score
    for liver transplantation. Liver Transpl. 2005;11(4):441-448.</p>

    <p>EASL. European Association for the Study of Liver (EASL) Clinical Practice
    Guidelines: Wilson''s disease. J Hepatol. 2012;56(3):671-685.</p>

    <p>Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification
    of Wilson disease. Liver Int. 2003;23(3):139-142.</p>

    <p>Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RD. Treatment of Wilson''s disease
    with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci.
    1986;292(6):344-349. Komatsu Y, Sadakata I, Ogra Y, Suzuki KT. Excretion of copper
    complexed with thiomolybdate into the bile and blood in LEC rats. Chem Biol Interact.
    2000;124(3):217-231.</p>

    <p>Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW,
    Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized
    serum creatinine values in the modification of diet in renal disease study equation
    for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.</p>

    <p>Lowndes SA, Adams A, Timms A, et al. Phase I study of copper-binding agent
    ATN-224 in patients with advanced solid tumors. Clin Cancer Res. 2008;14(22):7526-7534.</p>

    <p>Mason J, Lamand M, Tressol JC, Mulryan G. Studies of the changes in systemic
    copper metabolism and excretion produced by the intravenous administration of
    trithiomolybdate in sheep. Br J Nutr. 1988;59(2):289-300.</p>

    <p>Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified
    assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40-47.</p>

    <p>Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate
    on copper-metabolism in rats. J Inorg Biochem. 1981;14(3):189-207.</p>

    <p>Ogra Y, Ohmichi M, Suzuki KT. Systemic dispositions of molybdenum and copper
    after tetrathiomolybdate injection in LEC rats. J Trace Elem Med Biol. 1995;9(3):165-169.</p>

    <p>Ogra Y, Chikusa H, Suzuki KT. Metabolic fate of the insoluble copper/tetrathiomolybdate
    complex formed in the liver of LEC rats with excess tetrathiomolybdate. J Inorg
    Biochem. 2000;78(2):123-128.</p>

    <p>Plitz T, Boyling L. Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate)
    in a rat model of Wilson disease. Xenobiotica. 2019;49(3):332-338.</p>

    <p>Scheinberg IH, Sternlieb I, Schilsky M, Stockert RJ. Penicillamine may detoxify
    copper in Wilson''s disease. Lancet. 1987;2(8550):95.</p>

    <p>Strickland GT, Blackwell RQ, Watten RH. Metabolic Studies in Wilson''s Disease.
    Evaluation of Efficacy of Chelation Therapy in Respect to Copper Balance. Am J
    Med. 1971;51(1):31-40. Walshe JM. Copper chelation in patients with Wilson''s
    disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
    Q J Med. 1973;42(167):441-452.</p>

    <p>Weiss K, Askari F, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in
    patients with Wilson''s disease: an open-label, multicentre, phase 2 study. Lancet
    Gastroenterol Hepatol. 2017;2(12):869-876.</p></div>'
studyDesignElements: []
studyDesignEligibilityCriteria:
- - Inclusion
  - 1
  - IN01
  - null
  - Label
  - <p>Inclusion criteria text</p>
  - null
- - Exclusion
  - 1
  - EX01
  - null
  - Label
  - <p>Exclusion criteria text</p>
  - null
studyDesignEncounters:
- - E1
  - Screening encounter
  - Screening
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E2
  - Day -21 encounter
  - Day -21
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E3
  - Day -8 encounter
  - Day -8
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E4
  - Day -7 encounter
  - Day -7
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E5
  - Day -5 and Day -6 encounter
  - Day -6 through -5
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E6
  - Day -4 encounter
  - Day -4
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E7
  - Day -3 encounter
  - Day -3
  - Visit
  - Clinic
  - In Person, Telephone Call
  - null
  - null
  - null
- - E8
  - Day -2 encounter
  - Day -2
  - Visit
  - Clinic
  - In Person, Telephone Call
  - null
  - null
  - null
- - E9
  - Day -1 encounter
  - Day -1
  - Visit
  - Clinic
  - In Person, Telephone Call
  - null
  - null
  - null
- - E10
  - Day 1 encounter
  - Day 1
  - Visit
  - Clinic
  - In Person, Telephone Call
  - null
  - null
  - null
- - E11
  - Day 2 encounter
  - Day 2
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E12
  - Day 3 encounter
  - Day 3
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E13
  - Day 4 encounter
  - Day 4
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E14
  - Day 5 encounter
  - Day 5
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E15
  - Day 6 encounter
  - Day 6
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E16
  - Day 7 encounter
  - Day 7
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E17
  - Day 8 encounter
  - Day 8
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E18
  - Day 9 encounter
  - Day 9
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E19
  - Day 10 encounter
  - Day 10
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E20
  - Day 11 encounter
  - Day 11
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E21
  - Day 12 encounter
  - Day 12
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E22
  - Day 13 encounter
  - Day 13
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E23
  - Day 14 encounter
  - Day 14
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E24
  - Day 15 encounter
  - Day 15
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E25
  - Day 16 encounter
  - Day 16
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E26
  - Day 17 encounter
  - Day 17
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E27
  - Day 18 encounter
  - Day 18
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E28
  - Day 19 encounter
  - Day 19
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E29
  - Day 20 encounter
  - Day 20
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E30
  - Day 21 encounter
  - Day 21
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E31
  - Day 22 encounter
  - Day 22
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E32
  - Day 23 encounter
  - Day 23
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E33
  - Day 24 encounter
  - Day 24
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E34
  - Day 25 encounter
  - Day 25
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E35
  - Day 26 encounter
  - Day 26
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E36
  - Day 27 encounter
  - Day 27
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E37
  - Day 28 encounter
  - Day 28
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E38
  - Day 29 encounter
  - Day 29
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E39
  - Day 30 encounter
  - Day 30
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E40
  - Day 31 encounter
  - Day 31
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E41
  - Day 32 encounter
  - Day 32
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E42
  - Day 33 encounter
  - Day 33
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E43
  - Day 34 encounter
  - Day 34
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E44
  - Day 35 encounter
  - Day 35
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E45
  - Day 36 encounter
  - Day 36
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E46
  - Day 37 encounter
  - Day 37
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E47
  - Day 38 encounter
  - Day 38
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E48
  - Day 39 encounter
  - Day 39
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E49
  - Day 40 encounter
  - Day 40
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
- - E50
  - End of Study encounter
  - EOS
  - Visit
  - Clinic
  - In Person
  - null
  - null
  - null
studyDesignEpochs:
- - Screening
  - Screening Epoch
  - Screening
  - Screening Epoch
- - Check In
  - Check In Epoch
  - Check In
  - Run-in Period
- - Treatment
  - Treatment Epoch
  - Treatment
  - Treatment Epoch
- - Follow-Up
  - Follow-up Epoch
  - Follow Up
  - Follow-Up Epoch
studyDesignEstimands: []
studyDesignIndications: []
studyDesignInterventions: []
studyDesignOE: []
studyDesignPopulations:
- - Main
  - POP1
  - Patients with Probable Mild to Moderate Alzheimer's Disease
  - null
  - 300
  - 300
  - 18..100 years
  - BOTH
  - N
studyDesignProcedures:
- - VITALS_REST
  - Blood pressure and heart rate measurements should be preceded by at least 5 minutes
    of rest for the participant in a quiet setting without distractions (eg, television,
    cell phones). Ideally, the same arm for each participant should be used for measurements
  - Vitals procedure
  - null
  - 'SPONSOR: 124 = Vitals procedure'
studyDesignTiming:
- - TIM1
  - Screening timing
  - Screening
  - BEFORE
  - SCREEN
  - D1
  - 42 Days
  - S2S
  - 0..33 Days
- - TIM2
  - Discontinuation of zinc therapy timing
  - Discontinue Zinc
  - BEFORE
  - ZINC
  - D1
  - 21 Days
  - S2S
  - null
- - TIM3
  - Check in timing
  - Check in
  - BEFORE
  - CHECK_IN
  - D1
  - 8 Days
  - S2S
  - null
- - TIM4
  - Timing for day -7
  - Day -7
  - BEFORE
  - D-7
  - D1
  - 7 Days
  - S2S
  - null
- - TIM5
  - Cycle start for day -6 and -5
  - Day -6 & -5 Start
  - AFTER
  - D-6-5_START
  - D-7
  - 0 minutes
  - S2S
  - null
- - TIM6
  - Timing for day -6 and -5
  - Day -6 & -5
  - AFTER
  - D-6-5
  - D-6-5_START
  - 1 Day
  - S2S
  - null
- - TIM7
  - Decision for day -6 and -5
  - Day -6 & -5 Decision
  - AFTER
  - D-6-5_DECISION
  - D-6-5
  - 0 minutes
  - S2S
  - null
- - TIM8
  - Timing for day -4
  - Day -4
  - BEFORE
  - D-4
  - D1
  - 4 Days
  - S2S
  - null
- - TIM9
  - Timing for day -3
  - Day -3
  - BEFORE
  - D-3
  - D1
  - 3 Days
  - S2S
  - null
- - TIM10
  - Timing for day -2
  - Day -2
  - BEFORE
  - D-2
  - D1
  - 2 Days
  - S2S
  - null
- - TIM11
  - Timing for day -1
  - Day -1
  - BEFORE
  - D-1
  - D1
  - 1 Days
  - S2S
  - null
- - TIM12
  - Day 1 anchor
  - Day 1
  - FIXED
  - D1
  - D1
  - 1 Day
  - S2S
  - null
- - TIM13
  - Timing for day 2
  - Day 2
  - AFTER
  - D2
  - D1
  - 1 Days
  - S2S
  - null
- - TIM14
  - Timing for day 3
  - Day 3
  - AFTER
  - D3
  - D1
  - 2 Days
  - S2S
  - null
- - TIM15
  - Timing for day 4
  - Day 4
  - AFTER
  - D4
  - D1
  - 3 Days
  - S2S
  - null
- - TIM16
  - Timing for day 5
  - Day 5
  - AFTER
  - D5
  - D1
  - 4 Days
  - S2S
  - null
- - TIM17
  - Timing for day 6
  - Day 6
  - AFTER
  - D6
  - D1
  - 5 Days
  - S2S
  - null
- - TIM18
  - Timing for day 7
  - Day 7
  - AFTER
  - D7
  - D1
  - 6 Days
  - S2S
  - null
- - TIM19
  - Timing for day 8
  - Day 8
  - AFTER
  - D8
  - D1
  - 7 Days
  - S2S
  - null
- - TIM20
  - Timing for day 9
  - Day 9
  - AFTER
  - D9
  - D1
  - 8 Days
  - S2S
  - null
- - TIM21
  - Timing for day 10
  - Day 10
  - AFTER
  - D10
  - D1
  - 9 Days
  - S2S
  - null
- - TIM22
  - Timing for day 11
  - Day 11
  - AFTER
  - D11
  - D1
  - 10 Days
  - S2S
  - null
- - TIM23
  - Timing for day 12
  - Day 12
  - AFTER
  - D12
  - D1
  - 11 Days
  - S2S
  - null
- - TIM24
  - Timing for day 13
  - Day 13
  - AFTER
  - D13
  - D1
  - 12 Days
  - S2S
  - null
- - TIM25
  - Timing for day 14
  - Day 14
  - AFTER
  - D14
  - D1
  - 13 Days
  - S2S
  - null
- - TIM26
  - Timing for day 15
  - Day 15
  - AFTER
  - D15
  - D1
  - 14 Days
  - S2S
  - null
- - TIM27
  - Timing for day 16
  - Day 16
  - AFTER
  - D16
  - D1
  - 15 Days
  - S2S
  - null
- - TIM28
  - Timing for day 17
  - Day 17
  - AFTER
  - D17
  - D1
  - 16 Days
  - S2S
  - null
- - TIM29
  - Timing for day 18
  - Day 18
  - AFTER
  - D18
  - D1
  - 17 Days
  - S2S
  - null
- - TIM30
  - Timing for day 19
  - Day 19
  - AFTER
  - D19
  - D1
  - 18 Days
  - S2S
  - null
- - TIM31
  - Timing for day 20
  - Day 20
  - AFTER
  - D20
  - D1
  - 19 Days
  - S2S
  - null
- - TIM32
  - Timing for day 21
  - Day 21
  - AFTER
  - D21
  - D1
  - 20 Days
  - S2S
  - null
- - TIM33
  - Timing for day 22
  - Day 22
  - AFTER
  - D22
  - D1
  - 21 Days
  - S2S
  - null
- - TIM34
  - Timing for day 23
  - Day 23
  - AFTER
  - D23
  - D1
  - 22 Days
  - S2S
  - null
- - TIM35
  - Timing for day 24
  - Day 24
  - AFTER
  - D24
  - D1
  - 23 Days
  - S2S
  - null
- - TIM36
  - Timing for day 25
  - Day 25
  - AFTER
  - D25
  - D1
  - 24 Days
  - S2S
  - null
- - TIM37
  - Timing for day 26
  - Day 26
  - AFTER
  - D26
  - D1
  - 25 Days
  - S2S
  - null
- - TIM38
  - Timing for day 27
  - Day 27
  - AFTER
  - D27
  - D1
  - 26 Days
  - S2S
  - null
- - TIM39
  - Timing for day 28
  - Day 28
  - AFTER
  - D28
  - D1
  - 27 Days
  - S2S
  - null
- - TIM40
  - Timing for day 29
  - Day 29
  - AFTER
  - D29
  - D1
  - 28 Days
  - S2S
  - null
- - TIM41
  - Timing for day 30
  - Day 30
  - AFTER
  - D30
  - D1
  - 29 Days
  - S2S
  - null
- - TIM42
  - Timing for day 31
  - Day 31
  - AFTER
  - D31
  - D1
  - 30 Days
  - S2S
  - null
- - TIM43
  - Timing for day 32
  - Day 32
  - AFTER
  - D32
  - D1
  - 31 Days
  - S2S
  - null
- - TIM44
  - Timing for day 33
  - Day 33
  - AFTER
  - D33
  - D1
  - 32 Days
  - S2S
  - null
- - TIM45
  - Timing for day 34
  - Day 34
  - AFTER
  - D34
  - D1
  - 33 Days
  - S2S
  - null
- - TIM46
  - Timing for day 35
  - Day 35
  - AFTER
  - D35
  - D1
  - 34 Days
  - S2S
  - null
- - TIM47
  - Timing for day 36
  - Day 36
  - AFTER
  - D36
  - D1
  - 35 Days
  - S2S
  - null
- - TIM48
  - Timing for day 37
  - Day 37
  - AFTER
  - D37
  - D1
  - 36 Days
  - S2S
  - null
- - TIM49
  - Timing for day 38
  - Day 38
  - AFTER
  - D38
  - D1
  - 37 Days
  - S2S
  - null
- - TIM50
  - Timing for day 39
  - Day 39
  - AFTER
  - D39
  - D1
  - 38 Days
  - S2S
  - null
- - TIM51
  - Timing for day 40
  - Day 40
  - AFTER
  - D40
  - D1
  - 39 Days
  - S2S
  - null
- - TIM52
  - Timing for End of Study
  - End of Study
  - AFTER
  - EOS
  - D1
  - 53 Days
  - S2S
  - 2..2 Days
- - TIM64
  - Adverse event anchor
  - Adverse event
  - FIXED
  - AE
  - AE
  - 0 minutes
  - S2S
  - null
- - TIM65
  - Early termination anchor
  - Early termination
  - FIXED
  - ET
  - ET
  - 0 minutes
  - S2S
  - null
- - TIM53
  - PK/PD Profile -30 minutes
  - -30 minutes
  - BEFORE
  - PKPD -0-5
  - PKPD 0
  - 30 minutes
  - S2S
  - 3..3 minutes
- - TIM54
  - PK/PD Profile Start
  - Start
  - FIXED
  - PKPD 0
  - PKPD 0
  - 0 minutes
  - S2S
  - null
- - TIM55
  - PK/PD Profile 1 hours
  - 1 hours
  - AFTER
  - PKPD 1
  - PKPD 0
  - 1 Hours
  - S2S
  - null
- - TIM56
  - PK/PD Profile 2 hours
  - 2 hours
  - AFTER
  - PKPD 2
  - PKPD 0
  - 2 Hours
  - S2S
  - null
- - TIM57
  - PK/PD Profile 3 hours
  - 3 hours
  - AFTER
  - PKPD 3
  - PKPD 0
  - 3 Hours
  - S2S
  - null
- - TIM58
  - PK/PD Profile 4 hours
  - 4 hours
  - AFTER
  - PKPD 4
  - PKPD 0
  - 4 Hours
  - S2S
  - null
- - TIM59
  - PK/PD Profile 5 hours
  - 5 hours
  - AFTER
  - PKPD 5
  - PKPD 0
  - 5 Hours
  - S2S
  - null
- - TIM60
  - PK/PD Profile 6 hours
  - 6 hours
  - AFTER
  - PKPD 6
  - PKPD 0
  - 6 Hours
  - S2S
  - null
- - TIM61
  - PK/PD Profile 8 hours
  - 8 hours
  - AFTER
  - PKPD 8
  - PKPD 0
  - 8 Hours
  - S2S
  - null
- - TIM62
  - PK/PD Profile 12 hours
  - 12 hours
  - AFTER
  - PKPD 12
  - PKPD 0
  - 12 Hours
  - S2S
  - null
- - TIM63
  - PK/PD Profile 24 hours
  - 24 hours
  - AFTER
  - PKPD 24
  - PKPD 0
  - 24 Hours
  - S2S
  - null
- - TIM66
  - Unscheduled timing
  - Unscheduled
  - FIXED
  - UNSCHEDULED
  - UNSCHEDULED
  - 0 minutes
  - S2S
  - null
studyIdentifiers:
- - DUNS
  - '794325824'
  - ALEXION
  - Clinical Study Sponsor
  - ALXN1840-WD-204
  - 121 Seaport Boulevard||Boston|MA|02210|USA
- - USGOV
  - CT-GOV
  - CT-GOV
  - Study Registry
  - NCT04573309
  - 8600 Rockville Pike||Bethesda|MD|20894|USA
- - EU
  - EUDRACT
  - EMA
  - Study Registry
  - 2020-001104-41
  - Domenico Scarlattilaan 6||Amsterdam||1083 HS|NLD
- - USGOV
  - FDA
  - FDA
  - Regulatory Agency
  - '119006'
  - 10903 New Hampshire Ave||Silver Spring|MD|20903|USA
studyOrganizations:
- - DUNS
  - '794325824'
  - ALEXION
  - Alexion
  - Clinical Study Sponsor
  - 121 Seaport Boulevard||Boston|MA|02210|USA
- - USGOV
  - CT-GOV
  - CT-GOV
  - ClinicalTrials.gov
  - Study Registry
  - 8600 Rockville Pike||Bethesda|MD|20894|USA
- - EU
  - EUDRACT
  - EMA
  - European Medicines Agency
  - Study Registry
  - Domenico Scarlattilaan 6||Amsterdam||1083 HS|NLD
- - USGOV
  - FDA
  - FDA
  - Food & Drug Administration
  - Regulatory Agency
  - 10903 New Hampshire Ave||Silver Spring|MD|20903|USA
- - DUNS
  - '123456789'
  - SITE_ORG_1
  - Big Hospital
  - Clinical Study Sponsor
  - line|district|city|state|postal_code|GBR
